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ABSTRACT 
“Radiobiological Optimization of Lung and Prostate Radiotherapy Treatments 
- A Macroscopic Approach” - D Karia 
Radiobiological modelling is applied to different treatment individualization & optimization 
strategies and the resulting improvements in treatment outcomes quantified for lung and 
prostate cancer treatments; this is compared to current approaches based on delivering 
identical dose in fixed (size and number of) fractions to a given tumour type.  
In the first investigation, dose-based escalation (level 0) is compared to Iso-toxic (i.e. Iso-
NTCP) fixed fraction number prescriptions (level 1) and Iso-toxic prescription dose & 
fraction number optimization (level 2). NTCP, dose-scaling factor and number of fractions 
are the parameters used to optimize TCP; multiple dose-limiting OAR endpoints are 
accounted for in the above analysis. It is shown that Iso-toxic (at 8.6% NTCP) dose 
fractionation optimization improves the average TCP of the lung cohort by ~19% compared 
to standard dose fractionation (55 Gy in 20 fractions yielding 8.6% average NTCP). Similarly, 
for prostate cancer treatment, it is demonstrated that level-2 optimization is superior to 
standard treatment (60 Gy in 20 fractions): a population TCP increase of 12.6% (α/β=10 Gy) 
and 9.7% (α/β=1.5 Gy) is observed at 10% Iso-toxic NTCP. The entire analysis is performed 
with the software ‘RadOpt’ which was written as part of this PhD work and is described in 
detail in chapter three. ‘RadOpt’ will be made available for other researchers to perform 
similar cohort comparison analyses (to compare changes in parameters, regimens, etcetera 
as demonstrated in this thesis).  
In chapter 4, the effect of patient-specific radiosensitivity information on treatment 
optimization & strategy selection is explored. For lung-tumour treatments it is shown that if 
patients are stratified into 3 or 5 subgroups of tumour radiosensitivity, the average TCP of 
the cohort would increase by about ~7.5% at 15 fractions (for most patients) after 
implementing level-2 optimization, compared to the current scenario where patient-
specific radiosensitivity information is not available. For the prostate cancer cohort, level-2 
TCP is improved marginally by ~1-2% at a reduced NTCP (1.7% lower NTCP compared to 
optimization where such information is unavailable). Further, it is reported that patients at 
the extreme ends of normally distributed tumour radiosensitivity would benefit significantly 
from changes in treatment strategies if patient-specific tumour radiosensitivity information 
is accounted for in treatment optimization.  
In chapter 5, superiority of radiobiological-parameter-driven VMAT inverse treatment plans 
(in terms of TCP, NTCP and standard dose volume metrics) compared to dose-volume 
parameter based VMAT treatment plans for 4 patients (2 with lung & 2 with prostate 
cancer) is demonstrated. The analysis also shows that heterogeneous dose-distribution-
based planning can yield improved TCP and dose sparing of OARs compared to standard 
planning approach that aims for a fixed and homogeneous tumour dose deposition. 
Further, it is observed that employing radiobiological model-based objectives/constraints 
reduces the risk of cold spots in the tumour and improves planning efficiency as additional 
‘dummy structures’ for sparing an OAR (e.g. rectum) would not be required.  
Chapter 6 introduces a novel method of iso-NTCP conversion of normal-tissue dose volume 
metrics (Vxx) from one regimen to the other. The analysis is carried out for two (each) lung 
and prostate treatment endpoints. We introduce two methods to perform this analysis 
(graphical & mathematical). The graphical method allows a clinician to find the equivalent 
Vxx for the new regimen such that the NTCPs of the OAR for the two regimens are equal. 
ii 
 
Acknowledgement 
 
This quest of answers was actually a journey of questions where I learnt the most 
intriguing lessons of life and lessons about myself. Reflecting upon the last few 
years, I write this as a different man, a student, a scientist, a son and a proud 
husband.  
The most prominent contributors to this scientific endeavour were Prof. Alan E. 
Nahum and Dr Colin Baker. Both of these individuals not only contributed to my 
scientific development but also to my personality development. Both Alan and 
Colin, being on different sides of the spectrum in terms of thought processes, 
critical thinking and personality; helped me learn, the most interesting things about 
‘how to go about doing science and about life’. I cannot describe in words how 
thankful I am to both of them for guiding me to reach this far. I am thankful to Alan 
for the amazing extended conversations spanning a variety of topics and the 
philosophies about a lot of big and small things in life. I am thankful to Colin for the 
thought provoking lunchtime conversations and for shaping me to think out-of-the-
box and critically. I would specifically like to acknowledge Colin for strongly 
supporting me battle university bureaucracy that helped me get my current job. I 
would like to specifically acknowledge Alan & Colin’s mammoth effort towards the 
end of the write up period for the short notice corrections on the thesis. It goes 
without saying that I would not be writing these words without the support of both 
Alan & Colin.    
Further, I would like to thank Kjell Eriksson for availing the RayStation Treatment 
Planning System to me and also for reviewing chapter 5 of the thesis. I expend my 
gratitude to Henrik Magnusson & the technical team at RaySearch Laboratories®, 
Sweden for maintaining the system and for their technical support. I would like to 
thank Dr Julien Uzan for his support in the earlier part of my PhD for his scientific 
advice on programming, BioSuite, Radiobiology and the profound knowledge of ‘the 
never perfect coffee’. I would like to thank Danny (my colleague / scouse teacher / 
friend), George Georgiou, Alison Scott, Eva Onjukka and Rhydian Caines for their 
friendship and company during my time at Clatterbridge Cancer Centre. Lastly, I 
iii 
 
would like to thank all the beneficiaries of Clatterbridge Cancer Charity that 
financially sponsored this project.  
On a personal front, reaching at this stage of being able to submit my thesis in one 
piece was certainly an interesting journey. A path, I certainly did not travel alone. 
On this front, the most prolific support was given to me by Ms Chahna Mashru 
(…now Mrs Chahna Karia), who was always there ready for the next turn 
irrespective of the troughs and peaks that seemed to lay ahead. She supported us 
physically, mentally, financially and scientifically in this journey making her the 
ultimate life-partner. I will be in her debt forever for everything she has done to 
support me in this quest. Her most important contribution was in the form of 
working with me overnights, keeping me company and sane all the time. Further, 
she also helped me proofread the thesis and pushed me hard to achieve perfection 
in finishing the thesis.  
Other than Chahna, a lot of credit goes to Amit Shah & Dr. Niti Shah for taking good 
care of mom and dad & other family matters that I could not attend. I would like to 
thank Shilraj Jadeja & Dr Vimple Bhalani for being there as a solid support and for 
always making me feel ‘at home’ away from home. I would like to thank Pinki & 
Arpit for their support to us as friends and for making us fall in love with Scotland. I 
would like to heartily acknowledge Nisarg, Shikhar, Abhiram and Utsav for their 
personal contribution to my life, bearing with my craziness and the interesting 
experiences we shared during the last many years. Further, there were many other 
individuals who contributed to this journey of mine in some way or the other and I 
would like to thank them too.  
Lastly, I would like to acknowledge the support of my parents; who have made me 
what I am with their faith in me, their personal sacrifices for me & their life 
teachings. I would like to dedicate this work to my grandfather, Babulal Karia & my 
parents, Bharat & Geeta Karia.  
 
Thank you all 
Dhvanil 
iv 
 
Table of Contents 
Chapter 1 Introduction ............................................................................................................. 1 
1.1 Radiotherapy ............................................................................................................. 2 
1.1.1 Developments in EBRT ..................................................................................... 2 
1.1.2 Conformal Radiotherapy .................................................................................. 3 
1.1.3 IMRT, VMAT and IGRT ...................................................................................... 4 
1.2 Important Radiotherapy Concepts ........................................................................... 6 
1.2.1 Radiotherapy Treatment Planning ................................................................... 6 
1.2.2 Organs at Risk (OR / OAR) ................................................................................ 8 
1.2.3 Fractionation .................................................................................................... 9 
1.2.4 Dose-Volume Histograms .............................................................................. 11 
1.3 Radiobiology ...........................................................................................................13 
1.4 Normal-Tissue Radiobiology ...................................................................................15 
1.4.1 Cellular level radiation damage classification ................................................ 15 
1.4.2 Tissue-level radiation damage classification .................................................. 16 
1.5 Organ Architecture .................................................................................................19 
1.6 The 5 R’s of Radiobiology ........................................................................................20 
1.7 Tumour Radiobiology ..............................................................................................21 
1.7.1 Clonogenic Cells ............................................................................................. 21 
1.8 Mathematical Modelling .........................................................................................22 
1.8.1 Types of models ............................................................................................. 23 
1.9 Thesis Outline ..........................................................................................................24 
Chapter 2 Overview of Radiobiological Modelling .................................................................27 
2.2 Introduction ............................................................................................................27 
2.1.1 The Linear Quadratic model for cell survival ................................................. 27 
2.1.2 Biologically effective dose (BED) .................................................................... 29 
2.2 Radiobiological Modelling .......................................................................................30 
2.2.1 Basic assumptions about the models used in this research work ................. 31 
2.3 The Marsden TCP model .........................................................................................32 
2.3.1 Other Tumour Control Probability Models .................................................... 35 
2.4 Lyman-Kutcher-Burman (LKB) NTCP Model ............................................................36 
2.4.1 Relative Seriality NTCP model ........................................................................ 38 
2.5 Fraction size effect correction in NTCP models ......................................................38 
2.6 Clinical Radiotherapy Practice ................................................................................40 
2.6.1 Radiotherapy for Lung Tumour Treatment .................................................... 40 
2.6.2 Radiotherapy for Prostate Tumour Treatment .............................................. 41 
2.6.3 Use of radiobiological modelling in Clinical Practice ..................................... 44 
2.7 Individualization and Optimization of Prescription Dose & Fractionation .............49 
2.7.1 Biomarker based individualization approaches to optimize treatment ........ 50 
v 
 
2.7.2 Non- Biomarker based treatment individualization approaches ................... 51 
2.8 Radiosensitivity based treatment optimization ......................................................56 
2.9 Inverse-Treatment planning - New Approaches .....................................................60 
2.10 Iso-toxic Dose constraint conversion ......................................................................66 
2.10.1 Problem statement ........................................................................................ 66 
2.10.2 Dosimetric Parameter Conversion ................................................................. 70 
Chapter 3 Dose Individualization & Optimization in Radiotherapy: A Radiobiological 
Modelling-based approach  ...............................................................................................71 
3.1 Introduction ............................................................................................................71 
3.1.1 Analysis Goals ................................................................................................. 72 
3.1.2 Patient Data Sets ............................................................................................ 72 
3.2 Methodology ...........................................................................................................73 
3.2.1 Program Algorithm ......................................................................................... 75 
3.2.2 The Escalator .................................................................................................. 76 
3.2.3 The Optimizer ................................................................................................. 76 
3.2.4 The Selector ................................................................................................... 78 
3.2.5 ‘RadOpt’ User Interface ................................................................................. 80 
3.2.6 Interface Description ..................................................................................... 81 
3.2.7 Quality Check ................................................................................................. 82 
3.2.8 Output ............................................................................................................ 82 
3.2.9 Dose tolerance limits ..................................................................................... 83 
3.2.10 Optimizations and Individualization Techniques ........................................... 84 
3.3 Results .....................................................................................................................88 
3.3.1 Dose-Fractionation Optimization of Lung Cancer Treatments ...................... 89 
3.3.2 Dose-Fractionation Optimization of Prostate Cancer Treatments ................ 96 
3.4 Discussion ..............................................................................................................102 
3.4.1 Discussion: Lung Cohort Optimization ......................................................... 103 
3.4.2 Discussion: Prostate Cohort Optimization ................................................... 104 
3.4.3 Uncertainty analysis ..................................................................................... 106 
3.5 Conclusion .............................................................................................................115 
Chapter 4 Radiotherapy Treatment Optimization based on Patient-Specific Tumour Radio- 
sensitivity Information .....................................................................................................118 
4.1 Introduction ..........................................................................................................118 
4.2 Methodology .........................................................................................................120 
4.2.1 Radiosensitivity based Stratification of cohorts and TCP calculation .......... 120 
4.2.2 Individualization and Optimization .............................................................. 125 
4.2.3 Clinical Scenarios .......................................................................................... 130 
4.3 Results ...................................................................................................................133 
4.3.1 Lung Cohort Results ..................................................................................... 133 
vi 
 
4.3.2 Prostate Cohort Results ............................................................................... 142 
4.4 Discussion ..............................................................................................................145 
4.4.1 Discussion: Lung Cohort Result .................................................................... 146 
4.4.2 Discussion:  Prostate Cohort Results............................................................ 149 
4.5 Summary and Conclusions ....................................................................................150 
Chapter 5 Radiobiological Inverse-Planned Treatment Individualization and Optimization       
  ..............................................................................................................................152 
5.1 Introduction ..........................................................................................................152 
5.1.1 Treatment planning ..................................................................................... 152 
5.1.2 The RaySearch Treatment Planning System ................................................ 155 
5.1.3 Goals............................................................................................................. 157 
5.2 Methodology .........................................................................................................158 
5.2.1 RayStation System Quality Assurance.......................................................... 158 
5.2.2 Inverse Treatment Planning Methodology .................................................. 158 
5.2.3 Plan Ranking and Analysis ............................................................................ 163 
5.3 Results & Analysis .................................................................................................165 
5.3.1 Lung Cancer Treatment Plan Comparison ................................................... 166 
5.3.2 Prostate Cancer Treatment Plan Comparison ............................................. 174 
5.3.3 Dose Escalation (Standard versus Radiobiologically Based) ........................ 184 
5.4 Clinical Relevance, Conclusion and Future Work ..................................................186 
Chapter 6 Iso-toxic Dose Constraint Conversion ................................................................. 190 
6.1 Introduction ..........................................................................................................190 
6.2 Methodology .........................................................................................................192 
6.2.1 Goodness-of-fit ............................................................................................ 195 
6.3 Results ...................................................................................................................196 
6.3.1 Lung Cohort .................................................................................................. 196 
6.3.2 Prostate Cohort ............................................................................................ 202 
6.4 Discussion ..............................................................................................................204 
6.5 Clinical Relevance, Conclusion & Future Work .....................................................210 
Chapter 7 Conclusions ......................................................................................................... 211  
Bibliograhy ........................................................................................................................... 214 
Appendix A: List of Abbreviations  ....................................................................................... 237 
Appendix B: Additional Material …………………………………………………………………..…………………239 
 
 
 
1 | P a g e  
 
Chapter 1 Introduction 
Cancer by definition in the Oxford dictionary is “A disease caused by an 
uncontrolled division of abnormal cells in a part of the body”. The naming of 
different types of cancer involves using tissue type, location (lung, bone, blood, etc.) 
of the cancerous growth (commonly) and/or associated cell types involved in giving 
rise to the tumour (Non-small cell, melanoma, etc.). As per the latest report of the 
Office of National Statistics (UK), breast, lung, prostate and colorectal cancers 
formed about 53% of the total registered cases of cancers in 2013 (Office of 
National Statistics, 2015). The focus of attention here is on lung cancer and prostate 
cancer which are currently highly prevalent accounting for 13.7% (Prostate cancer) 
and 12.52% (Lung cancer) of the total registered cases of cancer (292,680 cases 
total) in the UK in 2013. The literature review covers different cancer types (of 
relevance to this work) in more detail along with the development of radiobiological 
models used to predict the response of patients with these cancer types to 
radiotherapy treatments.  Now certain features of radiotherapy that will illuminate 
the core research questions addressed in this work are discussed.  
Cancer is treated by surgery, chemotherapy and radiotherapy. Each of these 
treatment modalities has benefitted from rapid technological advances in recent 
decades. Radiotherapy has moved from using planar field X-rays (William & Wood, 
1900) to treating tumours with megavoltage photon based Volumetric Modulated 
Arc Therapy (VMAT) and three-dimensional (3D) proton / carbon ion therapy 
(Grutters et al., 2010; Komatsu et al., 2011; Ramaekers et al., 2013; Teoh et al., 
2011). This monograph is about generating evidence that will pave the way for 
current clinical cancer radiation treatments to move from today’s fixed (tumour) 
dose/fractionation regimens towards radiobiologically guided patient-specific 
regimens. The established practice is heavily focused on ensuring that complication 
rates in normal organs are acceptably low for a set radiation dose to the tumour. 
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1.1 Radiotherapy 
The term ‘Radiotherapy’ includes unsealed source therapy (radioisotope or 
‘molecular’ radiotherapy), sealed-source radiation therapy (brachytherapy), and 
external-beam radiotherapy (EBRT). All these forms of radiation therapy aim to 
impart a predetermined dose of ionizing radiation to the diseased part of the body 
to kill tumour cells. Sealed and unsealed sources of radiation include various 
chemical formulations of radium, iridium, iodine, etc. Early EBRT, also known as 
Röntgen therapy, involved directing kilovoltage X-rays towards a tumour to damage 
malignant tissue with poor or no control over the size and field of exposure. Despite 
this lack of geometrical precision (relative to current practice), there was sufficient 
reason to advocate the use of radiation to treat different types of cancer depending 
on the size and the extent of disease (Hirsch & Holzknecht, 1926; Pfahlery et al., 
1931).    
1.1.1 Developments in EBRT  
A successful cancer treatment means achieving local control of the tumour (this is 
assumed to equate to the eradication/killing of every clonogenic tumour cell) whilst 
avoiding serious damage to normal tissue cells. However, considerable harm can be 
done to surrounding normal (non-cancerous) organs. Early radiotherapy was 
performed by directing X-rays onto a rectangular area marked on the patient. The 
implications of this were quite severe as a high dose of radiation was imparted to 
the healthy parts of the patient’s body and also to the radiographers, which was 
gradually realised as the late effects of radiation exposure came to light (Lambert, 
2001; Stirling & Gee, 2002). 
The idea of dividing the total dose into smaller amounts (fractionation) was 
introduced in order to reduce normal-tissue complications for a given effect on the 
tumour (Chapman & Nahum, 2015; Lambert, 2001).  3-D treatment planning was 
later introduced with the development of three-dimensional conformal 
radiotherapy (3D-CRT). This not only involved deposition of radiation dose in the 
tumour by beams from various directions but also planning of the distribution of 
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the dose to organs at risk (OARs) according to a 3-D representation of the patient 
anatomy generated using computed tomography (CT). However, imparting a radical 
dose1 to the tumour can result in high dose deposition in the surrounding normal 
tissues with the risk of severe side effects (complications).  With the evolution of 
treatment delivery technologies, the therapeutic ratio2 has improved, i.e. lower 
toxicity levels for the same or improved tumour control. 
1.1.2 Conformal Radiotherapy 
The concept of 3D-CRT entails conforming (or ‘shaping’) the radiation dose to the 
3D tumour volume, thereby reducing the dose outside the tumour as much as 
possible. This is done using computer-controlled geometric field shaping as opposed 
to the rectangular-field radiotherapy employed earlier. The advantage of 3D-CRT is 
                                                          
1 ’Radical dose’ generally indicates a dose of a magnitude sufficient to eliminate the tumour in a 
substantial proportion of patients. 
2 “Therapeutic ratio is defined as the advantage in efficacy over the disadvantage in toxicity” (Joiner 
& van der Kogel, 2009)  or as defined in Zindler et al. (2016), “The therapeutic ratio denotes the 
relationship between the probability of tumour control and the likelihood of normal tissue damage. 
An improved therapeutic ratio represents a more favorable trade-off between tumour control and 
toxicity”. 
Figure 1-1 The concept of therapeutic ratio is explained in this figure. Number 1,2, and 3 denote three 
different prescription doses at which percentage probability of tumour control (blue) and percentage 
probability of normal organ toxicity (red solid) can be observed in the graph. The tumour control for 
prescription dose 1 is nearly 40% with a very low probability of toxicity. For prescription dose number 2, 
the tumour control is 80% and toxicity at 5%. For prescription dose 3, the tumour control is nearly 95% but 
the toxicity is 50% probable. Thus, in comparing treatment with prescription 1,2 or 3 it can be observed 
that prescription number 2 yields highest efficacy versus lowest possible toxicity (i.e. with highest 
therapeutic ratio compared to other treatment options) - Zindler et al. (2016) 
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that the amount of radiation imparted to normal organs is reduced for a given dose 
to the target volume. Further developments in radiotherapy delivery have involved 
the introduction of intensity-modulated radiotherapy (IMRT) from the early 90s 
and, in the last decade, Image-guided radiotherapy (IGRT).  
1.1.3 IMRT, VMAT and IGRT 
IMRT uses modulation of beam intensity and beam shape (using multileaf 
collimator). This is undertaken either continuously (dynamic / sliding window IMRT 
technique) or in step and shoot (static IMRT) mode delivered from different angles 
relative to the delivery target with the beam turned off between each delivery 
angle. The beam shape is constricted such that the OARs in the path of the beam 
(directed towards the target) are avoided as much as possible from a given delivery 
angle. IMRT enables development of concave and inhomogeneous dose 
distributions that selectively spare Organs-at-Risk (OARs) whilst depositing the 
required radiation dose in the tumour.    
Current IMRT planning systems use the beam’s eye view technique to design 
irregularly shaped radiation-dose fields that conform to the target volume in 3D. 
These fields are then delivered by means of the multileaf-collimator (MLC) 
controlled beam shapes (Gerstner et al., 1999). IMRT represents an improvement in 
conforming high dose to the tumour volume by modulating the intensity of each 
beam in a plane perpendicular to the beam direction (Bhide & Nutting, 2010). 
There is credible evidence that IMRT is better at sparing organs at risk compared to 
the MLC-shaped beams of 3D conformal therapy. For head and neck tumours, IMRT 
has been beneficial in the sparing of optical nerves, digestive-tract mucosa, salivary 
glands, cochlea, brain and spinal cord (Chao et al., 2001; Feng et al., 2007; Nutting 
et al., 2011). Reduction of doses to the above organs has resulted in significant 
improvements in patients’ quality of life post-radiotherapy. This improved normal-
organ sparing also presents clinicians with the opportunity to increase tumour dose, 
thereby increasing the chances of achieving local control.  
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Improved local control and reduction in OAR toxicities have been reported for 
prostate cancer treatments via the use of IMRT and other advanced radiotherapy 
techniques. Prostate tumour treatment dose is limited due to genito-urinary and 
gastrointestinal toxicities. There is considerable evidence that the use of IMRT has 
resulted in acceptable bladder and rectal toxicities even for hypofractionated 
escalated doses (Kupelian et al., 2005; Kupelian et al., 2002; Zelefsky et al., 2001, 
Dearnaley et al., 2016; Livsey et al., 2003; Wolff et al., 2015).  
A disadvantage of IMRT is increased delivery time which can result in patient 
discomfort, lower overall patient throughput and most importantly an increase in 
the possibility of patient movement. Further, compared to conventional conformal 
radiotherapy, IMRT plans require more monitor units (MUs) which results in 
increased radiation dose to the whole patient body.  The solution to the above 
disadvantages is the arc-based (rotational) therapies that deliver radiation through 
continuous rotation of the gantry allowing treatment over the full 360° arc around 
the patient (Teoh et al., 2011). The two primary forms of arc therapies are 
volumetric arc therapy and Tomotherapy. Tomotherapy is a hybrid of a linear 
accelerator (linac) and a CT scanner, delivering radiation from a continuously 
moving narrow slit while the patient is translated along an axis perpendicular to the 
slit direction. Tomotherapy can be delivered axially, serial (slice by slice) or helically 
(as a continuous spiral).  VMAT, on the other hand, is delivered by varying three 
parameters related to the delivery system which are beam dose rate, gantry 
rotation speed and beam shape (via movement of MLC leaves). Conventional linear 
accelerators can be configured to have VMAT capabilities which is a distinct 
advantage compared to Tomotherapy as investment in a new piece of equipment is 
not required. Compared to standard fixed-field IMRT, arc therapies are delivered 
faster which is very useful clinically. The most recognized arc therapy systems are 
Elekta VMAT (Elekta), RapicArc (Varian) and SmartArc (Philips).   
Image Guided Radiotherapy (IGRT) is characterised as “Increasing the accuracy by 
repeated imaging of target and/or healthy tissues before the therapeutic action and 
matching the image with the therapy” (van Herk, 2007).  
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The purpose of IGRT is to use advanced imaging methods to aid better delineation 
of tumours and OARs resulting in a potential reduction in margins and uncertainties 
in treatment planning. This results in more precise target dose deposition and 
improved sparing of OARs. During a course of radiotherapy, 3D imaging in the form 
of cone-beam CT is repeated multiple times to assess changes in tumour location, 
size and shape. Pre-treatment-fraction observation of these changes allows the 
treatment delivery to be modified to improve delivery of dose to the target and 
reduce the dose to the OARs. One other important use of IGRT is to accommodate 
organ motion (through pre-treatment 4D CT) especially in the case of lung, liver and 
prostate glands. IGRT also uses PET, SPECT and MRI marker based imaging 
techniques to guide precise target delineation (Arabloo et al., 2016).   
Today, it is well established that technological improvements in radiotherapy beam 
delivery and tumour & OAR delineation have delivered significant reductions in 
organ dose. However, the potential to individualize increase in tumour dose 
remains largely unexploited. Limiting the side effects of radiotherapy is essential 
but maximizing tumour control probability is of paramount importance as that is 
the primary objective of radiotherapy treatment.   
1.2 Important Radiotherapy Concepts  
Some of the important concepts of radiotherapy that are explicitly used throughout 
the thesis are now introduced.   
1.2.1 Radiotherapy Treatment Planning 
The present work involves analysing radiotherapy treatment data for cohorts of 
patients treated using radiotherapy. With advances in computer technology, 
radiotherapy has moved to computerised treatment planning in three dimensions. 
Thus, to ensure radiation treatment planning is consistent across centres, the 
International Commission on Radiological Units and Measurements (ICRU), 
established in 1925, coined the terms planning target volume (PTV), gross tumour 
volume (GTV) and clinical target volume in report 50 (ICRU, 1993a), report 62 (ICRU, 
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1999) and report 83 (ICRU, 2010). The upper and lower dose limits to the above 
volumes relative to the prescribed dose are also defined. GTV refers to the tumour 
that can be seen, palpated or imaged. GTV delineation aims to identify the 
demonstrable extent of the tumour and its location (See Figure 1-2).  The GTV 
should also include any involved lymph nodes or noticeable spread into adjacent 
tissues. Surrounding the GTV is the CTV which is GTV plus a margin that will cover 
the microscopic spread of disease. The addition of a margin to the GTV to create the 
CTV is a matter of clinical assessment through biopsy or judgement based on 
experience which should take into account microscopic infiltrations of disease 
outside the GTV (Burnet, 2004). The local infiltration of a given tumour delineated 
by CTV is very variable. Some of the anatomical structures like bone cortex, 
muscular fascia and ligaments act as barriers and limit microscopic tumour 
infiltration. CTV delineation ideally accounts for such clinical information. However, 
the CTV covers the volume suspected of harbouring clonogenic tumour cells and 
thus should be treated with the prescribed dose as survival of even a single 
clonogenic cell can result in tumour relapse (i.e. treatment failure).   
Figure 1-2 GTV, CTV and PTV as per ICRU report 50. 
As per Report 62 & 83 (ICRU, 
1999;2010), the PTV should 
account for internal variations 
such as changes in the position, 
size and shape of CTV due to 
movement of anatomical 
reference points or the tumour 
and external variations such as beam and patient positioning errors.  The PTV 
encompasses the CTV in order that the prescribed dose is delivered to the whole of 
the CTV ensuring there is no under dosage to any part of the CTV.  
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1.2.2 Organs at Risk (OR / OAR) 
The organs that surround a tumour or are in close proximity to the tumour, thereby 
receiving a high dose of radiation are known as Organs at Risk (OAR / OR) (ICRU, 
1999). 
The current work analyses lung and prostate radiotherapy treatment data. As far as 
clinical complications are concerned, both these tumour sites have OARs whose 
physiological function can be compromised as part of radiotherapy related side 
effects.  In the case of lung tumours, the OARs are healthy lung (ipsilateral and 
contralateral), heart, oesophagus, and spinal cord (Jiang et al., 2011). The 
radiotherapy related side effects to different OARs are usually reported using the 
radiation oncology group foundation’s reporting schema (RTOG, 2015) or the 
Common Terminology Criteria for Adverse Events schema [CTCAE v5.0] (National 
Institute of Health, 2010). Further, RTOG and EORTC developed the LENT-SOMA 
scoring system to further standardize global toxicity scoring of clinical adverse 
events (i.e. OAR toxicity). These scoring systems allow quantification of the severity 
of an adverse event by means of a grade. The grade of an adverse event refers to a 
defined level of severity of the adverse event in relation to a patient’s health. RTOG 
has defined toxicity grades from 1 to 5 for 15 tissues. Such scoring methods benefit 
clinicians as it allows justification for allocation and prioritization of resources 
required to manage a given patient’s condition based on the severity of the event.  
For healthy lungs, radiation pneumonitis3 of grade 2 or above was the primary 
endpoint considered in this research work (RTOG,2015). Symptoms included 
moderate symptomatic fibrosis or pneumonitis, low-grade fever and/or patchy 
radiographic appearances. For the heart, pericarditis is the complication (i.e. 
Moderate angina on effort, Mild pericarditis, Normal heart size, Persistent 
abnormal T wave and ST changes – refers to an echocardiogram’s QRS complex, 
Low ORS); for oesophagus, grade 2 oesophageal complication (i.e. patient unable to 
take solid food normally or swallowing semi-solid food only) and grade 2 spinal cord 
                                                          
3 As per CTCAE v4 Pneumonitis of lung is defined as a disorder characterized by inflammation focally 
or diffusely affecting the lung parenchyma. Coughing is a typical symptom.  
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injury (i.e. Severe L'Hermitte's syndrome alias radiation myelopathy) were 
considered in the current analysis. In the case of prostate tumours, rectal bleeding, 
incontinence and bladder complications were considered (RTOG,2015).  
1.2.3 Fractionation  
In the early 1980’s, it was established that early and late normal tissue reactions 
varied with change in dose per fraction of radiation treatment. This led to further 
study of radiobiology of normal tissues and the effect of changing fraction sizes on 
normal tissue responses (Joiner & van der Kogel, 2009). The term fractionation 
means the division of the total prescribed dose into smaller doses generally given 
once per day. Fractionation helps normal tissues recover from sub-lethal damage. 
Usually, the fractions are equal in size (dose), spread evenly over a given treatment 
period.      
In the 1920s, Regaud & Baclesse introduced the idea of dividing the total 
prescription dose into several small parts rather than one single dose (Hunter, 
2006). They were successful in improving uncomplicated laryngeal cancer control 
rates using low dose-rate protracted radiotherapy. They performed this over 2-3 
hour daily fractions and a total treatment time of 4-6 weeks; this was medically 
superior to what had been done before but was not viable economically and 
resource-wise. This led to an increased interest in treatment regimens which were 
shorter in duration and practically deliverable (Hunter, 2006). Schwarz, Pape, 
Holzknecht and others by 1937 used fractionated high-dose-rate-per -fraction 
schemes imparting 0.63 Gy three times a day with four-hour gaps to treat cancer of 
the larynx (Hunter, 2006)4. Different centres in different parts of the world in the 
early part of the twentieth century started treating cancer (of the larynx at the 
least) with varying schemes of fractionation.   
As of today, fractionation can be divided into the following categories: Hypo-
fractionation, Conventional fractionation, Hyper-fractionation, Accelerated 
                                                          
4 Hunter (2006) refers to - Schwarz G. Entwicklung, Prinzipien und biologische Grundlagen der 
Röntgentherapeutischen Bestrahlungstechnik. Strahlentherapie 1937, 58:523–544 
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fractionation and Protracted fractionation. The definitions of these fractionation 
types are taken from Dale & Jones (2007). 
Conventional fractionation refers to 1.8 - 2 Gy per day each weekday. Hypo-
fractionation schedules are of fraction size greater than 2 Gy/fraction, and hyper-
fractionation refers to fractions less than 2 Gy (1-1.2 Gy per fraction - The Royal 
College of Radiologists, 2016).  Accelerated fractionation means imparting more 
than 10 Gy per week total dose, and protracted fractionation refers to total doses of 
less than 10 Gy per week as per Dale & Jones (2007)5.  
The point being made here is that fractionation regimens are a compromise 
between many fractions or too few fractions to balance the sparing of normal 
tissues versus minimizing tumour repopulation.  One may justifiably ask why one 
should prefer empirically derived fractionation schedules when radiobiological 
modelling based analysis can yield a more rationalized patient-specific fractionation 
schedule. Also, it is important to remember that fraction size is not the only 
parameter to optimize; dose-rate within a fraction, total dose, tumour volume and 
overall treatment time have a complex inter-relationship that govern the success of 
treatment for a given patient. More details about fractionation and its effects on 
the radiobiology of tumours and normal tissues are discussed in later sections of 
this chapter.  
                                                          
5 Refer to: Chapter 4 Radiotherapy Fractionation, Page 52, Table 4.1 
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1.2.4 Dose-Volume Histograms 
Treatment planning software generates a significant quantity of data on the dose 
deposited in the tumour and the contoured OARs. This information is commonly 
represented visually as Iso-dose lines over sagittal, transverse or coronal planes of a 
CT scan. Analysis of this information across three dimensions is challenging. 
Drzymala et al. in 1991 proposed compressing a 3-D dose distribution into a 2-D 
format known as a dose-volume histogram (DVH). Creating DVHs of a 3D dose 
distribution compresses a lot of information on the dose received by the delineated 
target volumes and healthy organs in the treatment plan. This makes plan 
evaluation and inter-plan comparison process much less complex.  
Figure 1-3 Images from a prostate radiotherapy treatment plan showing Iso-dose lines in the transverse (a) 
and sagittal (b) planes and the DVHs (c) of various OARs delineated along with that of the PTV – Chapter 5, 
Nenoi (2015).  
A dose-volume histogram (DVH) is a histogram that relates radiation dose to the 
irradiated tissue volume in a given radiotherapy treatment plan. A DVH can be 
differential or cumulative in type. A histogram of the absolute (or percentage) dose 
received by a given structure versus the absolute (or percentage) volume of the 
structure receiving dose in a dose bin is called a differential DVH. The histogram can 
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also be cumulative which for a given dose (interval) can show the total volume 
receiving that given dose or greater. An example is of cumulative DVH is provided in 
figure 1-3(c). 
Figure 1-3 above shows the Iso-doses of a treatment plan in a) Transverse Plane b) 
Sagittal Plane and in c) the cumulative DVHs of all the delineated Target volumes 
and OARs of a prostate patient. It is quite evident that the analysis of the dose 
distribution becomes relatively easy on comparing figure a), b) and c). A set of DVHs 
can be used for preliminary plan analysis and/or to rank different plans. The DVHs 
are also used as inputs to radiobiological models to calculate tumour control 
probability (TCP) and normal tissue complication probability (NTCP). TCP and NTCP 
models together with DVHs are a means to assess treatment plans quantitatively. 
These are discussed in detail in the next chapter. The limitation of using DVHs is 
that the spatial information associated with the voxels is irreversibly lost. Cheng & 
Das, (1999) tried to overcome this pitfall by proposing a zDVH that would be a 
supplement to the standard DVH but providing dose volume information 
(differential) with respect to a CT slice number. The standard DVH is still commonly 
employed for plan scoring and dose reporting possibly due to its simplicity. 
As per (ICRU, 1993b), the dose planned for various organs and the tumour is to be 
reported using the below mentioned definitions of dose and volumes receiving 
radiation in Gray (Gy). The definition of various dose-volume metrics for tumour 
and normal tissue that can be derived using a DVH are given below. The current 
dose-volume limits for different OARs are described later when discussing clinical 
scenarios for lung and prostate tumour treatments. Dmean, Dmax, Dmin, Dref, and Vref 
are some of the metrics often reported.    
Minimum Dose (Dmin): The minimum dose received by a specific percentage (mostly 
it would be 95% or 99%) volume of a given structure. This is a useful metric in terms 
of target dose as minimum dose could be used to set a definite curative dose for a 
given tumour PTV. 
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Maximum Dose (Dmax): The maximum dose received by a specific percentage 
volume (mostly it would be 1% organ/tissue volume) of a given structure. This 
metric is used to limit dose to critical organs that have a serial architecture 
(discussed in section 1.5). This excludes very small hotspots as defined in the (ICRU, 
1993b) guidance report. 
VDref: It is the volume of the structure receiving greater than or equal to the 
‘reference’ dose. 
DVref: This is defined as the minimum dose received by a ‘reference’ percentage 
volume of a given structure.   
Report 83 (ICRU, 2010) superseded previous reports and defined three levels of 
recommendations for dose prescribing and reporting. Level 1 recommendations 
entail minimum standards for prescribing and reporting in radiotherapy sufficient 
for simple treatments and standards below which clinical radiotherapy should not 
be performed. Level 2 recommendations are for prescribing and reporting for state 
of the art techniques using computational dosimetry and 3D imaging. As per level 2 
recommendations, it is expected that all volumes of interests (GTV, CTV, PTV, OAR 
and planning organ-at-risk) are defined over a 3D-CT or MRI image set, and that 
absorbed doses (heterogeneity corrected) are available along with DVHs of all the 
volumes. Level 3 recommendations are optional and research orientated, which 
involve reporting radiobiological concepts like TCP, NTCP or EUD.    
1.3 Radiobiology  
Radiobiology is the study of effects of ionizing radiation on cells and living 
organisms. Radiobiological modelling combines the physics of radiation and the 
biology of living cells under one umbrella. The most basic unit of a living organism is 
a cell. The cell is formed of different biological materials. The most important part 
of any cell is the nucleus that houses the genetic material which governs the 
response of a cell to any stimuli. A cell is bound by a thin membrane housing 
organic and inorganic materials in its cytoplasm (i.e. materials like water, minerals, 
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liposomes, lysosomes, etc. - Podgorsak, 2005). Cells can be classified into two 
categories:  
1) Somatic cells: These are cells that can undergo mitotic division. A further 
classification of a somatic cell is a stem cell, transit cell and mature cell and the 
difference between these is explained in table 1-1.  Of these, stem cells are most 
important as they are the cells that have the most potential to differentiate into a 
particular type of cell to form a given tissue. 
Mitotic division of a cell leads to the formation of two daughter cells that have the 
same genetic material as the parent cell. Somatic cells are diploid with 46 
chromosomes in a human cell. 
2) Germ cells: The type of division that germ cells undergo is called meiosis which 
happens in two stages. Stage one is meiosis one where diploid parent cell is divided 
to form haploid daughter cells. In meiosis stage II, the haploid daughter cells; one 
from the male parent and one from the female each fuse to form a diploid daughter 
cell. In meiosis, the daughter cells have a mixture of genetic material derived from 
both parent cells through chromosomal crossover generating genetic diversity 
(Ohkura, 2015). Two cells from each parent combine to result into four daughter 
cells with genetic material from both male and female parents which further 
undergo mitotic cell division to form a group of cells. A group of cells of a given type 
forms a tissue that has certain characteristics / function and a group of tissues form 
an organ that performs a specific physiological function in the living organism 
(Podgorsak, 2005). 
Table 1-1 The difference between stem cells, transit cells and mature cells is explained in the image - Potten 
(1997). 
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1.4 Normal-Tissue Radiobiology 
When cells are exposed to radiation, the radiation passes through the cell, and a 
certain amount of energy is deposited in the cell. The cells may incur damage by 
acting as ‘resistance’, i.e. absorbers of energy in the path of radiation. The 
interaction of the radiation with the molecules in the cell produces excitation and 
ionization.  
1.4.1 Cellular level radiation damage classification 
There are two categories of damage to cells due to interaction with radiation: 
1.4.1.1 Direct Damage 
The ionization that directly interacts with the DNA and causes genetic cell damage is 
termed as direct damage. This type of cell damage is discussed in greater detail 
when the Linear-Quadratic model of cell killing is discussed in the literature review 
section 2.1.1.  
1.4.1.2 Indirect Damage 
The ionization of molecules in the cell produces free radicals that cause physical 
and/or chemical damage to other parts of the cell including the nucleus and the 
DNA within it. The majority of cell content is H2O and ionization of water molecules 
produces reactive H+ and OH- free radicals. These cause the chemical bonds in other 
cell structures including the DNA to break thereby inducing internal damage that 
results in physiological changes in the cell. The indirect damage is a mixture of 
chemical and biological damage that can be enhanced or reduced by chemical 
sensitizers or radiation protectors (Chapman, J.D. & Nahum, 20156; Dale & Jones, 
20077; Mayles, Nahum, & Rosenwald, 20078). 
                                                          
6 Refer Chapter 6, Page 66, Section 6.3 
7 Refer to Chapter 2 section 2.2       
8 Refer to Chapter 7 Section 7.5 
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1.4.2 Tissue-level radiation damage classification 
On a macroscopic level, the consequences of radiation damage can be classified 
according to the type of damage, the timescale of realization of damage, and the 
intensity of damage. 
1.4.2.1 Types of damage 
A) Potentially Lethal Damage: Damage that is repaired by mechanisms within the 
cell.   
B) Sub-lethal Damage: Repairable damage with more serious effects than 
potentially lethal damage. It takes about 4 to 24 hours for sub-lethal damage to be 
repaired provided that additional radiation damage is not incurred. Further, sub-
lethal damage if not fully repaired may lead to lethal damage (Podgorsak, 2005). 
There are criteria to further grade the level of sub-lethal damage in OARs (i.e. RTOG 
criteria for normal-tissue complication). 
C) Lethal damage: Irreparable damage is the type of damage that mostly leads to 
cell death. This type of radiation damage is irreversible. The aim of radiotherapy is 
to deliver lethal damage, i.e. cell death to 100% of the tumour clonogens without 
serious damage to normal tissues. After radiation exposure, cell death can occur by 
one of the many complex mechanisms as shown in figure 1-4.  In the cells of a 
hematopoietic system, apoptosis (programmed cell death) is the predominant 
mode of cell death after irradiation. Apoptosis is characterised by chromatic 
fragmentation, followed by cell shrinkage and then blebbing (Charras, 2008) of cell 
membranes. 
Senescence results in permanent cell-cycle arrest eventually leading to natural cell 
death whereas, secondary necrosis and necroptosis lead to plasma-membrane 
disintegration followed by mitotic catastrophe. Mitotic catastrophe is a condition 
that results in the formation of huge cells with hyper-amplified centromeres and 
multiple nuclei that live for a few days before transitioning into senescence or 
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apoptosis.  Details on each of these pathways of cell death are given in Joiner & van 
der Kogel (2009) and Orth et al. (2014).   
 
1.4.2.2 Timescale 
Radiation damage to the organism (e.g. to a human being) is generally not 
immediately apparent as would be the case with burns or cuts. The timescale for 
radiation damage to manifest itself depends on the intensity of radiation exposure, 
total exposure time and characteristic radiation sensitivity of the tissue. The 
physical realization of radiation damage can be divided into early and late tissue 
response.    
Figure 1-4 Different pathways of cell death after lethal radiation exposure - Orth et al. (2014) 
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A) Early effects 
Early effects of radiation damage occur within 3 months of radiation treatment / 
exposure. The tissues most susceptible to early acute effects are renewal tissue like 
basal layers of skin (mucosa), stem cells in the small intestinal crypts and bone 
marrow. Complications that are likely to manifest themselves as early effects of 
radiation exposure are oedema, haemorrhage, inflammation and denudation of 
epithelial and haemopoietic tissue. (Mayles et al., 20079; Podgorsak, 200510). 
B) Late effects 
With respect to normal tissue and clinical radiation treatment, late effects of 
radiation damage are chronic in nature. Late effects could be a result of depletion of 
stem cells, radiation damage to stromal elements of the tissue or because of 
repetitive radiation damage in overlying tissue. Late responses affect organ 
physiology in the long term. Fibrosis, ulceration, atrophy, obstruction or stenosis 
are some of the examples of symptoms associated with late chronic radiation 
damage (Chapman & Nahum, 201511; Mayles et al., 200712; Podgorsak, 200513).  
C) Extended germinal effects 
Radiation damage can either be fully repaired, lead to programmed cell death or 
result in genetic mutation. DNA damage due to free radical interaction with the 
chromosomes can sometimes lead to incomplete repair causing mutation and not 
cell apoptosis. This affects the germ cells of the organism. The effects of this kind of 
radiation damage are perpetuated and become evident in secondary, tertiary or 
later generations of the organism, many years after the original exposure 
(Podgorsak, 2005). 
                                                          
9 Refer to chapter 8 section 8.4 
10Refer to chapter 14 Section 14.6,14.7   
11 Refer to Chapter 9, section 9.1-9.2 
12 Refer to chapter 8 section 8.4       
13 Refer to chapter 14 Section 14.6,14.7  
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1.5 Organ Architecture 
Different organs are made up of specific types of cells and tissues. The physiological 
function of a given tissue depends on the functional output of these cells and 
tissues. Organs are believed to react to radiation or drug toxicity in two specific 
ways. Before discussing this, it is important to introduce the concept of functional 
sub-units (FSUs). An FSU is a unit element of a given organ that contributes to the 
functional output of the organ and can be regenerated by a single surviving stem 
cell of the same tissue. Alveoli of the lung and B-cells of the liver are examples of 
FSUs that are responsible for the functionality of the respective organs. Withers et 
al. (1988) proposed the idea of serial and parallel organs and explained the 
difference in radiation response of different organs using the concept of FSUs. 
There are three categories of organs based on their architecture that govern the 
intensity of response to any type of damage to the organ.  
The parallel architecture organs have FSUs working ‘in parallel’ just like several 
batteries connected in parallel to maintain a certain voltage (organ function) across 
the circuit (e.g. Lung, Liver). Total functional incapacitation is induced when a set 
percentage or majority of FSUs of the organ are damaged. The dosimetric factor 
associated with toxicity in parallel architecture organs is ‘mean dose (Dmean) to the 
organ’ (Källman et al.,1992). 
Second are serial architecture organs, wherein the FSUs are linked serially as a chain 
that breaks if any of the links is severely damaged. A series electrical circuit is a 
good analogy here. These types of organs present with functional loss above a 
certain threshold of physical or biological damage (e.g. Spinal Cord, Oesophagus). 
For serial organs “maximum dose (Dmax) to the OAR” is the dosimetric factor 
associated with toxicity. Källman et al. (1992) and Niemierko & Goitein (1993) 
developed NTCP models for inhomogeneous dose distributions using the serial and 
parallel organ architecture concepts as proposed by Withers et al. (1988).  
For tumours, unless all the stem cells (FSUs) are eradicated, the tumour regrows 
which indicates that tumours effectively have parallel architecture. Complications 
for different organs occur at different dose levels. Studies have indicated that 
normal tissues can contain a combination of parallel and serial structures (which 
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form the third category of organs). The properties of cells important for 
understanding the way tumour- and normal tissue cells behave in response to 
radiation exposure are enumerated below. These properties are referred to as R’s 
of Radiobiology.  
1.6 The 5 R’s of Radiobiology  
• Repair – Cells have many ways of ascertaining their general well-being and this 
self-diagnostic process is almost continuous. The moment after a finite amount 
of radiation damage occurs in a living cell, the cell diagnostics pick up the 
anomaly of DNA strand breaks and initiate a very sophisticated repair 
mechanism. However, the time it takes for complete repair (mostly but not 
always) depends on the type of cell and extent of damage encountered. 
• Redistribution – The radio-sensitivity of cells in different stages of the cell cycle 
varies. Some stages are more radio-resistant than others, and so cells in these 
stages of the cell cycle are more likely to survive a dose of radiation. However, 
radiation damage leads to two important cell-cycle phenomena where some cells 
get locked in the G2 phase of the cell cycle, and some are pushed into a 
radiosensitive phase of the cell cycle. This redistribution process contributes to 
radiation damage in subsequent fractions of therapy.  
• Reoxygenation – Hypoxic cells are relatively resistant to radiation (Brown, 2007). 
The surviving hypoxic cells after a fraction of radiotherapy are likely to be re-
oxygenated owing to angiogenesis and or a reduction in the number of oxygen-
consuming cells. This increase in oxygenation makes them more radiosensitive. 
Thus, the damage to the same set of cells in subsequent fractions is likely to be 
higher as they are rendered radiosensitive. This is one more factor contributing 
to adaptation of fractionation in radiotherapy.     
• Repopulation – Cells may move into the proliferative stage. Cell proliferation is 
advantageous for OARs and a disadvantage as far as radiotherapy treatment of 
tumours is concerned.  
• Radio-sensitivity – For a given single dose of radiation, the damage incurred by 
different types of cells varies. This characteristic (known as radio-sensitivity) of 
cells of different types (tumour or OAR) plays a vital role in determining the 
21 | P a g e  
 
response of cells to a given dose of ionizing radiation (Mayles et al., 200714; 
Withers, 1975). 
1.7 Tumour Radiobiology 
Any given tissue undergoes a process of cell renewal in order to maintain its natural 
form (i.e. constant size and volume). The well differentiated and mature cells are 
replenished over time by 
differentiation of basic stem 
cells that have very high 
proliferation & 
differentiation capacity. Stem 
cells form the base of the 
hierarchy of cells that make 
up the epithelial and 
haemopoietic tissues of the 
body.  Cancer tumour tissues 
also consist of these 
neoplastic stem cells at the 
base of their hierarchy that 
differentiate into malignant cells of carcinoma and undergo uncontrolled mitotic 
division (Reya et al., 2001). The total mass of a tumour also includes cells that are 
non-proliferative but have the same characteristics as those of the malignant cells. 
The aim behind any curative cancer treatment is to eradicate the malignant stem 
cells that have the proliferative capacity. If a tumour relapses post radiation 
therapy, then at least one stem cell must have survived the radiation exposure.  
1.7.1 Clonogenic Cells 
Clonogenic means capable of forming colonies. The term “clonogenic cell” refers to 
cancer stem cells (CSCs).  CSCs are very difficult to identify in situ, and generally 
                                                          
14 Refer to chapter 7 section 7.8 
Figure 1-5 Cell survival curves for four representative human 
tumour cell lines irradiated at high dose rate. HX142 
neuroblastoma; HX58 pancreatic; HX156 cervix; RT112 bladder 
carcinoma. From Steel (1991)  
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must be identified using in vitro cell-growth assays.  The main aim of curative cancer 
treatment is to eliminate clonogenic cells. The survival of irradiated cancer cell lines 
is studied by radiobiologists using clonogenic assaying techniques (Mayles et al., 
200715). The assays are controlled growth environments in which cancer cells are 
allowed to regrow post-irradiation. The growth environment is maintained at 37oC 
with aeration to promote normal cell growth. The cells that survive are counted 
once they have undergone several cycles of mitosis. The plot of surviving fraction of 
cells after correcting for plating efficiency (logarithmic scale) versus radiation dose 
(linear scale) known as cell survival curves are fitted with mathematical models to 
obtain radiosensitivity parameters for the cell type under study (IAEA, 2010).  The 
disadvantages of this process are that it deals with a limited range of doses and that 
the mitotic viability of cells cannot be tested using the assays. Nevertheless, many 
such studies have been undertaken and many papers published that validate the 
use of parameters for modelling cell survival (Burman et al., 1991; Chapman & 
Nahum, 2015; Chapman, 2003; Marks, Yorke, et al., 2010).  
Mitotic division leads to two daughter cells from one parent, and thus the number 
of tumour cells would be expected to grow exponentially, and the volume will 
increase as a logarithmic function of time. If the cells are continuously dividing, the 
tumour doubling time can be established. Modelling cell survival helps uncover 
characteristics of specific tumours (IAEA, 2010). An example of a cell survival plot 
for different cell lines is shown in Fig. 1-5 (from Steel, 1991). 
1.8 Mathematical Modelling 
The importance of a model lies in its ability to represent, define or explain a real-
time phenomenon or a problem and mimic its behaviour to a certain level of 
accuracy.  Testing a model on various independent known datasets is a good 
method of validating the applicability of the model. The right balance must be 
found between prediction accuracy and model complexity.  Further, it is also 
                                                          
15 Refer to chapter 7 section 7.2 
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important to note that a model with enough parameters can be a good fit to the 
data but may be incorrect in characterizing the data. 
1.8.1 Types of models  
Models can be built using two methods.  
1) Building a logical system based on a theory – Mechanistic Approach 
2) Fitting equations to observed data – Empirical Approach 
Mechanistic models specifically consider the mechanisms involved in the process 
being modelled. The analogy of a group of cells forming a tissue and a group of 
tissues forming an organ is quite applicable here. The design starts with modelling 
of simple processes which together form a complex process. Simple processes are 
governed by basic theoretical knowledge. These processes are then combined 
mathematically to form a complex mechanistic model. Next, the model is to be 
validated with known outcome/response data and refined to improve predictive 
accuracy. The Marsden model that predicts tumour control probability is an 
example of a simple mechanistic model (refer section 2.3). 
Empirical Models are built using data and may have no relation to the actual 
physical processes to which they are applied. In constructing an empirical model, an 
equation is fitted to the data observed or recorded. The goodness-of-fit metric 
associated with the model fitting process gives an indication of the accuracy of a 
model’s prediction. An empirical model aims to quantitatively take account of the 
different results that are expected from the system’s observed behaviour. However, 
the accuracy is heavily compromised if the quality of sample data used to build the 
model is not representative of the process being modelled. This is one of the 
biggest pitfalls of the empirical approach to modelling a process. The Lyman-
Kutcher-Burman (LKB) model that predicts normal tissue complication probability is 
an example of an empirical model (refer section 2.4).  
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1.9 Thesis Outline 
The primary aim of this research is the individualisation of radiotherapy treatment 
using radiobiological models to optimize treatment dose, no. of fractions and 
individual treatment plans. The available patient-specific clinical data are 
categorised below following West & Barnett (2011). All the possible patient-specific 
information below could be explored to design treatments on a patient-specific 
basis.  
Category  Patient Specific Information 
Tumour  Type, stage (tumour, node, metastases (TNM)), pathology, volume 
Patient Age, smoking history, alcohol use, ethnicity, weight, height, breast 
volume for breast patients (cup size), co-morbidity (for example, 
diabetes, collagen vascular disease, hypertension, inflammatory 
bowel disease) 
Treatment  Total dose, number of fractions, dose per fraction, overall treatment 
time, use of chemotherapy, use of hormone therapy, use of surgery 
and postoperative complications, concurrent medications (for 
example, statins) 
Physics  Total radiation dose, dose per fraction, overall treatment time, 
planned dose distributions to critical normal tissues 
Toxicity  Pre-treatment data, toxicity data collection at the end of treatment, 
post 6 months and then yearly.  
This work is concerned with radiotherapy and the use of radiobiological models of 
TCP and NTCP to optimize and individualize radiotherapy treatment response using 
patient-specific DVH datasets. The aim is to answer some of the below-listed 
questions from this research thesis. 
➢ How can treatment optimization and individualisation be performed using 
the mathematical modelling process?  
➢ What are the potential clinical benefits and or risks of applying treatment 
optimization based on radiobiological models?  
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This is undertaken by developing and applying a methodology to quantify the 
predicted improvement in clinical outcomes that is possible by individualizing 
radiotherapy treatments using mathematical radiobiological models. 
So far radiotherapy and associated concepts have been introduced. Chapter two 
describes the radiobiological models employed in this work.  A broad overview is 
given of the publications on different types of TCP and NTCP models. Treatment 
options for lung and prostate tumours are then described. After this, published 
papers that entail the clinical use of radiobiology are briefly discussed. Then, various 
dose-escalation and optimization strategies with or without the use of 
radiobiological modelling are presented. The literature associated with all the 
respective chapters is then presented section-wise. Lastly, inverse planning is 
discussed with respect to the use of radiobiological models; this is relevant to the 
research described in chapter five.  
Chapter three presents the results of implementing three different radiotherapy 
treatment optimization and individualization methods on two different patient 
cohorts, one of prostate tumours and one of lung tumours. Nahum & Uzan (2012) 
gave an overview of radiobiological-model based dose optimization in radiotherapy 
treatment planning. They introduced different levels of dose optimization. These 
optimization concepts are implemented for the two above-mentioned tumour types 
using an in-house MATLAB-based software with results presented in the form of 
novel population strategy assessment plots (with TCP vs NTCP curves).  
Chapter four explores how incorporating tumour radio-sensitivity information might 
impact treatment planning strategies. It is assumed that there is a method to 
stratify patients into different groups based on the radio-sensitivity of their 
tumours. A radiosensitivity assay or a biopsy could be one example or let us say the 
patient has been given medication that as a side-effect increases or decreases 
tumour radio-sensitivity as a part of combination therapy. Here, a technique that 
will help quantify the effect of this patient-specific radiosensitivity knowledge and 
show the potential benefit of using this knowledge via predictions of tumour 
control / normal tissue complication probability for a given cohort of patients is 
developed.  
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Chapter five describes the use of radiobiological models in the inverse treatment-
planning phase. Chapter six describes the NTCP-based conversion of dose-based 
normal-tissue treatment planning constraints (V20, V35,…, Vxx) for a given 
dose/fractionation scheme to a different dose/fractionation scheme. Currently, the 
prescribed dose is converted to alternate fractionation schemes using the Withers’ 
Iso-effect formula (Withers et al., 1983). This, however, does not help clinicians 
understand the relative effect of the change in prescription of the doses received by 
the normal tissues. A radiobiological model based Iso-toxic dose fractionation 
conversion scheme is thus developed to allow conversion of a given Vxx for a given 
dose fractionation scheme to an effective Vxx for a desired or proposed dose 
fractionation scheme. Further, details of the clinical usefulness of this technique are 
demonstrated for Lung and Prostate tumour cases. 
Chapters three to six have a structure and each have an introduction, methodology, 
results, discussion and a conclusion section. Chapter 7 summarizes each of the 
chapters and reflects on the results of each of the chapters drawing conclusions 
from this research work.  
 
 
 
 
 
 
 
 
2  
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Chapter 2 Overview of Radiobiological 
Modelling 
2.1 Introduction 
In this chapter, a detailed description of the mathematical models (used in this 
thesis) applied to radiobiology associated with tumours and normal tissues is 
provided. Current clinical practice in radiotherapy for lung and prostate tumour 
treatments is then described including a brief history of these treatments. The 
background literature relevant to the topics of subsequent chapters is then 
presented; this will emphasize the novelty of the presented approach compared to 
current practice (clinical or research) in the area.  
2.1.1 The Linear Quadratic model for cell survival 
Figure 1-5 in chapter 1 shows cell-survival data for a population of different cell-
lines. These data are fitted with an expression containing a quadratic function of 
absorbed dose as the exponent. The so-called linear-quadratic (LQ) equation fitted 
to the data is: 
                  Surviving Fraction SF= 𝒆−𝜶𝑫−𝜷𝑫
𝟐
                   Eqn. 2-1 
where,  
D is the radiation dose (Gy)  
α is a parameter that describes the initial slope (Gy-1)   
β describes the curvature of the survival curve on a semi-log plot 
The α-component relates to the direct radiation damage (‘one hit’ and irreparable) 
to cells also referred to as single-hit killing. The  component refers to cell killing 
which requires two sub-lethal events and is mostly DNA damage consisting of 
single-strand breaks, double strand breaks and base chain breaks (Chadwick et al., 
1973; Chapman, 2014).  The total dose, total treatment time and dose-rate have 
different effects on the tumour and the normal tissue reactions. These are 
described in the following sections of this chapter. Further, potentially important 
factors like clonogen repopulation and time-dependent sub-lethal damage repair 
have major implications on tumour control. As the overall treatment time increases, 
the tumour repopulates and the chances of tumour control diminish. Redistribution 
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and re-oxygenation work in favour of tumour control by increasing the sensitivity of 
a tumour to radiation damage. Looking at these from the normal-tissue point of 
view, a given dose of radiation is likely to produce α-inactivation dominant damage 
and fractionating enables more sub-lethal damage repair. The α/β ratio for a cell 
line is the dose at which the α-inactivation and β-inactivation are equal. The effect 
of different α/β ratios characterising the tissue response is shown in figure 2.1 by 
Mayles, Nahum, & Rosenwald (2007)16,17. 
 
The LQ expression can be written as 
               -ln(SF)= 𝜶𝑫 + 𝜷𝑫𝟐                                                  Eqn. 2-2 
Considering the effect of fractionation, the total prescribed dose D can be 
expressed as n equal-sized fractions of dose d; thus, - log (surviving fraction), E, can 
be written as 
                                               E= -loge(SF) = 𝒏 ∗ (𝜶𝒅 + 𝜷𝒅𝟐)                                    Eqn. 2-3 
Dividing both sides by  and recognising that n x d = D, yields 
                                                            
𝑬
𝜶
= 𝑫 {𝟏 +
𝜷
𝜶
𝒅 }                                                                Eqn. 2-4 
                                                          
16 See section 7.6 Chapter 7 Nahum & Mayles 
17 See section 9.3.2 Chapter 9 Nahum & Mayles 
Figure 2-1 Cell survival curve of early (high α/β ratio) and late responding tissue (low α/β ratio). A lower α/β 
ratio produces a relatively bendy curve - Mayles, Nahum, & Rosenwald (2007).  
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2.1.2 Biologically effective dose (BED) 
The linear quadratic model was first proposed by Chadwick et al. (1973), but it was 
the article by Fowler (1989) incorporating the overall treatment time factor in the 
LQ-equation and introducing the concept of BED (biologically effective dose), that 
was responsible for the renaissance in the use of mathematical models in the 
radiobiology of radiotherapy.   
Fowler (1989) coined  
𝐸
𝛼
 as the biologically effective dose (BED), which is radiation 
damage expressed as a function of total dose imparted. Thus, the total damage 
inflicted by a given prescription dose D in n fractions of size d is given by  
    𝑹𝒆𝒍𝒂𝒕𝒊𝒗𝒆 𝑬𝒇𝒇𝒆𝒄𝒕𝒊𝒗𝒆𝒏𝒆𝒔𝒔 (𝑹𝑬) =  {𝟏 +
𝜷
𝜶
𝒅 } 
where                                                   𝑩𝑬𝑫 = 𝑫 𝒙 𝑹𝑬                                                Eqn. 2-5 
Assuming now that there is a new fractionation regimen which yields the same 
biological damage, this new regimen will have the same BED as the reference 
regimen.  
So, assume that the standard fractionation schedule has prescription dose Dstd and 
the new prescription dose is Dnew which produces an equal biological effect. Then it 
is required that  
            BEDref = BEDnew 
       Dref{1+(
𝛃
𝛂
)dref} = Dnew{1+(
𝜷
𝜶
)dnew}                          Eqn. 2-6 
Rearranging eqn. 2-6 it is obtained,  
                                                 
𝑫𝒏𝒆𝒘
𝑫𝒓𝒆𝒇
=  
{𝟏+(
𝛃
𝛂
)𝒅𝒓𝒆𝒇} 
{𝟏+(
𝛃
𝛂
)𝒅𝐧𝐞𝐰} 
                   Eqn. 2-7 
This is the Iso-effect relationship initially developed and proposed by Withers et al. 
(1983). It is worth noting that delivering total dose D in many small fractions will 
allow clonogenic repopulation in a tumour (after approximately 3 weeks of 
radiotherapy in a lung tumour) which is not accounted for by the above formula.  
This was accounted for by Fowler (1989) as he factored delay in tumour 
repopulation and the tumour doubling time into the BED equation as shown below: 
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𝑬
𝜶
= 𝑫 {𝟏 +
𝜷
𝜶
𝒅 } − (𝒍𝒐𝒈𝒆𝟐 ∗ (𝑻 − 𝑻𝒌)/𝜶𝑻𝒅)                        Eqn. 2-8 
 
where D = n x d   
n= no. of fraction  d= fractional dose  D= Total dose T=Total treatment time 
Tk=Time to onset of repopulation Td= Tumour doubling time 
 
2.2 Radiobiological Modelling 
In this section, the basics of radiation-effect modelling in tumours and normal 
tissues are covered. The advantages and assumptions made in different published 
models are also presented. The models used here are of empirical and mechanistic 
types characterizing radiation biology.  
Chadwick and Leenhouts (1981) explain radiobiological modelling and associated 
caveats very efficiently as:  
“Any model is an attempt to generalize a series of experimental observations and 
therefore aims to reduce and simplify the parameters which describe the 
experimental data. In radiation biology, a model should have a basic simplicity 
which permits it to include many different physical, chemical and biological 
processes which may influence the biological effect. Ideally, the model should be 
capable of extensions to the description of more than one biological endpoint. At 
the same time, the restrictions and limitations in the validity of the model should be 
well delineated so that the area within which the predictive potential of the model 
is applicable is well defined.” 
Dale & Jones (2007) mention that a successful biological model needs to be able to 
produce results that agree with both clinical & experimental data.  
Radiobiological models are useful in radiation therapy for the following reasons18: 
• To compare different treatment plans. 
• To modify prescriptions to compensate for gaps in the treatment (Dale & 
Jones, 2007). 
                                                          
18 This list is not exhaustive. 
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• To compare the biological effects of different treatment schedules (Fowler, 
1989). 
• To predict TCP and NTCP effects of different types of particles and energies 
(photon vs proton treatments) for a given cohort (Fowler, 2010). 
• To design clinical trials with supporting evidence for a given hypothesis 
(Fowler, 2010). 
• To individualize and improve treatment strategies (Hoffmann et al., 2013; 
Nahum & Uzan, 2012). 
2.2.1 Basic assumptions about the models used in this research work 
• Cell survival after radiation exposure is binomial and follows Poisson 
statistics. This is applicable to the Marsden TCP model described in the 
next section. 
• Intra-OAR / Intra-Tumour radiosensitivity is constant. 
• Complete sub-lethal damage repair between fractions for a given OAR & 
tumour.  
The assumptions listed above are non-exhaustive in relation to radiobiological 
models but are taken into consideration to maintain the simplicity of these models 
(not developed as part of this research work). There are many known effects (e.g. 
hypoxia) that have an overall effect on model predictions which could be modelled 
for a given tumour type, but the inclusion of this would complicate the model. The 
availability of model parameters that account for such effects is limited which 
dictates the use of available set of model parameters with given assumptions. Also, 
some of the assumptions are based on the results of radiobiological studies on cell-
lines or animal tumour models. It is acknowledged that these assumptions 
contribute to the uncertainties associated with model predictions and necessitates 
qualification of model predictions against clinical response data.    
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2.3 The Marsden TCP model 
Clinical dose-response curves are found to have an approximately sigmoid shape. 
There have been attempts to fit functions to this curve shape to construct a model 
of tumour response (Carlone et al., 2006; Källman, Ågren, & Brahme, 1992; Walker 
& Suit, 1981) but it is not obvious how tumour-to-tumour variations in clonogenic 
cell density, dose distribution inhomogeneity, radiosensitivity and volume can be 
considered using a curve-fitting approach. Carlone et al.(2006) attempted to 
simplify the 8 parameter TCP equation into a 4-parameter based sigmoidal function 
built on D50 (Dose achieving 50% TCP), γ50 (Slope of the TCP dose response curve), 
heterogeneity in clonogen number and generalized radiosensitivity (fig. 2-2). They 
concluded that the 
dose response 
curves of TCP can be 
built based on D50 
and γ50 but would 
yield limited 
information in 
explaining the 
radiobiology of 
tumour control and 
absolute values of 
radiobiological 
parameters will 
need other physical 
measurements. An alternative is the mechanistic approach that may be able to take 
into account the above variations. A mechanistic model was proposed by Nahum & 
Tait (1992) which was further developed by Webb & Nahum (1993) and is 
commonly known as the Marsden model (Nahum & Sanchez-Nieto, 2001; Sanchez-
Nieto & Nahum, 1999; Webb & Nahum, 1993). The Marsden model is used for 
analysis in this work and is discussed in detail below. 
Figure 2-2 The eight parameter TCP model theorised by Carlone et al. (2006) 
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Following from equations 2-3 and 2-8, 
Let Rpop= (𝑙𝑛2(𝑇 − 𝑇𝑘)/𝜶𝑇𝑑) be the repopulation term in the surviving fraction 
equation 2.8 
 
𝑬 = 𝒆−𝜶𝑫 {𝟏+
𝜷
𝜶
𝒅 }+𝑹𝒑𝒐𝒑                                       Eqn. 2-9 
Let us assume that the number of (tumour clonogenic) cells before irradiation is No 
and the number that survives after total dose D in n equal fractions of dose d is N ; 
the surviving fraction will be given by  
    
𝑵
𝑵𝒐
= 𝒆−𝜶𝑫 {𝟏+
𝜷
𝜶
𝒅 }+𝑹𝒑𝒐𝒑                   Eqn. 2-10 
For any tumour to be ’controlled’, all the clonogens (aka stem cells) must be 
eradicated. Applying Poisson statistics, the probability of the number of surviving 
cells being zero if the average number of cells surviving is N, is given by  
                                       P (N,0) = 𝒆−𝑵          Eqn. 2-11 
Thus, the probability of controlling the tumour (TCP) is given by,  
TCP = 𝒆(−𝑵𝟎(𝒆(−𝛂𝑫{𝟏+ (
𝜷
𝜶
)𝒅}+𝑹𝒑𝒐𝒑)))      Eqn. 2-12 
This is the basic form of the model; it does not yet incorporate dose inhomogeneity, 
inter-patient radiosensitivity variation or clonogenic cell density.  
N0 being the initial clonogen number is equated to density of clonogenic cells (ρ) 
multiplied by volume (V) of the GTV giving, 
TCP = 𝒆(−𝛒𝑽(𝒆(−𝛂𝑫{𝟏+ (
𝜷
𝜶
)𝒅}+𝑹𝒑𝒐𝒑)))                   Eqn. 2-13 
The radiosensitivity of tumour clonogens in the patient population (or a 
representative sample) is assumed to follow a Gaussian (or ‘normal’) distribution 
with a mean (ᾱ) and a standard deviation (σα). The TCP value is an average of 
TCPα=1….i  with radiosensitivity (αi) over a population: 
              TCPpop = (g1TCPα1 + g2TCPα2 + g3TCPα3……………………gnTCPαn)                 Eqn. 2-14 
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where the weighting factors gi are calculated from the above-described Gaussian 
distribution such that gi 
Considering that the normally distributed patient population has a given number (g) 
of patients with radiosensitivity αi, then  
gi ∝ [𝒆(−(𝛂𝒊− ᾱ)
𝟐/𝟐𝛔𝛂
𝟐)]                       Eqn. 2-15 
The β sensitivity could also be represented as an independent gaussian distribution. 
However, Chapman (2003) suggests that -inactivation is the dominant effect 
causing cell inactivation for a clinical dose fraction >3 Gy, thereby variation in β is 
assumed to be causing no effect except for very large fractions. In practice ,the ratio 
 is kept constant. As per Chapman (2014) and Nahum et al. (2015) the quadratic 
component of the LQ based double hit cell killing will become significant at a higher 
dose. At high dose/fractions, the total dose required to achieve the equivalent 
biological effect as produced by a conventional or a low dose/fraction (say 2 
Gy/fraction) regimen will be thus lower. This is demonstrated in figure 2-3 for 
tissues of varying α/β. The effect of hypofractionation is larger in tissues with lower 
α/β compared to tissues with higher α/β. 
The Dose-Volume-Histogram (DVH) computed by a treatment planning system is a 
2-dimensional (2D) histogram (frequency distribution) of volume vs dose in a given 
delineated organ. Up to this point, the expression for TCP has assumed that the 
Figure 2-3 The figure shows the effect of fractionation for achieving a given iso-effect for tissues with different α/β 
values – Chapter 7, Mayles, Nahum & Rosenwald (2007) 
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dose is constant (or uniform) across the entire tumour (target) volume. However, 
using DVHs as the input to the TCP model, the inhomogeneity in the dose 
distribution can be taken into account. 
The DVH has dose bins and corresponding volumes that receive a dose in that bin. A 
TCP calculation for each dose bin (Bin Control Probability - BCP) considering the 
corresponding volume associated with the bin and taking a normalized value of the 
results should give the tumour control probability for the patient.  
        TCP= ∏ (BCPi)                                                          Eqn. 2-16 
The final formulation of TCP calculation that includes accounting for repopulation 
effect, inhomogeneity in dose distribution, and radiosensitivity variation across the 
population is given by the equation below from (Mayles et al., 200719): 
 𝑇𝐶𝑃 =  
1
𝜎𝛼√(2𝜋)
∫ (∏ 𝑒
[−𝜌𝑐𝑙𝑉𝑖∗𝑒
{−(𝛼𝐷𝑖(1+
𝛽
𝛼
𝑑𝑖)−(𝑙𝑛2(𝑇−𝑇𝑘)/𝛼𝑇𝑑))}]
𝑖
) ∗ 𝑒[−(𝛼− ᾱ)
2/2σα
2]𝑑𝛼
∞
0
 
          
                                       Eqn. 2-17 
2.3.1 Other Tumour Control Probability Models 
Zaider & Minerbo (2000) developed a TCP model based on the stochastic process of 
birth & death of a cell. Their model accounted for exponential tumour proliferation 
and regrowth between fractions. Their model was extended by Dawson & Hillen 
(2006) to incorporate cell cycle dynamics. Cells in the G0-phase of mitosis are radio-
resistant compared to the same cell in G1, G2, S or M-phase. Thus, Dawson & Hillen 
(2006) split the cell proliferation into two compartments (active and quiescent) 
accounting for repopulation in a more specific manner. This method of 
incorporating the biological process governing cells’ response to radiation exposure 
is quite complex (Dawson & Hillen, 2006; Zaider & Minerbo, 2000). O’Rourke et al. 
(2009) give a very good account of the application of different TCP models to 
radiotherapy critically assessing the benefits and pitfalls of the different models.      
                                                          
19 See section 36.2.14 Chapter 36, Mayles, Nahum & Rosenwald (2007) 
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2.4 Lyman-Kutcher-Burman (LKB) NTCP Model 
The LKB and Relative Seriality NTCP models (Lyman, 1985; Källman et al.,1992) are 
the most frequently employed models for predicting radiotherapy complications. 
The LKB model is represented by an error function and estimates complication 
probability considering the volume of the tissue and the dose. The best-fit 
parameters for each complication are derived using published outcome data. The 
model is based on three parameters: TD50, the (uniform) dose for which the chances 
of a given complication are 50% (assuming that this dose covers 100% of the normal 
tissue volume, sometimes written as TD50(1)), n is the ‘volume effect’ parameter 
and m is related to the slope of the NTCP vs dose curve (‘volume effect’ is explained 
at the end of the current section). 
The equations for the model are given below, 
𝑵𝑻𝑪𝑷 =
𝟏
√(𝟐𝝅)
∫ 𝒆
−
𝒕𝟐
𝟐 𝒅𝒕
𝒕
−∞
                         Eqn. 2-18 
    𝒕 =
𝑫𝒆𝒇𝒇−𝑻𝑫
𝟓𝟎(
𝑽
𝑽𝒓𝒆𝒇
)
𝒎∗𝑻𝑫
𝟓𝟎(
𝑽
𝑽𝒓𝒆𝒇
)
                          Eqn. 2-19 
 𝑻𝑫𝟓𝟎(𝟏) = 𝑻𝑫𝟓𝟎( 𝑽
𝑽𝒓𝒆𝒇
)
∗ (
𝑽
𝑽𝒓𝒆𝒇
)𝒏                     Eqn. 2-20 
The above equations assume a homogenous dose distribution. The DVH must be 
corrected for fractionation which is described in the next section. To account for in-
homogenous dose distribution, the effective volume method proposed by Kutcher 
et al. (1989) is implemented. The correction method converts the non-uniform DVH 
into a uniform one with an effective volume (Veff) that will result in the same 
biological effect as the non-uniform DVH in a given tissue (Niemierko, 1997). 
      𝑽𝒆𝒇𝒇 = ∑ ∆𝑽𝒊 ∗ ⌊
𝑫𝒊
𝑫𝒎𝒂𝒙
⌋
𝟏/𝒏
𝒌
𝒊=𝟏                                                                         Eqn. 2-21 
i=1 to k represents the number of the bin in the differential DVH.              From Mayles, Nahum & Rosenwald (2007)20 
                                                          
20 See section 36.3.2.2 Chapter 36, Mayles, Nahum & Rosenwald (2007) 
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It is possible to use any effective volume or dose from a family of equivalent 
uniform DVHs defined by the power-law relationship. Thus, an effective dose Deff 
(also known as EUD) applied to the whole organ (VT) is used which gives the same 
NTCP.  
                    𝑫𝒆𝒇𝒇 = ∑ ⌊𝑫𝒊
𝟏
𝒏 ∗
𝑽𝒊
𝑽𝑻
⌋
𝒏
𝒊                                                Eqn. 2-22 
Figure 2-4 shows the recommended predictive dosimetric and NTCP model parameters reported by various 
studies.  
This transformation is based on the assumption that the whole organ has a 
homogeneous response to radiation and obeys the power-law relation. Also, small 
values of n will mean that volumes at lower doses will contribute less to the 
effective volume making the effective dose more or less equal to the maximum 
dose. If n=1, the effective dose will be equal to the mean dose.  
When n is close to 1, the normal tissue behaves like a ‘parallel’ organ with mean 
dose governing the complication probability (i.e. lung, liver); when n is really small 
38 | P a g e  
 
(<=0.1), the organ behaves as a ‘serial’ organ with the maximum dose determining 
the complication probability (e.g. spinal cord).  
The LKB NTCP model has been used extensively in the analysis of radiotherapy 
outcome data and model parameters for various organs have been reported 
regularly in the literature (Emami et al., 1991; Marks, Yorke, et al., 2010; 
Seppenwoolde et al., 2003).  A copy of the table of parameters published for 
pericarditis complication NTCP model and dosimetric predictive parameters is given 
in Figure 2-4 from Gagliardi et al. (2010). 
2.4.1 Relative Seriality NTCP model 
Proposed by Källman et al. (1992), this NTCP model is a quasi-mechanistic model 
that takes account of normal-tissue architecture. The model involves the concept of 
functional subunits (FSUs) that contribute to the overall function of the organ. The 
serial or parallel arrangement of the FSUs define the response of the organ which is 
described by parameter ‘s - relative seriality’ in the equation below. The model also 
accounts for non-uniform dose distribution and is completely defined by parameters 
TD50, s, and γ. 
             𝑷(𝑫𝒕𝒐𝒕) = 𝟐
−𝒆
[𝒆𝜸(𝟏−
𝑫𝒕𝒐𝒕
𝑻𝑫𝟓𝟎
)]
                       Eqn. 2-23 
P(Dtot) = probability of no cell surviving  
γ= normalised dose response gradient        
TD50= Dose causing 50% response rate 
 
 
                     𝑵𝑻𝑪𝑷 = [𝟏 − ∏ [𝟏 − 𝑷(𝑫𝒊)
𝒔]∆𝑽𝒊𝑴𝒊=𝟏 ]
𝟏
𝒔⁄
         Eqn. 2-24 
where ΔVi is the fractional volume at doses Di from the bins of a differential DVH  
2.5 Fraction size effect correction in NTCP models 
The LKB NTCP model described above takes into account inhomogeneous dose 
distributions and the ‘organ architecture’ (via the volume parameter). However, it 
does not explicitly correct for fraction size. In other words, differences in fraction 
size, for a given total dose (distribution) will have no effect on NTCP prediction 
(using Eqn. 2-18 to 2-20) which is obviously incorrect. The parameters predicted for 
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the quasi-empirical LKB model are mostly based on data of treatments with 1.8-2 
Gy (tumour) fraction sizes.  
Thus, Fowler in (2001) proposed using the linear quadratic formulae to correct the 
DVH for fractionation effect. The dose bins in the DVHs are corrected to be 2-Gy 
equivalent. These fractionation-corrected DVHs are then used to evaluate NTCP. 
The formula for correcting the dose bins is given below. Fig 2-5 shows the effect of 
using the linear-quadratic fraction-size correction where the overestimation of 
volumes below 2 Gy fraction size (~60Gy) and under-estimation above this size is 
corrected.          
                                              𝑬𝑸𝑫𝟐 =  𝑫𝒕𝒐𝒕,𝒋 [
𝜶
𝜷
+𝒅𝒋
𝜶
𝜷
+𝟐
]                                                      Eqn. 2-25 
where Dtot,j = DVH Bin dose     
dj=the fraction size of the proposed regimen   
α/β= Normal Tissue α/β ratio21 
Figure 2-5 EQD2 conversion of a conformal plan based cumulative DVH of the lung to 2 Gy per fraction 
equivalent DVH (α/β=3.3 Gy, 60 Gy prescription dose). All volumes at doses below the total dose at which the 
fraction size is 2 Gy (~60 Gy in this case) are shifted to lower LQED2 doses, and all volumes above this 
(prescription) dose are shifted to higher EQD2 doses - Mayles, Nahum & Rosenwald (2007).  
The effect of this correction on the NTCP calculations has been described in Mayles 
et al. (2007) by a simple exercise. For a given DVH of rectum OAR of a patient 
prescribed with 74 Gy prescription dose, the NTCP is calculated after varying 
                                                          
21 See section 36.3.4 Chapter 36 Nahum & Mayles 
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fraction from 1.6Gy to 5.9Gy keeping the total OAR dose Iso-effective. As the dose is 
Iso-effective, the change in NTCP should ideally be zero or negligible.  
However, without any DVH dose correction, the NTCP varies from 15.7% and 0.1%.; 
which is incorrect. Using the LQED based DVH dose correction as shown in equation 
2-25, NTCP variation is minimized (7.3% to 8%) for the range of Iso-effective dose 
calculated for different fraction sizes. The effect of such correction on a DVH is 
shown in figure 2-5 
2.6 Clinical Radiotherapy Practice 
2.6.1 Radiotherapy for Lung Tumour Treatment 
Currently, radiotherapy remains the only option of treatment for inoperable 
advance stage NSCLC. The 5-year survival is less than 10% with local relapse being 
the major cause of mortality (Cox et al., 1991; CTCA, 2015; Perez et al., 1987; 
Saunders et al., 1997, 1999).  
At the time of writing, two radiotherapy regimens were in common use for treating 
NSCLC across different centres in the UK (1,2 below): 
As per NICE guidelines “Patients with stages IIIA or IIIB NSCLC who are eligible for 
radical radiotherapy and who cannot tolerate or do not wish to have 
chemoradiotherapy should be offered the CHART regimen. If CHART is not available, 
conventionally fractionated radiotherapy to a dose of 64–66 Gy in 32–33 fractions 
over 6 1/2 weeks or 55 Gy in 20 fractions over 4 weeks should be offered.” (NICE 
Guideline Lung cancer: diagnosis and management, 2011). 
The SOCCAR trial (Maguire et al., 2014) assessed tolerability of concurrent & 
sequential chemotherapy with radiotherapy (55 Gy in 20#) in stage III inoperable 
NSCLC patients and concluded that accelerated hypofractionated radiotherapy was 
a feasible (2 year OS 46% sequential arm & 50% concurrent arm) and well-tolerated 
approach (grade 3 oesophagitis - 8.5-8.8% in both the arms) that should be 
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compared with standard 2 Gy/fraction NSCLC radiotherapy treatment (Kaster et al., 
2015; Schuster-Uitterhoeve et al., 1990; Williams et al., 2006) 
The CHART Trial delivered continuous, hyper-fractionated, accelerated 
radiotherapy; a 54Gy radiation dose was delivered in 36 fractions over a period of 
only 12 days, thus 3 fractions a day with 6 hours between fractions. The CHART 
regimen showed a 22% reduction in mortality, improving the 2-year survival from 
20% to 29% compared to conventional radiotherapy (60 Gy in 30 fractions) in the 
randomised trial for NSCLC radiotherapy treatments (Saunders et al., 1997, 1999).  
RTOG 9410 was a randomised phase III multi-centre trial comparing concurrent 
chemotherapy (cisplatin-based treatment) plus radiotherapy with radiotherapy 
alone. The radiotherapy treatment was 1.8-2 Gy/fraction in arm 1,2 and 1.2 Gy 
twice daily fractions in arm 3. After a mean follow up time of 11 years, it was 
reported that concurrent chemo-radio-therapy improved 5-year survival rates 
compared to radiotherapy alone or to sequential chemo-radiotherapy and also 
reported that late toxicities were similar in all arms (Curran et al., 2011; Fournel, 
2011).   RTOG 0617 trial compared 60Gy in 30 fractions concurrent chemotherapy 
(paclitaxel and carboplatin) treatment with 74Gy in 37 fractions concurrent. The 
escalated dose arm had poorer overall survival compared to the standard arm.  
2.6.2 Radiotherapy for Prostate Tumour Treatment 
The broad categories of treatment regimens are hyperfractionated, conventional 
and hypofractionated radiotherapy. The most recent publication by Dearnaley & 
Hall (2017) shows that there is good evidence based on recently concluded trials’ 
(like CHHiP, HYPRO) results that α/β for the prostate tumour is less than 3 Gy. The 
software built for chapter 3 allows comparative analysis of different types of 
regimen for a given cohort considering different values of α/β for the prostate 
tumour.  
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1) Conventional regimens 
74 Gy in 37 fractions is a regimen mostly adopted in the UK to treat prostate cancer 
until recently (NICE, 2014). There have been a number of clinical trials that looked 
into benefits of dose escalation. The trials from MD Anderson, USA; the Royal 
Marsden, London and a Dutch institute compared conventional 2 Gy per fraction 
treatments of escalated dose regimens (70-78 Gy in 35-39 fractions) with standard 
regimens (Dearnaley et al., 2005; Peeters et al., 2005; Pollack et al., 2002; Zietman 
et al., 2005). Late rectal and bowel complications increased following the dose 
escalation with minimal improvement in overall failure-free survival over 3-6 years. 
Long term results of the RT01 trial show that escalated dose group had better 10-
year biochemical progression free survival (55% in 74Gy 34# group) versus the 
control arm (43% in 64Gy in 32 fractions) as per Dearnaley et al.,(2014). 
2) Hypofractionated regimens 
Hypofractionated versus conventional radiotherapy of prostate cancer has been 
trialled; the results are summarised below. One of the trials used 55 Gy in 20 
fractions (Yeoh et al. 2003), and the other used 52.5 Gy in 20 fractions (Lukka et al., 
2005) versus 64Gy and 66Gy total dose regimens (delivered as 2 Gy/fraction). Lukka 
(2005) study reported lower 5-year freedom from biochemical failure with 
hypofractionation. However, the Yeoh (2003) study reported a higher biochemical 
relapse-free survival at 4 years for the hypofractionated group concluding that 
hypofractionated radiotherapy for prostate was equally effective and well tolerated 
compared to conventional regimens.  Recently, the CHIPP & PROFIT trials 
completed recruitment of over 4000 patients comparing 2 Gy per fraction regimens 
(Total dose 74-78 Gy) with 3 Gy per fraction regimens (total dose 57-60 Gy). 
Dearnaley & Hall (2017) report non-inferiority of the 60Gy in 20 fraction regimen 
over the conventional 74Gy in 37 fraction regimen. They also recommend 
establishing 60 Gy in 20 fractions as the new standard of care regimen as this would 
reduce the overall treatment time for patients and aid resource utilization. The 
Christie hospital in Manchester has reported a biochemical-free survival (bNED) at 5 
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years of 65% (T1), 62% (T2) and 38% (T3/4)22 compared to other protracted 
treatment schemes (Livsey et al., 2003). Another trial looking at hypofractionated 
regimens was reported by Norkus et al. (2013) where they compared 76 Gy in 38 
fractions to 63 Gy in 20 fractions. The reports indicated that hypofractionated 
treatment was well tolerated and the overall toxicity of gastrointestinal and 
gastrourinary types were the same (Dearnaley & Hall, 2017).  
3) Hyperfractionated regimens 
Very few studies have reported using hyperfractionation in prostate radiotherapy 
treatments (67-83Gy dose in 1.2-1.5 b.i.d 23 schedules). The conclusion drawn from 
those studies suggests that compared to conventional regimens, hyperfractionation 
regimens reduce late genitourinary complications with no major improvement in GI 
toxicity (Forman et al., 1996; Valdagni et al., 2005). Forman et al. (1996) conducted 
a study comparing conventional 2 Gy fractionation (78 Gy prescription dose and 
n=24) with a (Iso-effective adjusted dose) hyperfractionated regimen (82.8 Gy 
prescription 1.15 b.i.d and n=25) for a cohort of total 49 advanced stage prostate 
cancer patients. They concluded that hyperfractionation allowed for safe dose 
escalation and histologic control was markedly improved in hyperfractionation over 
a follow up period of 20 months. Valdagni et al. (2005) compared standard 74 Gy in 
37 fraction regimen (n=209) to radiobiologically adjusted Iso-effective 
hyperfractionated regimen (1.2 Gy b.i.d for 162 patients prescribed a median EQD2 
dose of 73.9 Gy) in a prostate cancer treatment study. The biochemical recurrence-
free survival (bRFS) for hyperfractionated regimen was reported to be no less 
effective than the standard regimen. Also, based on a median follow up of 29.4 
months the authors concluded that α/β for the prostate tumour was close to 10 Gy 
and their results were not consistent with the low value of α/β reported by other 
groups. Currently, there is rather strong evidence from analysis of CHHiP and 
PROFIT Trial results indicating that α/β for the prostate tumour is low (1.3 Gy based 
on PROFIT Trial results and 1.8 Gy from CHHIP trial results -- (Dearnaley & Hall, 
                                                          
22 T1-4 corresponds to TNM disease staging for prostate tumour as defined by American Society for Therapeutic 
Radiology and Oncology (http://www.cancer.org/cancer/prostatecancer/detailedguide/prostate-cancer-staging)  
23 b.i.d - "bis in diem" – Twice a day 
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2017) and that hypofractionation is therapeutically equally effective compared to a 
conventional 2 Gy regimen.  
2.6.3 Use of radiobiological modelling in Clinical Practice 
Radiobiological metrics like BED, EUD, TCP, NTCP and P+ (Probability of 
complication free survival) have played a minor role in clinical practice for many 
years.  Applications of radiobiological models in radiotherapy are summarised 
below.  
One of these is to convert between dose fractionation schemes keeping the 
biological effect on tumours and normal tissues constant (Jones & Dale, 2000). 
Radiobiological modelling is also used to (via the use of the BED concept) correct 
prescription doses for gaps in treatments or schedule alteration due to unforeseen 
circumstances (RCR, 2008). 
Radiobiological model-based metrics have also been used to compare treatment 
modalities or strategies for a given tumour type. Comparison of 3D CRT and IMRT 
(using NTCP metric) has been reported by many groups demonstrating the superior 
OAR sparing capability offered by IMRT (De La Fuente Herman et al., 2010; Deb & 
Fielding, 2009; Luxton 2004) based on a comparison of radiobiological and 
dosimetric metrics. De La Fuente Herman et al. (2010) compare 10 Head & Neck 
Glioblastoma 3D CRT plans to IMRT plans using LQ based TCP model by Niemierko & 
Goitein (1993) and the LKB NTCP model-based on parameters published by Burman 
et al. (1991). They demonstrate that the variability in TCP for both the treatment 
methods was nominal and that the average NTCP for the IMRT plans was lower by 
7% in the escalated dose cohort. Deb & Fielding (2009) use the Kallman TCP model 
to calculate TCP, the relative seriality model to calculate NTCP and the P+ metric to 
show that the IMRT plans are superior to 3D CRT plans for a single prostate patient 
CT structure set. They used the radiobiological evaluation module of Pinnacle (v7.6) 
software to undertake the analysis. The parameters used for radiobiological models 
were obtained from the Pinnacle treatment planning system database and were 
assumed to be based on published data by the same authors. The analysis is based 
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on data from one single patient and lacks any form of validation of model 
parameters. Koontz et al. (2009) reported no difference in gains in NTCP when 
comparing 3D CRT plans versus IMRT plans developed for 15 post-prostatectomy 
radiation treatment patients. Although dose sparing was observed for both rectum 
and bladder, the difference in NTCP values was very small (Koontz et al., 2009). 
Chatterjee et al. (2011) compared helical tomotherapy, forward planned IMRT and 
two-phase conformal treatment plans for 5 head & neck squamous cell cancer 
patients using a combination of dosimetric and radiobiological metrics (TCP & NTCP 
using BIOPlan software by Sanchez-Nieto & Nahum, 2000). They present qualitative 
and quantitative evidence supporting the superiority of helical tomography 
compared to forward planned IMRT. There have been other instances where 
radiobiological metrics have been used to compare forward versus inverse IMRT 
(Ferreira et al., 2010), Low dose rate brachytherapy versus High dose rate 
brachytherapy (King, 2002) or effects of using different energies for a treatment (6 
MV compared to 15 MV (Hussein et al., 2012). All these studies are retrospective 
and demonstrate the usability of radiobiological models for the purpose of 
comparative analysis.  
None of the studies have undertaken validation of model parameters but use 
model- based metrics in addition to dose-based metrics in their analyses. A 
combinational approach in the absence of resources to validate model parameters 
is not ideal but viable. The pitfall associated with comparative analysis using 
radiobiological metrics is that due to the high degree of uncertainty, exaggeration 
of results is possible. As an example, if one is calculating the TCP at two different 
doses say 78 Gy and 60 Gy for conventional 2 Gy fraction treatment plan for a given 
patient. It is likely that TCP of the plans will be higher/lower than the true TCPs 
resulting in the perceived difference to be more/less than expected between the 
plans. However, as long as the base assumptions about the model hold true (in 
relation to the tumour/OAR), the model is likely to provide the correct 
understanding of the trend when comparing different dose/fractionation schemes. 
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Another important use of radiobiological modelling as reported in the literature is 
to quantify setup errors and effects of organ movement management methods. 
Roland et al. (2009) use the LQ based TCP model described in Mavroidis et al. 
(2001) and relative seriality NTCP model to analyse the effect of undertaking 4D CT 
based treatment planning versus 3D CT based treatment planning. Their study 
based on 6 patient datasets concludes that 4D CT based planning does not provide 
additional benefit compared to 3D CT (static or gated) based treatment planning. 
The observed difference in the P+ metric was in the range of 1-3% with a large 
standard deviation. These radiobiological metric-based results were also in 
alignment with the dosimetric analysis of the plans reported by them and in line 
with other similar studies they quoted.  
Siochi et al., (2015) quantified the effects of tumour motion in terms of reduction in 
TCP. Their analysis over 5 NSCLC patient datasets showed that motion greater than 
5 mm resulted in TCP reduction of 1.7% up to 11.9%. They calculated TCP for all the 
plans using the Poisson TCP model and Logistic TCP model using 5 different 
parameters sets for each TCP model. The difference in TCP values as calculated by 
both the models  for different sets of parameters (Fitted over 1 and 2-year local 
progression-free survival data by Martel et al., 1999; Wilner et al., 2002; 
Guckenberger et al.,2009) was maximum 2% in 23 of 25 reported values. This shows 
good compliance between the two models. Partridge et al. (2009) have used the 
logistic TCP model to quantify the therapeutic gains of implementing active 
breathing control for an NSCLC cohort (n=28). Their method does not require an 
increase in normal lung dose to improve tumour dose and they also demonstrate 
the possibility of Iso-NTCP dose escalation (quantified using mean lung dose and 
TCP metrics). Many other post treatment  data analysis studies have been reported 
that use radiobiological metrics (TCP/NTCP/P+/EUD) to quantify the possible clinical 
gain of a proposed clinical methodology / update to treatment technique (Lee et al., 
2015; Mavroidis, 2013; Miller et al., 2009; Wang, 2010).  
Further use of radiobiological models has been to perform dose escalation and 
treatment strategy analysis. Fenwick et al., (2009) compared different NSCLC dose 
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escalation approaches prevalent in the UK using radiobiological models and 
concluded that the 30-month progression free survival could be improved by up to 
20% at safely deliverable escalated dose schedules. Nahum & Uzan (2012) 
introduced biological optimization that uses TCP & NTCP models in different ways 
to optimize a given treatment plan. The approaches they introduced start with 
retrospective optimization of clinical data and are later applied to pre-treatment 
phases. Also, they only account for a single principal OAR complication during the 
analysis whereas in reality there are likely to be more than one dose limiting OAR. 
There have been a handful of approaches where radiobiological models are used as 
a part of pre-treatment analysis. One of these approaches was shown by Syndikus 
et al. (2011) where they used radiobiological modelling based inverse treatment 
planning to form prostate RT plans to boost dose to the tumour keeping conditions 
Iso-toxic for the normal tissue. Further, the use of radiobiological model-based 
analysis has been reported by Ko et al. (2011) where the linear quadratic model has 
been used to assess the validity of the hypofractionation approach in treating 
prostate cancer. Geng et al. (2017) have recently developed a mathematical model 
that predicts the local response of tumour for combined chemo-radiotherapy of 
advanced NSCLC patients. They use the exponential Gompertz model to account for 
tumour growth along with the LQ model for radiation-based cell kill and log-cell kill 
model to account for chemotherapy-based cell kill. They validated their predictions 
for sequential, concurrent and radiotherapy only NSCLC clinical response data of 
RTOG 8808 and RTOG 9410 trials. The model predicts the data on which they are 
based very well, however, the performance of the model for hypo/hyper 
fractionated regimens is pending. Also, the data is fit to a limited set of outcome 
data which is not ideal.  
Above instances demonstrated the use of radiobiological models using 
retrospective data. A small number of commercial treatment planning systems now 
include radiobiological-model-based planning and / or plan assessment tools. These 
include systems by RaySearch®, Monaco® V1.0 (CMS/Elekta, Maryland Heights, 
MO), Research Pinnacle® V8.0h (Philips Medical Systems, Andover, MA), and Eclipse 
V10.0 Allen Li et al. (2012).  The effectiveness of such an approach has been 
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advocated by Syndikus et al. (2011) who employed radiobiological models as cost 
functions in inverse treatment planning. The results of the pilot study were recently 
reported by Onjukka et al. (2017) where they concluded that radiobiological 
optimization based hypofractionated dose-painting escalated radiotherapy (over 28 
prostate patients) results in plans with higher average PTV dose and the observed 
toxicity over median 38 months results in low  gastrointestinal and gastro-urinal 
toxicities (i.e. an acceptable safety profile). However, it is to be noted that the 
authors strictly recommend the use of online image guidance using fiducial markers 
to manage inter-fraction tumour motion and the use of MRI to target intra-prostatic 
boost region accurately. The same approach has been proposed by other users in 
the field previously (Semenenko et al., 2008; Tai et al., 2008; Zaider et al., 2005).  
Model-based metrics have been used in many ways as described in the previous 
paragraphs, however, these are only good if the parameters used to calculate such 
metrics are correct and validated. There has been a lot of literature published that 
gives an account of model parameters to be used for analysis purposes (Gagliardi et 
al., 2010; Gulliford et al., 2012; Marks et al., 2010; Michalski et al., 2010). The 
validity of the available model parameters and uncertainty associated with them is 
certainly up for debate, but it is aimed to address these in the discussion section of 
relevant chapters. One of the most comprehensively reviewed publications for this 
purpose is the Quantec 2010 (Jackson et al., 2010) review supplement that gives 
recommendations on the use of dosimetric constraints and NTCP model parameters 
for different OARs. Caution has been advocated in the literature about reliance on 
radiobiological models and the uncertainties associated with absolute model 
predictions (Marks et al., 2010; Wang, 2010). 
In recent years, radiobiological information is frequently used in designing clinical 
trials which form a relatively safe and established method of assessing/validating 
radiobiological assumptions about biological responses of a given cohort. The lack 
of robust model parameters and assumptions behind the underlying biological 
processes (where there are many unknowns) that govern the biological response 
contribute majorly to lack of confidence in the predictive power of models. The 
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reluctance in the clinical use of absolute predictions by radiobiological models is 
thus expected. The designing of the CHHiP trial based on the assumption that α/β 
for prostate tumour is lower than 3 Gy and its recently published results is a very 
good example of the above approach (Dearnaley & Hall, 2017).  In the subsequent 
chapters, the use of radiobiological models to optimize radiotherapy treatments 
over a cohort of prostate and lung patients is explored. The relevant literature in 
relation to each of the chapters is presented in the upcoming sections.  
2.7 Individualization and Optimization of Prescription Dose & Fractionation 
The conformity of dose to the respective tumour and OARs has improved 
significantly but the way dose is prescribed has remained the same: a “one size fits 
all” approach.  Section 2.6 reviews current clinical protocols that have been 
developed so far for the radiotherapy of non-small cell lung cancer and prostate 
cancer. As per the literature studies in the paper by Yaromina et al. (2012), many 
different factors lead to differences in the treatment response of a given patient. 
These factors, which have been studied extensively in the literature, include tumour 
re-oxygenation capacity, tumour hypoxia, tumour repopulation rate, radiosensitivity 
(an extensively studied parameter for major cancer types) of tumours & normal 
tissues and the number & density of stem cells in a tumour. Possible methods to 
individualize a treatment plan are enumerated below 
▪ The first step is the individualization of patients’ treatment plans; as 
accomplished in a study by van Baardwijk et al. (2012).  
▪ A second possibility is the use of biological information on patient-specific 
tissue (OAR/tumour) characteristics (like radiosensitivity) through cellular 
assays (biopsy) and hormone tests (indicating disease state) that are known 
to influence a patient’s response to a given treatment (West et al., 2014).  
▪ The third is incorporating patient-specific, non-invasive diagnostic functional 
information (Hypoxia / Angiogenesis) from PET / MRI scans that show 
regions of different physiological activity that could be targeted to improve 
local disease control (Alonzi, 2015).  
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▪ Fourth is using radiobiological models, assimilating the currently available 
information on the normal tissue & tumour characteristics (i.e. volume, 
density, best estimates of α/β and organ architecture) and individualising / 
boosting tumour prescription dose. This can be based on evidence from 
retrospective radiobiological analysis of treatment plans to individualize 
treatments (Onjukka et al., 2017).  
It is likely that a combination of the above mentioned methods can be used to 
individualize treatment plans (e.g. identification of hypoxic region using advanced 
imaging method - PET-boost trial - ClinicalTrials.gov Identifier: NCT01024829) and 
boosting the dose to the hypoxic region using an online adaptive or radiobiologically 
advanced treatment plan (Christodoulou et al., 2014).  
2.7.1 Biomarker based individualization approaches to optimize treatment 
The group of patients with tumour (or normal tissue) radiosensitivity far from the 
population mean may suffer the extreme effect of over / under dosage of radiation 
for a given dose of radiation. Various attempts to identify and utilize biomarkers to 
individualize treatments are presented below. 
Individualization of treatments has been advocated in a few publications with one 
of the early entries by Slevin et al. (1999) where they suggest individualization of 
radiotherapy prescriptions in head & neck tumours on the basis of histological 
grade as well as cell kinetics/loss/response indices. Mariano Ruiz de Almodóvar et 
al. (2002) reported the use of a DNA damage assay on lymphocytes to classify 
breast cancer patients on the basis of normal tissue radiosensitivity. They concluded 
that this DNA damage assay had a fair-poor discriminating capacity to classify 
patients that have a higher risk of acute reactions to breast radiotherapy.  
Nordsmark et al. (2007) studied five hypoxia specific markers (carboxyanhydrase 9 
(CA9) by immunohistochemistry, hypoxia inducible factor 1α (HIF-1α), pre-
treatment plasma osteopontin – ELISA test, pO2 needle electrode based tumour 
oxygenation and tumour osteopontin (OPN) levels) for 76 patients over a five-year 
follow up period and reported that “High plasma osteopontin, high HIF-1α and high 
51 | P a g e  
 
proportion of tumour pO2 ⩽ 2.5 mm Hg (HP2.5) related significantly with poorer 
loco-regional control, whereas CA9 and tumour OPN failed to predict local control”. 
Yaromina et al. (2012) in their review article summarised that in-vitro osteopontin 
levels in head & neck patients appeared to be negatively correlated with oxygen 
partial pressure (PO2) levels of the tumour24. Further, they also referred to evidence 
indicating biopsy-based testing of pimonidazole as a biomarker for hypoxia. 
Additionally, they shed light on genetic markers such as Epidermal Growth Factor 
Receptor (EGFR), γH2AX protein and poly(ADP-ribose)-polymerase-1 (PARP-1) 
protein that have been shown to correlate with cell growth, single DNA strand 
breaks and double DNA strand breaks.  They also reported on studies investigating 
biomarkers to identify cancer stem cells (CSCs) responsible for tumour regrowth.  
Based on the above, it is clear that there are multiple methods that can provide 
information about patient specific biology to help individualize treatments. The 
results reported in relation to the above methods are mostly from underpowered 
studies, observational or retrospective data from large trial subgroups. Biomarker 
based individualization although promising in smaller studies requires primary data 
from randomized, statistically powered and validated large studies. This will allow 
unbiased estimation of the efficacy of such methods and help in standardization of 
these methods; for adoption in clinical practice.    
2.7.2 Non- Biomarker based treatment individualization approaches 
Alonzi (2015) and Lambin et al. (2010) have provided a detailed account on 
individualization that can be introduced alongside radiotherapy using imaging 
markers like FDG, 61Cu-ATSM, FAZA & FMISO through PET modality, T2 Weighted to 
dynamic contrast enhanced techniques in MRI and a combinational approach using 
PET-MRI modality.  The patient specific information gathered through above 
imaging methods can be used to selectively increase or decrease prescribed dose to 
the tumours and / or change the treatment method altogether to improve outcome 
using radiotherapy.   
                                                          
24 Yaromina et al. (2012) refer to Le et al. (2003) 
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Mackay & Hendry (1999) published a simulation-based study looking at potential 
benefits of individualizing radiotherapy treatments using patient specific 
radiosensitivity derived from surviving fraction at 2 Gy (SF2) data of fibroblasts. The 
information was incorporated into TCP and NTCP models to see if dose escalation 
could be achieved for the breast cancer patients keeping toxicity to less than 5% (in 
terms of NTCP). They concluded that a tripartite division of population could 
provide good benefit of treatment individualization and this approach is likely to be 
robust against assay result uncertainties.   
Yaromina et al. (2012) have given a critical review of the use of the F18-FDG tracer as 
a marker to be used for dose escalation in radiotherapy. Some groups believe that 
areas of a tumour with no / less F18-FDG tracer uptake show hypoxic / necrotic 
regions and some groups report similar areas of tumours as rather aggressive, 
leading to disease relapse.  
Lievens et al. (2011) and Warren et al. (2014) performed a treatment planning study 
demonstrating evidence in favour of individualized prescription dose escalation. The 
retrospective planning studies reported that using IMRT, dose escalation & 
individualization was achievable keeping within recommended OAR tolerances. 
Warren et al. (2014) reported that mean escalations of dose by around 19% (3D-
CRT) and 25% (IMRT) respectively were possible whilst maintaining recommended 
OAR dose tolerance constraints in Stage II-III NSCLC patient cohort of 20 patients. 
Lievens et al. (2011) showed that dose escalation could be performed on an 
individual basis and prescription dose escalated by 15-21% for NSCLC patients 
keeping in recommended dose tolerance limit for OAR complications. Marshall et al. 
(2016) performed a similar treatment planning comparison study in the NSCLC 
cohort of 24 patients utilizing PET imaging to escalate dose to tumours. They 
showed that PET imaging could be used to boost tumour dose without violating 
OAR dose tolerance limits. C11- and F18- PET probes like choline and fluciclovine are 
now FDA approved for use in medical imaging of prostate cancer. Clinical trials 
assessing possible improvement in prostate radiotherapy plans after inclusion of 
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choline/ fluciclovine based PET imaging data have been recently reported and some 
are still underway (Calais et al., 2018). 
Further, van Baardwijk et al. (2008, 2010, 2011, 2012) of the Maastro group have 
implemented the concept of individualized radiotherapy clinically. In 2008, they 
reported a feasibility study with 28 NSCLC patients all of whom were prescribed 
radiation dose individually using a hyper-fractionated accelerated routine with 
twice daily fractions of 1.8 Gy. The main OAR constraints were set around keeping 
mean lung dose, doses to the spinal cord, main brachial plexus and main bronchi 
under clinically recommended dose tolerance limits. They reported the mean total 
tumour dose as 63 Gy (range - 46.8-79.2) with a median survival of 19.6 months and 
1-year overall survival of 57.1%. The toxicities observed in the patients were 
reported to be acceptable. The success of the feasibility study led to a Phase II trial 
on the same lines where 166 patients (Stage I-III NSCLC) were included in the trial 
with sequential chemo-radiotherapy or radiotherapy alone. The results were 
reported in 2010 for Stage I-III patient and in 2011 for Stage III alone cohorts by van 
Baardwijk et al. (2010, 2011). As per the 2010 paper, the mean prescribed dose was 
64.8+/-11.4 Gy with the 1-year overall survival of 68% and 2-year overall survival of 
45% with acceptable acute and late toxicities. The 2012 paper by the same group 
reported the results of the phase II concurrent chemo-radiotherapy trial (137 
patients) based on individualized accelerated radiotherapy as in other trials 
mentioned above. Even in patients with large tumours and multimodal disease, the 
results were better compared to previous trials (reported in 2008, 2010 & 2011) 
with an improved 2-year overall survival of 52.4% and similar acceptable acute and 
late toxicities. All the treatments were delivered using conformal radiotherapy.   
This initiated a series of IMRT based feasibility trials in the UK on an Iso-toxicity 
approach. ISOTOXIC IMRT (ClinicalTrials.gov Identifier: NCT01836692 – ISOTOXIC 
IMRT: A Feasibility Study) is an Iso-toxic hyperfractionated accelerated radiotherapy 
trial where radiotherapy will be delivered in sets of 2 fractions a day (Haslett et al., 
2016). I-START is an Iso-toxic hypofractionated radiotherapy study where the 
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number of fractions to be delivered to the patients is fixed (20) but tumour dose is 
escalated up to known limits of OAR doses.   
IDEAL-CRT (Iso-toxic, concurrent chemo-radiotherapy; Clinical Trial Identifier: 
ISRCTN12155469) is an individualized prescription dose escalation trial with fixed 
30-fraction treatments with concurrent chemotherapy. Landau et al. (2016) 
reported on the observed survival and toxicity in the IDEAL-CRT trial. For 
oesophageal toxicity, 68 Gy was declared to be the maximum tolerated dose. The 
overall toxicity (radiation pneumonitis and oesophageal toxicity) observed in the 
IDEAL-CRT trial was comparable to that observed in other concurrent CRT studies 
(e.g. RTOG 0617, MAASTRO Study). Intensification of treatment dose in a defined 
range was shown to be feasible with acceptable survival rates (based on a median 
follow-up of 35 months, median overall survival was 36.9 months, 2-year overall 
survival and progression-free survival was 68.0% and 48.5%). 
Sanchez-Nieto & Nahum (2000) put forward treatment individualization as one of 
the uses of radiobiological models, introducing the BIOPLAN software tool for 
treatment-outcome prediction in radiotherapy.  Further, Fenwick et al., (2009) 
performed a radiobiological model based retrospective study of NSCLC data 
(reporting on oesophagitis, lung fibrosis, pneumonitis, spinal cord and the 30-month 
progression-free survival) for different dose escalation approaches. They report  
“Worthwhile (approximately 20%) gains in 30-month local progression-free survival 
should be achievable at safely deliverable levels of dose escalation. The analysis 
suggests that longer schedules may be more beneficial than shorter ones, but this 
finding is governed by the relative rates of tumour and oesophageal accelerated 
proliferation, which are quite imprecisely known”. 
Nahum & Uzan (2012) introduced four levels of prescription dose individualization 
that could be undertaken using radiobiological models to improve radiotherapy 
response.  
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1) The first method consists of escalating dose for a patient at a fixed NTCP and 
constant fraction number for a given treatment.  
2) The second level looks for fraction number that maximises TCP at a set Iso-
toxic limit.  
3) Level 3 incorporates radiobiological models as cost functions for inverse 
treatment planning.  
4) Level 4 takes into account patient-specific biological markers to improve 
prescription dose estimate using TCP / NTCP models to individualize 
treatment plans.  
 
They considered the toxicity of a single OAR when optimizing the doses for a given 
tumour (i.e. radiation pneumonitis for lung cancer treatment). In reality, 
Oesophagitis, Pericarditis and or spinal cord myelopathy can become dose limiting 
OARs in lung tumour dose escalation which limits the applicability of the results of 
Nahum & Uzan (2012) in clinical practice.  
 
In chapter 3, a dose escalation methodology that accounts for multiple OARs / 
toxicity endpoints when escalating dose to the tumour for a large cohort is 
introduced. Syndikus et al. (2011) report a study (BioProp) that uses radiobiological 
model-based inverse treatment planning to increase TCP in 6 patient plans. 
Azzeroni et al. (2013) provide evidence in support of biological optimization with 
regards to boosting dose to intra-prostatic lesions. In the paper, they evaluate the 
feasibility of boosting doses to dominant intra-prostatic lesions (DILs) using TCP and 
NTCP. They reported large variation in TCP values for the DILs because of variation 
in TCP model parameters. The result of such parameter variation is likely to affect 
dose optimization, and biologically based treatment plans should thus be evaluated 
carefully. van Baardwijk et al. (2010) report results of a single arm study where the 
prescription doses were escalated on an individual basis in cases of NSCLC stage I to 
III (166 patients) under normal-tissue tolerance limits. They concluded that 
“individualized prescribed radical radiotherapy based on normal tissue constraints 
with sequential chemoradiation shows survival rates that come close to results of 
concurrent chemoradiation schedules, with acceptable acute and late toxicity. A 
prospective randomized study is warranted to further investigate its efficacy.”      
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Zindler et al. (2016) report another retrospective analysis for prescription dose 
individualization in Stereotactic Ablative Radiotherapy (SABR) treatments. They 
propose dose escalation to tumours at the highest levels until set OAR dose 
tolerance limits are not exceeded. Zhang et al. (2010) demonstrate the use of 
individualization to escalate prescription dose in intensity modulated proton 
therapy compared to standard photon based IMRT in a retrospective study of 20 
patients. Their analysis also reports that an increase in prescription dose is possible 
keeping normal tissue doses under standard published tolerance limits.  
All these above approaches support the work in chapter 3 where a software system 
that allows comparison of radiotherapy treatment strategies and optimizations over 
a large cohort is showcased. This system is used to show the effect of changes in 
regimens, optimization strategies and model parameters on lung and prostate 
cohorts as a whole through TCP-NTCP graphs. 
2.8 Radiosensitivity based treatment optimization 
The susceptibility of a given tissue to radiation exposure is called radiosensitivity. It 
is quantified in terms of α, β and surviving fractions (e.g. SF2 is surviving fractions at 
a 2 Gy in-vitro dose on a cell line) for the LQ model.  It has been shown that 
radiosensitivity correlates with the outcome at least for head & neck and cervical 
cancers (West et al., 1997). Studies by Menegakis et al. (2009) and Olive & Banáth 
(2004) show that assessment of γ-histone H2AX (A DNA damage marker) immuno-
histo-chemically would shed some light onto intrinsic radiosensitivity of a tumour. A 
few prominent methods used to quantify tissue radiosensitivity are listed in the 
upcoming sections.  
First and the most common (even referred to as the gold standard) is the method of 
clonogenic assays. In this method, cells are extracted from a tumour and divided 
into two samples where one of the samples is irradiated and the other is not 
(control sample). Both the samples are placed in an identical growth environment 
allowing them to form sizeable colonies over a predefined growth period. The 
number of colonies in both the samples are now counted and corrected for plating 
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efficiency to establish cell surviving fraction. Undertaking the same exercise over 
different irradiation doses allows formation of a cell survival curve which can be 
modelled using the LQ equation by fitting α and β parameters (Joiner & van der 
Kogel, 2009)25.This method takes a long time to give results and therefore 
alternative assay techniques have been proposed which are faster for measuring 
radiosensitivity. These include DNA damage assays, apoptosis and micronucleus 
assays (West & Barnett, 2011).   
DNA damage assays (e.g. alkaline comet assay) measure single or double DNA 
strand breaks induced post irradiation. The comet assay requires few cells and 
allows processing of results within hours of sample collection. Although sensitivity 
of DNA damage assays has been found questionable in the past, the phosphorylated 
histone H2AX assay as a surrogate marker for double-strand breaks has been found 
very promising (Dunne et al., 2003).  
Micronucleus assays measure micronuclei that are formed by a chromosome break 
or when the chromosome is lagging in the anaphase post radiation damage. The use 
of cytoplasmic division inhibitor upon formation of micronuclei arrests the cell 
division process allowing identification of binucleated cells that are counted. This 
forms a very sensitive method of assessing the sensitivity of cells to radiation 
damage. (Vral et al., 2011). 
Apoptosis is a radiation-induced cytotoxic response in a cell that is expressed very 
quickly after radiation damage to a cell. Cytotoxicity can be evaluated rapidly using 
flow cytometry. This added with the sensitivity of the method and ease of sample 
collection (i.e. blood) make apoptosis assays very attractive for measuring 
radiosensitivity (Azria et al., 2008; Crompton & Ozsahin, 1997) compared to the 
clonogenic assay method.  
Compared to clonogenic assays all of the above methods of assessing 
radiosensitivity are significantly quick due to their mechanism of action, sample 
collection and or sample processing techniques. Some pitfalls of the clonogenic 
                                                          
25 Refer Chapter 4 Section 4.2 for more details on clonogenic assay technique 
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assay methodology for assessing radiosensitivity (intrinsic or clinical) are discussed 
below. 
First is the time it takes for the cell-survival data to be determined. Secondly, the 
conversion of in-vitro results to patient tumour/OAR radiosensitivity is not ideal as 
the in-vivo growth environment of the tissue is different to in-vitro conditions. 
Thirdly, studies reporting on this do so with variations in methodology which can 
make radiosensitivity estimates non-reproducible (i.e. standardization of assay 
technique is important). Also, not many validation studies are reported that detail 
the quality of published work on a given tumour type. Assay techniques are not 
available in the clinic for various reasons that include the complexity of processes, 
clinical implementation issues, and the availability of samples as the process is 
invasive.  
As far as non-invasive methods of assessing radiosensitivity-related tissue 
characteristics are concerned, advances in diagnostic imaging technology 
specifically PET & MRI have played a major role that allows assessment of hypoxia 
and angiogenesis in a tumour. It is common knowledge that hypoxia leads to radio-
resistance and poor radiotherapy response in patients (Krause et al., 2006). In their 
paper, Krause et al. (2006) discuss the role of PET/CT in IMRT regarding hypoxic 
region dose boosting (also referred to as “dose painting”). Dubois et al. (2011) have 
shown in in-vivo studies that [18F]HX4 is a very promising hypoxia marker for PET 
imaging. However, incorporating this kind of imaging information into standardized 
clinical practice will require a large body of clinical evidence (to demonstrate the 
efficacy of the method).  
There is a lot of literature on using genetic markers to individualize treatments and 
thereby improve treatment outcomes (Barnett et al., 2015; Coco Martin et al., 
1999; Liu et al., 2015; Wang et al., 2006; West et al., 2014; West & Barnett, 2011; 
Williams et al., 2008).  There have been instances where mixed reviews about a 
correlating factor to toxicity have been published (Girinsky et al., 1994; Stausbøl-
Grøn & Overgaard, 1999). Either way, the point is that a single genetic marker or a 
biomarker that conclusively predicts the radiosensitivity of a given cell sample from 
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a patient has not been reported to date. However, evidence has been accumulating 
in the direction of assimilating more than one type of genetic marker to stratify 
patients into specific categories of radiosensitivity (Barnett et al., 2012; Hall et al., 
2014). ‘Radiogenomics’ as it is known looks into genetic variation associated with 
response to radiotherapy and attempts to uncover groups of genetic markers that 
can predict individual response to treatments (Kerns et al., 2014; Rosenstein, 2011). 
The biomarker grouping that can predict specific radio-response is achieved by 
conducting large genome-wide association studies (GWAS). The final aim of the 
whole exercise would be to formulate a clinically feasible predictive profiling test 
enabling the individualization of patient treatments. Such evidence correlating 
genetic variation and radiotherapy toxicity is presented by Barnett et al. (2014) and 
Kerns et al. (2014, 2016). 
Tumour dose, cell density and tumour volume are important variables that help 
predict tumour control probability. However, only assumptions or best estimates 
are available for the tumour’s intrinsic radiosensitivity, hypoxic tumour cell mass 
and rate of tumour cell proliferation. The best estimates are from published studies 
based on in vitro experiments which come with uncertainties of their own (Fertil & 
Malaise, 1985; Słonina & Gasińska, 1997).  
In a report on human radiosensitivity (Public Health England, 2013), radiosensitivity 
is defined on different levels ranging from whole organism radiosensitivity to organ 
radiosensitivity to cellular level radiosensitivity. The report comprehensively 
explains radiosensitivity for tumours and normal tissues. It also looks at different 
factors that are believed to affect normal tissue (clinical) radiosensitivity. In 
summary, it states that sex, body mass index, alcohol consumption or diet may or 
may not influence clinical radiosensitivity but increase in age, genetic variation, 
diabetes, smoking and collagen vascular disease are very likely to increase clinical 
radiosensitivity.  
In chapter 4 of this thesis, a hypothetical study to assess the effect of using patient 
specific radiosensitivity information on radiotherapy treatment individualization & 
optimization is undertaken. This involves segregating patients into three groups 
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based on tumour radiosensitivity and applying different optimization 
methodologies to optimize treatments. The results are presented as a large table of 
analysis comparing the clinical scenario of  
1) Optimization of treatment plans ‘without’ versus ‘with’ stratification of patients 
based on patient specific tumour radiosensitivity information  
2)  If patients could be stratified into subgroups based on radiosensitivity 
information what difference is observed in the optimization if the stratification was 
used ‘before‘ vs ‘after’ treatment planning 
2.9 Inverse-Treatment planning - New Approaches 
Inverse treatment planning is defined as a computerised iterative process of 
optimising dose fluence from every beam direction to develop a dose distribution 
(i.e. treatment plan) that conforms to a given set of objectives and constraints. The 
aim of the iterative inverse plan algorithm is to find a solution that has the lowest 
cost function value (the quantified difference between expected ideal dose 
distribution and the dose distribution of a given iteration). This is discussed in more 
detail in Chapter 5, section 5.1 of this thesis.   
From the radiotherapy treatment planner’s point of view, the goal is to form a dose 
distribution keeping OAR doses within ‘tolerance’ limits whilst forming a plan that 
would deliver the prescribed radiation dose to the PTV. From the inverse planning 
software point of view, the aim is to find beam-intensity profiles (and beam 
directions) that satisfy the objectives & constraints set by the planner. A clinically 
unacceptable plan is likely to result if the objectives and constraints are not defined 
precisely. There have been different approaches to achieve the ‘ideal treatment 
plan’ (i.e. class solution) that are discussed next.  
Amongst the new and interesting clinical approaches to treatment planning are 
Knowledge-Based treatment planning® (KBRT), Online adaptive planning and 
Radiobiological Model-based treatment planning. KBRT is a novel way to create 
effective treatment plans using a database of clinically approved treatment plans. 
The premise behind knowledge-based treatment planning is to find an improved 
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starting point for the treatment plan optimizer allowing it to find a solution faster 
than the standard iterative solution finding process.  
The KBRT system houses a database of patient structure sets and clinically approved 
treatment plans. When a new plan is to be created for a given patient, the CT 
structure set ‘query set’ of the patient is given as input to the KBRT system which 
looks into the database to find a closely matching patient structure set ‘match set’ 
using ‘Mutual Information’ metric (which is a metric for image matching, allowing a 
purely statistical comparison of image histograms between given image datasets). 
The ‘mutual information’ metric (MI) is generated by comparing two dimensional 
BEV images of two CT structure sets from one angle. The MI value generated for 
different angles of the 3D CT structure set are averaged to form a composite MI 
metric which is used as the final similarity score of a given comparison iteration 
(Chanyavanich, 2011).  
The algorithm tries to find a ‘match case’ with the highest ‘mutual information’ 
within the patient plan library. Once a matching patient dataset is found, the 
system adapts the treatment plan associated with the matching patient dataset and 
optimizes it for the current patient structure set.  The knowledge-based planning 
system then allows manual adjustments of objective/constraint to further improve 
the plan once an automated solution has been formed. The successful application of 
this methodology has been reported by many (Cao et al., 2015; Chanyavanich et al., 
2011; Good et al., 2013; Nwankwo et al., 2015; South et al., 2015). However, the 
caveat here to keep in mind is that the plans will be as good as the initial library and 
for situations where plans matching a given anatomy are not available, results may 
not be optimum.  
Next, adaptive radiotherapy treatment planning is briefly discussed. Adaptive 
radiotherapy (ART) is a technique whereby the treatment plan is modified between 
fractions to adjust for inter-fraction variation in a tumour/organ position, size and 
shape (Ghilezan et al., 2010).  Different ART techniques are shown in figure 2-6 
(Kibrom & Knight, 2015). 
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Adaptive radiotherapy can be divided into two categories 1) Offline (a.k.a 
composite method) ART technique and 2) Online ART technique. The offline ART 
method involves using CBCT images of the patient taken in the early weeks of 
treatment period to amend the treatment plan to match various organ’s shape, size 
and position during a given (later) period of treatment. Although some of the 
reported studies show a reduction in PTV volume by up to 40% and reduced OAR 
irradiation, the offline method only accounts for systematic error between the 
planning and treatment phase and is not optimal when there are frequent (possibly 
daily) changes to patient anatomy (e.g. bladder size).  
The Online ART method is categorised further into ‘plan of the day’ (PoD) ART 
technique and daily plan re-optimization technique. The PoD ART technique has 
been further classified into non-individualized and individualized categories. In the 
non-individualized PoD ART method, a library of plans is created for a given patient 
CT dataset. The PTV is created for each plan in the library by adding population-
based isotropic or anisotropic margin around the CTV.  At the time of treatment, a 
Figure 2-6 Various Adaptive Radiotherapy techniques and sub techniques are shown in the flow chart. 
From Kibrom & Knight (2015) 
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CBCT image-set taken prior to the treatment is used to select the plan in the library 
that provides the best coverage of the target. 
In the individualized PoD ART method, an individualized patient plan library is 
created for each patient using the initial planning CT and combination of CBCTs 
from the first week of treatment resulting in three plans with small, medium and 
large CTV. The plan providing the best coverage when compared to the CBCT prior 
to treatment is selected for the given fraction. Another type of individualized PoD 
ART method is the adaptive predictive organ localization (A-POLO) method. In this 
method, a library of plans is created by taking a set of CT scans of the patient with 
an empty bladder and then after consumption of water (at least two separate scans 
over an interval of roughly 20 mins) during the planning stage.  
This allows the formation of plans that cover all the anatomical scenarios in relation 
to the bladder shape and size. Using the pre-fraction delivery CBCT, the plan 
providing the best coverage of the target is chosen from the library for delivery. It 
has been shown that online ART method is successful in reducing the size of the 
irradiated target volume and also spares OARs considerably compared to 
conventional radiotherapy technique.  Daily plan re-optimization which is the latest 
reported Online ART technique could be very useful in improvising treatment 
response. Different methods of achieving this have been reported by Li et al. (2013) 
and Ahunbay et al. (2010) where the inter-fraction variation in patient anatomy are 
accounted for in the treatment ‘plan on the day’ (automatically and dynamically). 
The daily planning technique has been shown to be very useful at target volume 
reduction and sparing OAR dose but requires a large resource commitment (i.e. 
involvement of personnel participating in various aspects of clinical RT and increase 
in total time for treatment which reduces patient throughput) which may 
jeopardize its clinical feasibility.  
Attempts to use radiobiological models to optimize radiotherapy treatment plans 
are presented next. Optimization of treatment plans using radiobiological models 
was first introduced by Raphael et al. (1992). They present the model-based 
radiotherapy optimization in its mathematical form and use a computer program-
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based experiment to show the difference between constraint-based optimization 
plan and probabilistic model-based optimization plan. The study is very theoretically 
orientated providing a very clear and concise explanation of difference between 
constraint-based planning and model-based planning. The idea was taken further by 
Alber et al. (1999) who developed & demonstrated use of different types of models 
to form objectives/constraints and how these are likely to affect optimization 
compared to using dose volume-based metrics for optimization. They demonstrated 
the mathematical integration of radiobiological models into objective/constraint 
functions for inverse treatment-planning purposes. These papers thoroughly 
discussed ways of adding different types of models to the inverse optimization 
algorithm but there was a lack of clinical evidence of such planning methodology; 
which can be attributed to the era of publication where inverse treatment planning 
was in its infancy.  
The apprehension in relation to lack of clinical data to validate model parameter 
based absolute TCP/NTCP metrics was raised against this methodology by Bortfeld 
et al. (1996). The superior dose sparing achieved through biologically based 
optimization (using EUD metric) was presented by a few authors which include (Das, 
2009; Qi et al., 2009; Semenenko et al., 2008). EUD26 is a useful metric that is 
simpler to calculate and accounts for tissue volume effect, but it does not account 
for radiosensitivity of the target tissue. In Chapter 5 using RayStation for inverse 
treatment plan individualization, the approach differs from the one presented by 
above authors as Iso-toxic plan optimization is undertaken (based on the Marsden 
TCP and Lyman-Kutcher-Burman NTCP models) with an aim to increase the dose in 
the tumour without increasing OAR toxicity.   
                                                          
26 “EUD is defined as the equivalent uniform dose, which if distributed uniformly across the 
target volume, would lead to the same level of cell killing as the actual dose distribution of 
interest. Based on the EUD concept, a complex dose plan with 3D dose distribution can be 
reduced to a single EUD parameter, which relates to treatment outcome of a biologically 
equivalent dose delivered in 2-Gy fractions of EBRT” - Wang et al., 2008 
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Schell et al. (2010) used LQ-model-based objective functions to optimize an inverse 
treatment plan for a head & neck patient dataset and a prostate cancer dataset as a 
case study to introduce “Radiobiological-effect-based treatment plan optimization”.  
They implemented radiobiological-model-based cost functions in their in-house 
treatment planning software KonRad and compared conventional treatment plans 
to LQ-model-based inverse treatment plans. They emphasized the assumptions, 
advantages and pitfalls of using the LQ model-based objectives for the inverse 
planning process. However, they did not use NTCP model based constraints as dose 
limiting functions for the OARs.  
Radiobiological-model-driven inverse treatment planning was demonstrated by 
Nahum & Uzan (2012) where they used the Marsden TCP as an objective function, 
and the LKB NTCP (for lung-GTV) as a constraint function to form an inverse 
treatment plan (3-field IMRT plan) of an NSCLC patient; the planning software was 
the in-house-modified Research Pinnacle system. They obtained an increased TCP 
for the “Bio-plan” compared to the conventional plan, with OAR constraints being 
the same for both plans. Details about the constraints/objectives used for other 
OARs were not given.      
Conventionally, treatment planning approaches do not involve radiobiology; plans 
are based solely on (physical) dose-volume (D-V) objectives & constraints with the 
additional key assumption that a uniform/homogenous dose distribution in the 
target volume yields the best solution. In this work, it is demonstrated that the use 
of radiobiological-model-based objective / constraint functions can yield treatment 
plans with a higher therapeutic benefit than plans created from D-V objectives.  The 
D-V metrics of the plans generated using both methods are also reported for 
comparison.  
In chapter 5, conventional Dose-volume Based (DB) planning is compared to 
radiobiological objective & constraints based (RB) planning for lung and prostate 
cancer patients. The findings are reported in terms of the therapeutic gain as a 
function of TCP, NTCP and dose-volume-based parameters. TCP-NTCP graphs (cf. 
Chapter 3) and DVHs are used to illustrate the differences between overall 
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conventional dose-escalation strategy and the radiobiologically individualized 
inverse-planning strategy.  
2.10 Iso-toxic Dose constraint conversion 
Dose-based metrics like V20Gy, V50Gy (i.e. Vxx Gy) are widely used in clinical 
radiotherapy treatment plan assessment that is based on published clinical reports 
that correlate OAR toxicity risk to such metrics (Jackson et al., 2010). Several 
publications on estimates of best-fit parameters for various NTCP models have been 
published and are extensively used by various research groups all over the world. 
Gulliford et al. (2012), Marks et al. (2010) & Werner-Wasik et al. (2010) give a 
comprehensive review of reported NTCP model parameters for different 
complications like radiation pneumonitis, rectal bleeding and oesophagitis.   
Gulliford et al. (2012) concluded that there was considerable variation in derived 
model parameters for different endpoints related to rectum which suggests that it 
is likely that there is more than one pathophysiological process that governs the 
response of rectum to radiation exposure. Werner-Wasik et al. (2010) point out the 
variability associated with using single threshold dose volume constraints to predict 
esophagitis and also caveat the tentativeness of the models and recommend 
performing internal (centre specific) data based validation of model predictions 
before using them in clinical decision making.  Currently, ICRU (2010) requires the 
reporting of Vxx Gy and Dyy % (Level 2 mandatory requirement) parameters for 
treatment plans and recommends reporting of TCP, NTCP & EUD values (Level 3 
Optional reporting). The QUANTEC (Jackson et al., 2010) review papers provide 
recommendations for both dose-volume based constraints and NTCP model 
parameters for complication rates in different OARs.  
2.10.1 Problem statement 
A diagram depicting the IGRT workflow is shown in Figure 2.7 (Gupta & Narayan, 
2012). Once the patient’s tumour has been diagnosed and referred for 
radiotherapy, the patient visits the treatment centre for a CT scan. A CT scan is used 
for target and OAR delineation which is essential for planning purposes. The patient 
may also be referred for a PET / MRI scan that gives functional information about 
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the cancer and its spread in the part/whole of the body.  At this point, the 
oncologist prescribes the dose regimen and the physicist, dosimetrist or therapy 
radiographer form a clinically acceptable ‘geometric’ treatment plan to impart the 
prescribed dose.  
Figure 2-7 Workflow of a routine clinical IGRT radiotherapy treatment (redrawn from Gupta & Narayan, 2012) 
Each centre would follow a protocol to deliver a given regimen. Depending on the 
extent of disease, the oncologist decides on the standard regimen, a research 
regimen (clinical trial) or a palliative regimen of radiotherapy. These regimens (aka 
protocols) consist of dose and fractionation details along with OAR dose limits or 
NTCP limits and target coverage requirements. The treatment planner may use a 
manual (aka ‘forward’) or an ‘inverse’ (automated) treatment planning technique to 
create the treatment plan. This plan is then independently verified by a physicist for 
correct radiation dose and dose distribution in the tumour and OARs. Once a plan 
passes through the plan quality check (QC), it is ‘signed off’ by the oncologist for 
implementation. The patient is then treated as per the schedule of fractions that 
will deliver the prescribed dose to the tumour.  
The above describes an ‘ideal world’ scenario. There are a small number of 
situations where the scheduled treatment fraction cannot be given to the patient; 
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these may include machine breakdown, staff unavailability, public holidays, a 
serious problem with the patient’s health and even transport problems (public or 
private). If a ‘gap’ in the treatment occurs, this may result in increased clonogen 
repopulation and therefore the treatment prescription may need to be changed to 
achieve an unchanged treatment outcome. Thus, take for example a 55 Gy in 20 
fractions lung treatment protocol with a normal lung (OAR) radiation pneumonitis 
dose limit of V20< 30% (Marks, Bentzen, et al., 2010). After a treatment gap, how 
does the clinician decide on the new regimen keeping the OAR dose/NTCP to the 
same limit? Or, simply put, how can a clinician obtain equivalent dose limits from 
one regimen to another?  The BED formula is currently used to address the 
questions above which is described in the upcoming sections. 
Another scenario where a similar question arises is when the treatment strategy is 
to be decided for a patient or even a cohort. For many years, 2 Gy/fraction was a 
standard treatment for lung cancer. Per the published literature, many centres have 
tried different protocols, some preferring hypofractionated, accelerated or hyper-
fractionated treatments as shown by Méry et al. (2015) in their review of NSCLC 
treatments. So, if a centre following a given radiotherapy regimen wants to change 
to a different regimen, how do clinicians establish new OAR tolerance dose limits 
that will not exceed OAR tolerance dose limits of previously established protocols? 
A new approach based on NTCP modelling addressing the above questions is 
described in Chapter 6. 
Few of the methods that have been established in the literature to compensate for 
treatment gaps and or dosimetric limit conversion are described in the next section. 
These methods are described in detail in RCR (2008) guidelines.  
2.15.1.1 Accelerated Scheduling 
When the treatment gap is not very big (<=3 days) it is easy to compensate for the 
missed fractions by treating the patient on a weekend to maintain the same total 
dose delivered in prescribed treatment time. Per this scheme, multiple fractions are 
delivered in a single day until the total dose is ‘compensated for’. However, the 
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assumption here is that sub-lethal repair of normal tissues between fractions is 
complete, i.e. fractions are planned with a gap of at least 6 hours between them.  A 
strong word of caution has been given for the safety of this method  when the 
fraction sizes are greater than 2.2 Gy (Barrett, 2008; Thames, Peters, & Ang, 1989). 
This does not require any conversion of the dosimetric constraints as the 
prescription dose and fractionation do not change.     
2.15.1.2 Biological effectiveness compensation 
Further, a modelling approach can be used as shown by (Fowler, 1989) where BED 
term is used to compare dose regimens. The BED is a single metric for comparing 
dose/fraction equivalence between any two regimens (Dale & Jones, 2007).   
2.15.1.3 Increasing Total Dose 
The last resort to any treatment rescheduling is to increase the total treatment time 
to compensate for the loss of dose due to the gap(s). This raises the issue of 
repopulation. The precise time when the gap occurred is critical, as later treatment 
gaps tend to result in higher repopulation that must be accounted for if the 
treatment time is to be increased. Conventionally lung tumour treatment gap 
compensation would need a higher extra total dose to compensate for 
repopulation. In the case for prostate, repopulation conventionally is assumed to be 
negligible so the total dose can remain the same (assuming less than 58 days’ total 
treatment time - repopulation is quoted to start after 58 days with 90% confidence -  
Gao et al., 2010). The proposed method in the literature uses a K(T-Td) factor along 
with the BED equation to compensate for the radiation ‘wasted’ in counteracting 
the repopulation that occurs due to increase in total treatment time. The best 
estimated recommended value of the K-factor used in the BED formula is 0.9 Gy 
day-1  for head and neck cases (Dale et al., 2002). The same publication also 
provides worked examples and enumerates all pros and cons of using different time 
gap compensation methods applicable to radiotherapy.   
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The next section describes the current method that is employed to convert 
tolerance dose limits of different OARs to find their equivalent for different 
treatment schedules. 
2.10.2 Dosimetric Parameter Conversion 
To convert Vxx of a given OAR in regimen A to an equivalent Vxx in regimen B, one of 
the simplest methods available is as follows. Convert the DVH dose bins of one DVH 
using the Withers’ correction formula to the other regimen (Withers et al., 1983). 
The Vxx value of both the schedules can be now compared on an Iso-BED basis.  
The BED formulation is so far the most useful and a simple way to convert dose in 
one regimen to dose of another regimen or compensate for treatment gaps. The 
BED Iso-effect formula is heavily reliant on the α/β parameter that has errors of its 
own contributed by derivation of α and β from laboratory experiments on cell lines 
or data fitting over clinical studies. Further, the BED formula fails to account for the 
effect of total volume or organ architecture in the conversion of metrics. NTCP 
models address the above pitfalls and are utilized in the Iso-toxic conversion 
method that is developed.  
In chapter 6, an NTCP-model based conversion platform is described; where LKB 
NTCP model (see the literature review section) is used to perform the conversion of 
Vxx constraint from one regimen to the other in Iso-toxic conditions. Here, the OAR 
DVHs are the input, along with conversion the metric in terms of Vxx, the current 
regimen (A) and the new regimen (B). The method uses Iso-toxic OAR complication 
probability as the bridge to link regimen A and regimen B.  
 
 
1  
2  
3  
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Chapter 3 Dose Individualization & 
Optimization in Radiotherapy: A 
Radiobiological Modelling-based 
approach 
3.1 Introduction 
Current treatment strategies for lung & prostate tumours and the progress to date 
on establishing prescription doses and regimens for improving the overall 
population response to radiotherapy are discussed in chapter 2. It was emphasised 
that fixed dose and fractionation regimens are prescribed to all the patients eligible 
for curative radiotherapy. The current regimens for (non-small-cell) lung cancer 
treatment in the UK are 52.5-55 Gy in 20 fractions and 60 Gy in 30 fractions (Bezjak 
et al., 2012; Haslett et al.,2014). For prostate, it is 74 Gy in 37 fractions or 60 Gy in 
20 fractions (Dearnaley et al., 2016).  
However, in a patient cohort (or population) not all tumours have the same 
size/volume or the same radiosensitivity (West et al., 1997). Concurrent 
chemotherapy has been shown to radiosensitize tumour cells. It has been observed 
that radiation treatments are more effective with concurrent chemotherapy 
(O’Rourke et al., 2010; Rowell & O’Rourke, 2004). The radiosensitivity of tumour 
cells can only be determined via a biopsy followed by a clonogenic assay which 
takes several weeks because of which it cannot be taken into account in 
radiotherapy dose prescription. Cell-survival curves as a function of radiation dose 
have been published for many cell lines for various tumours. Using these data, the α 
and β parameters have been derived (Chapman and Nahum, 2015; Chapman, 2003). 
Tumour size can be estimated via various methods (Imaging methods like CT, MRI, 
etcetera) and this allows a crude estimate of total clonogen number to be made. 
Further, the location of a tumour with respect to normal tissues can be used to 
escalate dose to the tumour limiting the normal tissue complication rate. DVHs 
obtained from treatment plans are used to estimate TCP and NTCP for a given 
patient (DVHs described in Chapter 2). An Iso-toxic approach could be used to 
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individualize the dose to the tumour (thereby improving TCP). However, 
individualized radiotherapy dose prescription is not a standard clinical practice 
currently except in research radiotherapy treatment protocols (e.g. lung cancer RT 
treatments).  
In the research described in this chapter, the potential effects of individualizing 
treatment prescription for each patient by varying the plan dose on an Iso-toxic (or 
Iso-NTCP) basis are demonstrated. Treatment individualization (in terms of 
prescription dose and no of fractions) is performed for all the patients (one at a 
time) in the cohort. The change in overall population response to individualized RT 
treatment is then reported (in terms of population-averaged TCP & NTCP).  
3.1.1 Analysis Goals 
The current analysis focuses on dose-fractionation optimization on an individual 
patient basis for lung and prostate tumour plans. The primary goal is, for different 
strategies of dose optimization, to compare the population-averaged TCP and NTCP 
in order to identify the strategy that would yield the most impactful improvement 
in clinical outcomes compared to the standard fixed dose and fractionation 
approach. 
3.1.2 Patient Data Sets 
 Two cohorts of patients have been used for the 
dose-fractionation-optimization analysis. There are 
59 lung tumour DVH datasets, for 3D-CRT and IMRT 
patients that were prescribed 52.5-55 Gy in 20 
fractions. The datasets consist of DVHs for GTV, 
PTV, total paired lung (Lung- GTV), Spinal Cord, Oesophagus, and Heart. It is to be 
noted that some of the datasets did not contain DVHs of Oesophagus and Heart.  
The data made available was completely anonymized (per conditions of REC 
application reference: 14/NW/1345 IRAS project 
ID: 159143) and therefore the reasons for the 
exclusion of DVHs of Oesophagus and Heart in 
individual plans could not be investigated. One can 
assume that in these cases the organs were not in 
Table 3-1 PTV Lung 
Tumour Volume (cc) 
Min 8.3 
Max 344.3 
Median 82.8 
Mean 100.1 
Table 3-2 PTV Prostate 
Tumour Volume (cc) 
Min 111.7 
Max 241.2 
Median 156.6 
Mean 161.4 
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the treatment field and therefore were not in the ‘at risk’ category. For the prostate 
tumour cohort, 56 DVH datasets consisting of DVHs of PTV, prostate, rectum, 
bowel, urinary bladder and femoral heads are analysed. These patients were 
treated with 60 Gy (to the tumour volume) in 20 fractions. It is again to be noted 
that not all the datasets included all the above-mentioned DVHs for the reasons 
stated above. All datasets included DVHs of PTV, prostate, rectum and the urinary 
bladder. 
3.2 Methodology 
This section describes the current approach to radiotherapy treatment dose & 
fraction-size optimization presented as a population response to different strategies 
of individual dose customization. This prescription-dose-fractionation 
individualization is purely based on dose-volume data derived from treatment 
plans. Incorporating biomarker or diagnostic information into the analysis would 
most likely further improve the treatment plan to achieve a better therapeutic gain 
for patients. In the analysis that follows, the published dose-volume constraints 
and/or published NTCP model parameters are used to derive the individualized 
prescription doses. The results are expressed as population-averaged TCP (TCPpop) 
as a function of NTCP (NTCPpop).  
For the lung tumour treatment plans, the tumour DVH is formed of the PTV DVH 
(i.e. derived from the dose distribution in the PTV) but with the volume of the GTV. 
As per ICRU report 83, GTV is the gross demonstrable extent of a tumour that 
consists of the primary tumour and any regional tumour nodes. Tumour control 
probability might therefore be expected to be a function of the DVH of the GTV. It is 
however important to account for geometric uncertainty in the location of the GTV 
due to organ motion and geometrical setup variations (consisting of patient 
positioning and beam alignment errors). Thus, PTV is defined in treatment plans and 
is planned to receive 95% to 107% of the prescribed dose to be treated. PTV volume 
is formed by adding margins to the CTV; and the CTV is formed by adding a margin 
to GTV to account for the suspected clonogen presence beyond the edges of the 
GTV (ICRU Report 83; Burnet,2004). However, for estimating the average number of 
tumour cells, the best approximation of the volume is the structure delineated as 
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the GTV.  Hence in this work the predicted tumour control probability is based on 
the dose distribution of the PTV and the volume of the GTV.  
The aim is to determine the maximum dose that can be delivered to the tumour 
without exceeding NTCP for the principal OAR. The optimization parameters for the 
DVH dataset in terms of radiobiological models are TCP, NTCP and fraction number. 
Other OAR toxicity is accounted for using organ-specific NTCP limits or dose-volume 
based parameters like Vxx, mean organ dose and maximum tolerance dose (only 
when NTCP model is unavailable for the OAR) to limit the escalation of the 
prescription dose (Dpres).   
This entire analysis is performed using an in-house software with a GUI shown in 
Figure 3-4. The computation of TCP & NTCP was checked against the Biosuite (Uzan 
& Nahum, 2012) software package. The results of the quality control are shown in 
the results section. The absolute errors and uncertainty associated with the TCP and 
NTCP models are discussed in section 3.4.3.   
Table 3-3 The Marsden TCP model parameters used in this analysis are shown above.  
LKB NTCP MODEL 
End Point 
Radiation 
Pneumonitis 
Oesophagus 
Complication 
Myelopathy Heart 
Rectal 
Bleeding 
Faecal 
Incontinence 
Bladder 
Complication 
  
m 0.45 0.44 - 0.64 0.13 0.42 -  - 
n 1 0.32 - 0.13 0.09 1 -  - 
TD50 (cGy) 3140 5100 -   7690 10570 -  - 
α/β OAR (cGy) 300 1000 87 250 300 300 600 600 
Vxx V20 - - V30 V50 V50 V80 V65 
Vxx Limit 30% - - 46% 50% 50% 15% 50% 
Dmean (cGy) - 3400 -       -   
Dmax (cGy) - - 5000           
Reference 
Uzan (2012) 
Chapet et al. 
(2005)  
Kirkpatrick 
(2010) 
Martel 
et al. 
(1998) 
Michalski 
et al. 
(2010)  
Peeters et 
al. (2006) 
Viswanathan 
(2010) 
  
Marks et al. 
(2010) 
    
Wei 
(2008) 
    
  
  
Table 3-4 LKB NTCP model parameters and dose-based constraints for different endpoints/complication; 
accounted for in this analysis are shown above.  
MARSDEN TCP MODEL 
Tumour Lung Lung2 Prostate1 Prostate2 Prostate3 Prostate4 
α (Gy-1) 0.307 0.293 0.3 0.258 0.218 0.155 
ασ 0.037 0.051 0.114 0.099 0.082 0.058 
α/β (cGy) 1000 1000 1000 500 300 150 
Clonogenic Density 10^7 10^7 10^7 10^7 10^7 10^7 
Repopulation Constant 3.7 3.7 - - - - 
Delay to repopulation (days) 21 21       - 
Reference 
Uzan 
(2012) 
Baker et al. 
(2015) 
Uzan 
(2012) 
Uzan 
(2012) 
Uzan 
(2012) 
Uzan 
(2012) 
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The LKB NTCP model is used for calculating NTCP of OARs in this work.  An EQD2 
correction (see chapter 2) is performed to convert the OAR dose distributions (in 
the form of DVHs) to equivalent 2 Gy-fraction (total) dose distributions as LKB NTCP 
model does not explicitly account for the effect of different fraction sizes. In 
contrast, the LQ-based mechanistic Marsden TCP Model has the fraction size as an 
explicit parameter in its formalism; therefore, no EQD2 correction to the target-
volume DVH is required. The NTCP calculations are performed using model 
parameters taken from the QUANTEC review (Jackson et al., 2010) or later 
publications as shown in Table 3-3 and Table 3-4. 
3.2.1 Program Algorithm  
Figure 3-1 Flow diagram of the in-house graphical user interface based program “RadOpt”.  
The ‘RadOpt’ software is made up of three components: Input | Engine | Output. 
The ‘input’ section allows the user to specify modelling and optimization conditions 
as well as input data from different sources. The ‘engine’ part uses three software 
modules, namely the ‘escalator’, the ‘optimizer’ and the ‘selector’ to analyse the 
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data. The roles played by these modules are explained in the sections below. The 
output section allows data QC, displays results (strategy assessment plots) and 
outputs important metrics about the most recently completed optimization. The 
graphical user interface (GUI) is shown in Figure 3-4 (and its modules are explained 
in section 3.2.2-3.2.4). The software was developed in the MATLAB environment 
version R2015b licensed from MathWorks®. The code was gradually built in 
successive versions after testing and adding extra features, all of which are included 
in the version employed to generate the final results of this chapter. 
3.2.2 The Escalator 
This part of the program multiplies the doses in a DVH of a given patient by a factor 
(also referred to as ‘dose scaling factor’ (DSF)) in the range from 0.01 to 3. So, if the 
nominal prescription dose at a scaling factor of 1 is say 55Gy than this can be scaled 
from 0.55 Gy to 165 Gy for the purpose of dose escalation/dose reduction.  The 
range of the dose scaling factor is selected such that all possible scenarios can be 
covered for the OAR and tumour DVHs. This is equivalent to dose scaling function 
available in treatment planning systems that allows modification of the treatment 
dose of a plan by means of a multiplication factor.    
3.2.3 The Optimizer 
The Optimizer scans the range of a given input variable and evaluates a cost 
function trying to minimize target cost. Thus, the optimizer will accept the dose 
range as the input variable to optimize the cost function ([ f(dose)current - 
f(dose)target], where f(dose) can be NTCP or TCP). The optimization is denoted here 
by the phrase ‘window scanning’ and is similar to an interval halving search 
optimization method. The variable is bound at the lower limit (a) and upper limit 
(b). An analogy of this optimization is a sliding shutter window, where the window 
aperture represents the cost function, and the shutters act as boundaries (fig 3-2).  
 
 
 
Figure 3-2 explains the optimizer function program in terms of an analogous sliding shutter window. The 
boundary conditions of the optimized variable ‘x’ are ‘a’ and ‘b’ and the blue aperture of the window is the 
cost function to be minimized for a given value of ‘x’. 
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The algorithm takes the mean of the upper and lower bounds of the variable and 
computes the cost function. If the cost function is positive the upper bound is 
replaced by the mean value of the variable and if negative, the lower bound of the 
window is replaced by the mean value. Continuing this for about 25 iterations will 
reduce the cost function to within +/- 10-6 tolerance.  
x= Variable to optimize, V= Target limit where V=f(x) 
For a<x<b, m=(a+b/2) 
g(x) = VXm- Vtarget 
While |g(x)|>= 0.001   if  g(x)<0, b=mean(a,b)    
if g(x)>0, a=mean(a,b) 
 
 
 
 
    Figure 3-3 shows that at optimized ‘x’ the window aperture is smallest. 
As the optimizer finds the optimum variable value for the associated cost function, 
the window aperture shrinks until no further improvement in the optimized value of 
the variable can be achieved. The important thing about the algorithm is that it can 
find an optimum value of the variable within 20 iterations and the 
precision/tolerance can be specified. Also, the programming is quite efficient for the 
algorithm. Performing a literature search after originally programming the optimizer 
with the above algorithm, it became apparent that this method was not original 
(Press et al., 1992). This algorithm is efficient where the optimization search is 
limited to analysis resulting in a unique maximum. For optimizations resulting in 
multiple maxima, the window scanning approach is likely to yield sub-optimal 
results. The TCP and NTCP being exponentially increasing functions (due to the 
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increase in dose) will have a single maximum with respect to dose escalation and 
thus are suitable to be used with the window scanning optimization method. 
3.2.4 The Selector 
 
This module scans through a matrix of optimized values of different variables 
associated with the optimization process and selects the appropriate combination 
of values for each variable in the order of preference. Assume there is a table of 
three related variables where VarX has the highest importance (weight) followed by 
VarY, followed by VarZ. 
                                                 
             Table 3-5 Example table 
VarX 
C1 
VarY 
C2 
VarZ 
C3 
65 7.3 12 
56 3.2 13 
79 6.1 14 
88 5.4 19 
88 8.1 20 
Ci = Column i 
The selector is required to select a combination of VarX, VarY and Var3 such that  
VarX= max(C1); then VarY = C2(row of max(C1)) and VarZ= C3(row of max(C1)) for a unique 
maximum value of VarX 
If there are more than one maximum values of VarX= max(C1), then;  
VarY = minimum (C2(row of max(C1))) 
if VarY has more than one similar values then;  
VarZ= minimum (C3(row of min(C2))).  
The VarX corresponds to TCP, VarY corresponds to NTCP and VarZ corresponds to 
fraction number. The aim of the selector is to find a combination of these variables 
where TCP is maximum at minimum NTCP (below a given set Iso-toxic limit; say 10% 
in the example above so all the VarY NTCP limits are valid to be considered for 
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selection) and at minimum fraction number. The numbers in table 3-5 are randomly 
chosen merely to demonstrate the working of the selector module of the software. 
Thus, the selector will choose the maximum of VarX with the minimum of VarY at 
the minimum of VarZ; if there is repetition in either VarX or VarY values. In the 
example table above the selector will choose  
 VarX=88  VarY=5.4  VarZ=19 
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3.2.5 ‘RadOpt’ User Interface 
Figure 3-4 The Graphical User Interface of the ‘RadOpt’ Software built in-house for this analysis. Plot 1 shows 
the comparison between different optimizations. Plot 2 shows individual patient DVH dose response curves – 
orange curves are TCP vs Dose with green demonstrating the population average and red curves are NTCP vs 
Dose with a dotted red curve showing population average. Plot 3 shows cumulative PTV DVH and principal 
OAR DVH of each patient for visual QC of input data. Plot 4 is a plot of Vxx vs NTCP to enable the clinician to 
assess the correlation between V20 and NTCP (in the current figure).   
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3.2.6 Interface Description 
3.2.6.1 Regimen & Optimization Range Input 
The user interface shown in Figure 3-4 has the input section on the left-hand side 
and the output display section on the right (covering most of the area of the ‘GUI’). 
The software can simulate various radiotherapy regimens (accelerated & / or 
hypo/hyper-fractionation). The process starts with the input of the ‘original’ 
regimen in order to access the treatment DVHs. ‘RadOpt’ performs uniform dose 
escalation (Level 0), Iso-toxic prescription dose individualization (Level 1) and Iso-
toxic optimum dose/fractionation individualization (Level 2). Level 1 and level 2 
optimizations require NTCP values and the fractionation range in order to achieve 
patient-specific individual optimum treatment prescription. The optimizations 
mentioned above are described in section 3.2.10 of this chapter.  
The dose-response curve of tumour and OARs are sigmoidal in shape and plateau 
beyond a given prescription dose as the slope of the respective curves become very 
small (as prescription dose increases). A limit on TCP for dose escalation at this 
point is placed (called TCPcap). Continuing dose escalation beyond TCPcap will 
increase NTCP to an unacceptable value without a significant increase in TCP. A 
value of 95% was thus chosen for TCPcap.  Figure 3-4 depicts this in quadrant 2 with 
the orange curves showing the dose-response curves for various tumour DVHs and 
the red curves showing the same for OAR DVHs.  
3.2.6.2 Models and File Input 
Specific models for TCP and NTCP calculations and the type of subsequent analysis 
must be selected for the respective tumour and primary OAR endpoints by the user. 
Following this, the user can choose to turn on/off the ‘repopulation effect’ in the 
TCP calculation. Next, the optimization to be performed on a given set of DVHs is to 
be selected using the checkboxes. Thus, the informational inputs required to steer 
the optimization correctly are set for the software. Clicking the ‘load’ button allows 
the user to input DVH files.  
82 | P a g e  
 
The program can process Eclipse and Pinnacle DVHs or VODCA Database DVH 
output files. The data used in this thesis was obtained from Pinnacle & Eclipse27 DVH 
output files (Eclipse DVH Data – 29 Lung Patient dataset, 56 Prostate Patient 
datasets & Pinnacle DVH Data – 30 Lung Patient Dataset). The ‘plot cumulative DVH’ 
button converts all the loaded differential DVHs into the cumulative format and 
plots individual cumulative DVHs for visual quality checking in the section marked 
by ‘3’ in figure 3.4. Using this feature, ‘rogue’, incorrectly loaded and/or non-
curative treatment DVH datasets (i.e. palliative treatment DVHs) can be identified, 
and either corrected or removed.  
3.2.6.3 Additional Features 
There are additional functions built into the software that allows the user to export 
the results of the analysis, clear the output display area, plot individual patient 
TCP/NTCP against Dose data separately on a different graph, and manually scale the 
dose of a given DVH.  
3.2.7 Quality Check 
The ‘check data’ function checks if the no. of DVHs loaded for TCP and NTCP 
calculations match. If they do not match an error is generated. Further, when 
exporting DVHs from the VODCA28 radiotherapy database, a separate file with 
patient IDs is also exported for Tumour DVHs and OAR DVHs. If VODCA datasets are 
processed, the program also matches the IDs of tumour and OAR DVH export files 
and flags up an error if a mismatch is found.    
3.2.8 Output 
The output has a text display and a graphical display of the outcomes of the chosen 
types of analysis. The text display gives information on the number of files loaded 
and the loading sequence number of rogue DVH datasets (if any are detected by 
means of sanity checking the value of rise in TCP after level ‘0’ optimization. If the 
rise in TCP after dose escalation is ‘nil’ or negligible this indicates an error in the 
                                                          
27 Pinnacle and Eclipse are treatment planning systems by ‘Varian’ and ‘Elekta’.  
28 Visualization & Organization of Data for Cancer Analysis (VODCA) is the database used in this work to collect 
radiotherapy treatment data. Further information about it can be found at www.vodca.ch 
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data which is flagged by the system for review and excluded from TCPpop & NTCPpop 
calculation). Further, on completion of level 2 optimization (described in section 
3.2.10.3 of this chapter), the mean fraction number at 10% toxicity for the 
population yielding the highest TCP is displayed. The results are available for 1% to 
50% NTCP, but 10% is the arbitrarily chosen value for the display of the results; this 
can be modified as required.           
In figure 3-4, there are 4 display graphs that give different information. Graphs 2 & 
3 (numbered in figure 3.4) are for visual quality-checking of the data. Graph 2 is a 
plot of all the cumulative DVHs loaded for the analysis. This helps the user identify 
any rogue or invalid DVH datasets. Graph 3 is a plot of TCP & NTCP versus dose (i.e. 
prescribed dose) in the scenario of fixed-fraction-number dose escalation. This 
helps the user ensure that the DVHs are from curative and not palliative treatments.  
Graph 4 plots the NTCP of all the DVHs of the principal ‘dose-limiting’ normal tissue 
versus Vxx (e.g. V20<30% for radiation pneumonitis risk of healthy lung as per Marks 
et al., 2010). This helps the user assess the correlation between NTCP model values 
derived from the normal-tissue DVHs under analysis and the selected Vxx metric29.  
Graph 1 is a plot of population-averaged TCP versus population-averaged NTCP for 
all selected optimization types. This graph enables the user to rank various 
treatment optimization strategies in terms of cohort-mean TCP at a given NTCP. All 
the analyses can be performed accounting for single/multiple dosimetric and/or 
NTCP-based OAR tolerance endpoints. 
3.2.9 Dose tolerance limits 
Reliable LKB model parameters for all OAR complications are not always available 
(e.g. Bladder complication). Some OARs (like the spinal cord) having serial 
architecture have maximum dose thresholds beyond which toxicity is clinically 
observed. This needs to be accounted for whilst performing dose individualization 
and optimization for a given patient. The Level 1 & Level 2 analysis program 
modules (see section 3.2.10.2 & 3.2.10.3) account for various dosimetric and NTCP 
model based endpoints and constraints (Dmax, Dmean, Vxx & NTCP) and limit dose 
                                                          
29 Chapter 6 of this thesis discusses in detail the co-relation between NTCP and Vxx and how this can be used to 
Iso-toxically convert Vxx for one regimen to another.  
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escalation to maintain an acceptable complication risk scenario for all OARs. Dose-
based constraints for a given OAR are used in this analysis only when the NTCP 
model for the OAR is not available. Dose-volume parameters limiting the escalation 
of dose for various OARs for cancer treatment optimization are listed in Table 3-4 
for both prostate and lung treatment OARs. 
3.2.10 Optimizations and Individualization Techniques 
The following subsections describe different optimization techniques applied to 
generate pseudo-clinical optimization results for lung and prostate treatment plan 
data.    
3.2.10.1 Dose Escalation (Level 0)  
This approach is not an optimization but instead a straightforward increase in 
(nominal prescription) dose, showing how TCPpop (average of TCP of all patients at a 
given prescription dose) increases as a function of NTCPpop (average of NTCP of all 
patients at a given prescription dose) for the principal OAR/complication endpoint 
in lung and prostate cancer treatments. This curve is shown in Figure 3-4 (plot no 2) 
for all the patients of the lung cohort and also for the population TCP (green curve, 
plot 2, fig 3-4) and NTCP (red curve, plot 2, fig 3-4) at 20 fractions. Further, the same 
analysis is performed after adding other OAR constraints (like spinal cord 
complication or oesophagitis complication for lung treatment; faecal incontinence 
and bladder complication for prostate treatment) to see how this changes the TCP 
and NTCP (for the primary complication). The analysis is performed using both the 
NTCP model & standard dose-volume constraints for OARs.  
3.2.10.2 Iso-toxic Fixed Fraction Dose Optimization (Level 1) 
Level 1 Iso-toxic optimization applies the prescribed dose to the tumour at the 
(original) fixed fraction number corresponding to a given NTCP.  The analysis is 
initially performed considering a single primary OAR DVH as well as the tumour DVH 
and subsequently extended to include other secondary OAR complications. The 
standard regimens used are 55 Gy in 20 fractions for (non-small-cell) lung tumour 
treatments and 60 Gy in 20 fractions for prostate treatments for Level 1 analysis. 
The analysis proceeds by supplying to the software the parameters of the standard 
treatment regimen (Number of fractions, Fractions/Day, Treatment days/week), 
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TCP model (Tumour clonogen density, α, σα, β, Tpot, Td) and NTCP (n, m, TD50) model 
parameters as per latest available peer-reviewed & or task-group recommended 
literature. There are two parts to the level 1 optimization module (shown in Figure 
3-1) - the dose escalator and the optimizer (explained in section 3.2.2 and 3.2.3). 
First, the escalator is used to find the dose scaling factor (DSF) that yields the set 
(Iso-toxic) NTCP for the principal OAR. Using this DSF, the tumour DVH doses are 
rescaled and then it is checked whether the TCP maximum level (aka ‘cap’ or ‘upper 
bound’) is reached (e.g. 95%, 99.9 %, etc.). If the TCPcap has been reached, the 
optimizer will search to find the dose-scaling factor that yields TCP within 0.01% of 
the upper bound level. Thus, a new DSF is determined that is lower than the 
IsoNTCP based DSF; this new DSF is used to rescale the OAR DVH dose resulting in 
the new, slightly reduced NTCP. 
Figure 3-5 Level 0 and Level 1 optimization TCPpop-NTCPpop plot for lung cancer cohort for a 20-fraction 
schedule. The Therapeutic Operating Curve (TOC) graph was first proposed by Hoffmann, Huizenga, & 
Kaanders (2013) where they plotted TCP against NTCP for a single patient to assess the therapeutic index. 
This concept is used here to plot the therapeutic response of a population of patients. 
Next, the NTCP is increased by 1% (as defined in range input in section 3.2.6.1) and 
the exercise as described above is repeated to derive the doses corresponding to 
this new NTCP value. Once the exercise is completed for a given patient (for the 
defined range of NTCP of the primary OAR of a patient), other patients’ DVH 
datasets are analysed in a similar fashion. The final result is a matrix of TCP, NTCP & 
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Level-1 Optimum Dpres (L1Dopt pres) for each patient. The TCP, NTCP and L1Dopt pres of 
all the patients, when averaged, form the population TCPpopL1, NTCPpopL1 and L1Dopt 
pop. Further, the same exercise is performed with multiple organ tolerances limiting 
the escalation of prescription dose. Thus, the dose corresponding to a range of 
NTCP limits (i.e. 1%-10% for the primary endpoint) with set constraints of NTCP/ 
Dose-Volume parameter for other OARs is computed. The algorithm escalates the 
dose until the NTCP value is reached for a given iteration without violating the 
specified tolerance limits of other OARs. An example of such a TCP vs NTCP curve is 
shown in Figure 3-5.  
3.2.10.3 Iso-toxic Dose/Fractionation Optimization (Level 2) 
The level-2 algorithm chooses the optimum dose-fractionation schedule (as 
explained in the example in section 3.2.4) for a given patient DVH dataset at set 
tolerance limits (NTCP based & or DV constraint based). The level 2 algorithm 
requires input(s) similar to those for level 1 algorithm along with the additional 
input of the range of fraction numbers. For IMRT and 3D-CRT, the range of 1 to 40 
fractions is considered reasonable.  The algorithm for level 2 optimization has three 
important components. One is the dose escalator (section 3.2.2), second is the 
optimizer (section 3.2.3), and the third is the selector (section 3.2.4).  
For each patient DVH dataset, the algorithm scales the nominal prescription dose 
for a fixed NTCP limit of the primary OARs at a given fraction number. If TCPcap of 
95% is reached, the optimizer reduces the dose scaling factor and also the NTCP 
until the TCP is within 0.01% of the TCP upper bound value, i.e. 95% TCPcap. 
Summarizing, the ‘scaler’ algorithm searches for maximum DSF for which the 
tolerance limit of the principal OAR is not exceeded (or the selected Iso-toxic/NTCP 
limit is just reached). If at this point the TCPcap is exceeded, the optimizer reduces 
the DSF and hence the NTCP until the TCP is within 0.01% of the TCPcap. The 
improvement in the therapeutic gain (increased TCP at Iso-toxic NTCP) as a result of 
the optimization is shown in the results section (e.g. section 3.3.1 figure 3-12).  The 
above procedure is performed at a fixed fraction number, starting at the lowest 
number in the input range, for one patient dataset at a time. The fraction number is 
then increased by one and the procedure is repeated until the entire range of 
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fraction numbers has been processed for a given patient DVH dataset, as shown in 
Figure 3-6.  All OAR DVHs are corrected for fractionation using the EQD2 correction 
as proposed by Fowler (2001) with every change of the number of fractions in a 
given cycle. 
Thus, for each patient, a matrix of values of TCP, NTCP and fraction number is 
formed. This can be compared to performing level-1 optimization for each fraction 
number in turn and the results gathered together. After the results at all the 
fraction numbers in the provided range have been ‘processed’, the ‘selector’ 
module is activated to examine the generated matrix of values to select the highest 
TCP that was achieved across the range of fraction numbers (under 0.01% tolerance 
of the selected TCP and NTCP) for each patient; if this maximum TCP is equal to the 
‘cap’ then several fraction numbers may fulfil this and the minimum fraction 
number is chosen. The calculations are performed such that the set NTCP limit or 
dosimetric constraint is never exceeded during optimization. Summarizing, the 
‘selector’ selects the fraction number for each patient that gives the highest TCP at 
Iso-toxic/lower NTCP (not compromising TCP) for the lowest fraction number for 
the entire range of fraction numbers.  
Figure 3-6 A level 2 optimization result for a single patient with lung cancer treatment is shown here from 
Nahum & Uzan (2012) NTCP was set to 10% in this example. In this research work, the ‘selector’ module is 
used to select the fraction number yielding the highest TCP (15 in this case) at a chosen NTCP. This process is 
repeated for all the patient DVH datasets to yield Iso-toxic individualised treatments for each dataset.   
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The primary OAR NTCP limit is now increased (by 1%) and the entire procedure is 
repeated. The result for each patient is a matrix of TCP, NTCP, Optimum Fraction 
number (OPT frac) and Level 2 Optimum prescription dose (L2D opt pres). These values, 
when averaged over the entire cohort, yield the population averaged TCPpop, 
NTCPpop, OPTfrac, and Dpop that can be compared with level-1 results for each Iso-
NTCP limit. The results are reported for both Lung and Prostate Cancer cohorts in 
the next section. 
3.3 Results 
This section gives the results for various dose-fractionation optimization strategies 
discussed in the methodology section.  
a) Quality check of TCP and NTCP calculation algorithm : Initially, a snapshot of the 
software user interface is shown that allows the user to visually check cumulative 
DVHs to ensure if all the loaded DVHs correspond to curative treatments and that 
there are no rogue datasets. A quality check of TCP and NTCP calculations of the 
system against the ‘Biosuite’ software module developed by (Uzan & Nahum, 2012) 
for 56 patients was performed with and without considering the repopulation 
effect. The results showed that the maximum absolute difference in TCP values 
calculated using ‘RadOpt’ are within +/-0.04% of the TCP calculation by Biosuite and 
the standard deviation is 0.02%.  Similarly, the difference in NTCP values between 
‘Biosuite’ and ‘RadOpt’ is +/-0.01% with a standard deviation of +/-0.01%.  
b) Quality check of Iso-toxic Optimization Algorithm : The difference in fixed-
fraction Iso-toxic optimization results between ‘BioSuite’ & ‘RadOpt’ algorithm was 
assessed next (fig 3-7). It is reported that the maximum error in the calculation of 
level 1 optimized TCP results at different fraction numbers is +/-0.25 with the mean 
%error of 0.01 and a standard deviation of 0.06. The error is nominal considering 
the variations in the rounding errors employed by the programming languages and 
the algorithm coding itself.  The errors quoted here are strictly associated with 
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systematic calculation errors. Errors associated with TCP & NTCP calculations due to 
uncertainties in model parameters are addressed in the discussion section.   
Figure 3-7 shows the % difference between level 1 TCP optimization calculation between RadOpt’ and 
‘Biosuite’ performed for a single patient dataset. The oscillations are higher at low fraction numbers where 
TCP values are very small, i.e.  %differences are higher.  
3.3.1 Dose-Fractionation Optimization of Lung Cancer Treatments 
The DVHs of the lung cancer datasets for a visual quality check of the data are 
shown in Figure 3-8. It can be seen that D95 of the DVHs are spread around the 
55Gy prescription dose region. Typically, a tumour DVH is highly concentrated 
around the D95 point in the plot. The data used here was provided in a completely 
anonymised form and thus there was no way to quality check the data except for a 
visual QC of the DVHs.  
Figure 3-8 The cumulative DVHs of the tumour and the principal OAR (healthy lung) of the lung cohort are 
shown above. 
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In figure 3.9 the population-average curves formed by averaging individual TCP-
Dose curves (orange) and NTCP-Dose curves (pink) are shown by dashed green and 
dash-dotted blue curves respectively.  
Figure 3-9 shows the dose response curves of all the patient tumour DVH TCP and principal OAR (healthy 
lung) NTCP with X-axis corresponding to prescription dose (obtained by multiplying scaling factor to the 
prescription dose of the original DVHs) in 20 fractions. The population average dose response curves are 
shown by the green (TCPpop) and blue sigmoid curves(NTCPpop). This is a visual QC to ensure no rogue datasets 
are used in the analysis. 55Gy in 20 fractions corresponds to 45% average TCP and 8.6% average NTCP of the 
entire cohort as indicated by the bright red arrow.   
The population dose-response graph shown in Figure 3-9 looks quite cluttered and 
does not provide a straightforward assessment of the population’s behaviour to a 
given strategy of treatment. Thus, the TCP curves are averaged to create the 
TCPpopulation dose-response curve (green curve) and similarly the NTCPpopulation (blue 
curve) dose-response curve as shown in Figure 3-9. It is emphasized that the aim of 
this work is to assess the population response of different optimization & 
individualization strategies in terms of therapeutic gain for a large cohort of 
patients. In order to make this assessment simpler, the population average TCP 
versus NTCP for each proposed strategy of optimization is plotted. This creates the 
TCP-NTCP population strategy assessment graphs that are extensively used in this 
work.  
The power of this graphical analysis is realized when comparing treatment 
strategies, parameter variations, and/or treatment techniques over multiple 
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cohorts. This graphical method of analysis enables a large amount of data to be 
compressed & summarized. Using this type of plot, the population response to 
different prescription dose-fractionation optimization techniques is compared in 
the upcoming section. 
Figure 3-10 shows the population strategy assessment graph of a cohort of lung patients. The graph shows 
the spread of therapeutic responses over a cohort of patients. The red curve is representative of the central 
tendency of the cohort response in the area covered by the therapeutic response of most favourable and the 
least favourable patients.  
Next, the population averaged TCP-NTCP graphs obtained after subjecting each of 
the patient datasets to level 0, level 1 and level 2 optimization is displayed. Firstly, 
the results of the analysis considering the tumour DVH and the primary OAR DVH 
that limits dose escalation is shown.   
Figure 3-11 shows that for Lung-tumour patients, Iso-toxic prescription dose 
individualization (level 1) would yield improved therapeutic results compared to 
uniform dose escalation (level 0), at a constant total number of treatment fractions 
(20 here for lung cancer treatments). Further, if the number of fractions is 
optimised (as a variable), it is observed that population response in terms of 
average TCP and NTCP (level 2 vs level 1 vs level 0 in Figure 3-11) is further 
improved with better therapeutic results achieved at a lower total number of 
fractions. At NTCP of 10%, it can be seen that TCPpopulation for level 0 is about 64.5% 
whereas level 1 (in 20 fractions) results in TCPpopulation of 73.5%. For level 2 
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optimization, TCPpopulation is about 75% at 10% NTCP at an average of 16 fractions. 
The optimized number of fractions vary from patient to patient. 
Figure 3-11 above shows the population average TCP-NTCP (TCPpop & NTCPpop) graph after applying different 
dose optimization methods on a cohort of lung patients considering the primary tumour and principal OAR 
complication (radiation pneumonitis).  
The clinical 55Gy20# regimen corresponds to NTCPpop=8.6% and TCPpop=45%. The 
TCPpop for level 1 (62%) and level 2(64%) optimization at 8.6% Iso-toxic NTCP yield 
significant TCP increases (17% at 20 fractions using level 1 optimization and 19% in 
at a mean of 15 fractions using level 2 optimization). However, considering just a 
single OAR as the basis for optimizing the prescription dose would be clinically 
unrealistic and possibly dangerous; it is essential to account for other possible 
complications. 
For lung cancer radiotherapy, myelopathy of the spinal cord, pericarditis of the 
heart and oesophagitis of the oesophagus are the most reported complications 
after radiation pneumonitis and all of these potential complications must be 
addressed as a part of the treatment planning process (in terms of radiation dose) 
as per Marks et al. (2010). Thus, the recommendations of dose-tolerance limits of 
these OARs are taken from the QUANTEC review (Gagliardi et al., 2010; Mayo et al., 
2010; Werner-Wasik et al. 2010) and included as dose-limiting constraints (as per 
Table 3-4) when optimizing the dose and fractionation for each patient. The dose is 
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escalated (resulting in an increase in TCP) until either the selected NTCP level of the 
principal OAR or a dosimetric constraint of the additional OAR is breached. The 
results have been calculated for each strategy for each patient and averaged to 
form the population response plot (Population TCP-NTCP curve) shown in Figure 
3-12. 
Figure 3-12 above shows the population-average TCP-NTCP graph after applying different dose optimization 
methods on a cohort of lung patients considering the primary tumour and multiple OAR complications such as 
radiation pneumonitis, myelopathy, pericarditis and oesophagitis. 
NTCPpop is the average of NTCP of principal OARs at the optimized dose scaling 
achieved after considering other OAR constraints during the optimization. At 
NTCPpop of 8.6% (NTCPpop of the lung cohort at the standard 55Gy20# schedule), it is 
seen that TCPpopulation for level 0 is about 44% whereas for level 1 (in 20 fractions) 
TCPpop = 60%. For level 2 optimization, TCPpop reaches about 63% at 8.6% NTCP for 
an average of 16 fractions. At the 8.6% Iso-NTCP limit, the TCP for multiple-OAR-
constraint based optimization is lower for all three strategies by about 1-2% 
compared to single-OAR-constraint-based optimization.  
Comparing the three different optimization strategies, it can be seen that inclusion 
of multiple OARs in the optimization limits dose escalation but still results in 
improved therapeutic response for level 2 optimization compared to level 1 and 
level 0 strategies for a cohort.  
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‘RadOpt’ software output for level 2 optimization provides TCP, NTCP, optimum 
fraction and prescription dose scaling factor for each DVH dataset. The graph in 
Figure 3-13 depicts the optimized fractions resulting in the population average 
curve of level 2 (Average Fractionoptimum versus Iso-toxic NTCPlimit). It is observed 
that the number of fractions varies considerably, ranging from 5 to 34 for level-2 
fraction-number individualization. However, for most patients, the optimum 
fraction number at Iso-toxic limit of 8% NTCP or above was in the 15-17 range.  The 
reader is reminded that NTCP = 8.6% corresponds to the standard 55Gy20# 
regimen. The graph in Figure 3-14 (Prescription dose versus NTCP) shows the 
population mean prescription dose that results from level-2 individualization at 
optimum fraction number (see Figure 3-13).  It is inferred that there is considerable 
variation in prescription dose that could individualize the treatment and improve 
the therapeutic ratio of TCP-NTCP at a lower fraction number compared to a fixed 
20-fraction regimen. Figure 3-12 to 3-14 are linked by the Iso-toxic NTCP limit which 
forms the x-axis of the respective figures.  
Figure 3-13 shows the graph of the range of Optimum Fraction number vs NTCPpop for level-2 optimization. 
The green line represents the average no. of fractions for which the level-2 optimizer yields highest TCP. The 
NTCP on the X-axis can be correlated to the X-axis of Figure 3-12. The yellow and blue data points represent 
the maximum and minimum fraction numbers at which patients in the cohort reached the highest TCP at the 
corresponding Iso-toxic NTCPpop.   
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Figure 3-14 shows the range of Dpres as a function of NTCP as per the level-2 dose individualization results for 
the cohort of lung-tumour patients. The green line represents the average NTCP-specific prescription dose of 
the population. The blue and yellow lines show the minimum and maximum values of Dpres over the entire 
cohort. 
3.3.1.1 Estimating population response to change in model parameter 
During the course of this work, the Marsden TCP parameters for (non-small cell) 
lung tumours were revised using recent clinical published data;  the new 
parameters are  αnew=0.293 -1Gy and σα=0.051 for NSCLC tumours (Baker et 
al.,2015).     
Figure 3-15 shows the effect of using αold=0.307 -1Gy, σα=0.037 Gy-1 versus the new estimate of αnew=0.293 Gy-
1, σα=0.051 Gy-1 for individualization and optimization of radiotherapy treatment for 3 strategies using 
‘RadOpt’ software. The solid lines are constructed using the (α, σα)old and broken lines using (α, σα)new. The 
brown line corresponds to NTCPpop=8.6% which relates to the 55Gy 20 fractions regimen.  
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For NSC lung tumours the parameters used in the Marsden TCP model to generate 
all the results reported up to this point were α=0.307 -1Gy and σα=0.037 (also 
mentioned in Table 3-3). TCP based on the revised parameters have been computed 
in order to compare the results produced by the two sets of parameters.   
It is observed that using (α, σα) new in the TCP model reduces the TCPpop results for 
all forms of optimization. At 10% NTCPpop, the TCPpop values are about 10-12% lower 
for all the individualization methods (Level 0-2) compared to TCPpop for Level 0-2 
individualization calculated using the (α, σα) old. The TCPpop at NTCP=8.6% for the (α, 
σα) new parameter set is 35% compared to 44% for the (α, σα)old parameter set. In the 
two parameter sets, the change in α is minimal but the change in σα is significant 
and is responsible for the large change in TCPpop. However, the relative 
improvement in TCP from level 0 to level 1 to level 2 is very similar for both the sets 
of parameters. This emphasizes the usefulness of the TCP-NTCP population strategy 
assessment graphs developed in this work.  
3.3.2 Dose-Fractionation Optimization of Prostate Cancer Treatments 
The cumulative DVHs of all prostate cancer patient datasets are plotted on a dose-
volume graph shown below. The tumour DVHs shown in Figure 3-16 have D90 
between 95% and 107% of the prescription dose, thus qualifying them to be valid 
plans. 
Figure 3-16 shows the cumulative DVHs of the prostate tumour and the principal OAR (rectum) of the 
prostate cohort. 
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Similarly, none of the principal OAR DVHs have V40.8 Gy>50% or V60 Gy>5% and thus 
conform to their respective clinical protocol tolerance standards (data derived from 
patients treated under the CHIPP protocol).  
Figure 3-17 shows a dose response graph of constant fraction number (20) dose escalation for all the 56 
prostate patients calculated using prostate1 (α/β=10 Gy) TCP parameter set in table 3-3 and LKB NTCP model 
parameter set from table 3-4). Green dashed line represents TCPpop dose response curve and the blue line 
represents NTCPpop dose response curve. 
The uniform trends and absence of abnormalities in fig 3-17 suggest that the 
‘escalator’ module of the program is working correctly. The orange curves show 
Dose vs TCP and the pink curves show Dose vs NTCP. The population average TCP 
(TCPpop) curve is shown in green and the population average NTCP (NTCPpop) is 
shown in blue.  Tumour α/β=10 Gy is assumed here; later the difference in 
optimization for α/β=3 Gy and α/β=1.5 Gy is explored. 
Figure 3-18 above shows the population average TCP-NTCP (TCPpop & NTCPpop) graph after applying different 
dose optimization methods on a cohort of prostate patients considering the primary tumour (α/β=10 Gy) and 
principal OAR complication (rectal bleeding). 
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This analysis takes rectal bleeding as the primary endpoint limiting the prostate 
tumour dose. The uniform dose escalation (level 0) and Iso-toxic fixed-fraction-
number optimization (level 1) are performed considering 20-fraction treatments, 
and level 2 optimization optimizes over the range of 1-50 fractions. The result of the 
single OAR based optimization strategies are shown in fig 3-18. 
To make the scenario truly clinically realistic, two other complications based on 
dose volume constraints rather than a full NTCP optimization are considered. The 
population-averaged TCP-NTCP curves for level (0-2) optimization taking into 
account faecal incontinence and bladder complication are shown in Figure 3-19. 
During each iteration of the program, the optimizer checks the tolerance of the 
additional OARs and stops dose escalation if the set constraints are breached for 
either of the OARs in terms of NTCP/dose-based constraints.  
The additional OAR dose tolerance constraints (bladder complication and faecal 
incontinence) act to provide a limit to the permitted increase in dose and this limits 
the TCP gain. This is the same method as applied in lung cohort optimization 
accounting for multiple OAR dose constraints. It was observed that the inclusion of 
other OAR constraints (such as faecal incontinence and bladder complication) did 
not result in any notable change in the optimization results for the prostate cohort. 
This is likely to reflect the fact that the treatments were planned to minimize dose 
to the bladder volume. Also, these patient datasets came from a single centre 
where the prostate treatment planning protocol was probably applied in a uniform 
way across the entire cohort.  
It can be observed that Iso-toxic optimal dose-fractionation (level 2) offers a higher 
therapeutic ratio (i.e. higher TCP at a given NTCP) compared to fixed-fraction Iso-
toxic dose optimization (level 1) and uniform dose escalation (level 0).  However, 
the level-2 result is achieved at a higher fraction number (50) than the standard 20-
35 fraction range. This can be attributed to assuming zero prostate clonogen 
proliferation and the ‘classical radiobiological’ result of larger numbers of fractions 
minimizing the complication rate at a given TCP. In this particular case, α/β=10 Gy 
has been assumed for prostate tumour clonogens with α/β=3 Gy for rectal bleeding.  
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Figure 3-19 above shows the TCPpop-NTCPpop graph after applying different dose optimization methods for a 
cohort of prostate patients considering the primary tumour and multiple OAR complications such as rectal 
bleeding, faecal incontinence and bladder complication. a) Results for α/β =10 Gy b) Results for α/β =1.5 Gy. 
The prostate cohort optimization results for α/β =10 Gy show that at a 10% 
complication rate, level-2 optimization yields the highest TCP, being superior to the 
level 1 and level 0 strategies by approximately 12%.  This difference is achieved at 
an average of 50 fractions. If the tumour clonogen α/β=1.5 Gy, based on findings 
reported by Dearnaley & Hall (2017), then large fractions would yield the highest 
TCP at really low fraction numbers for a given Iso-toxic limit (see fig 2-3 for 
explanation). The difference in the population TCP & NTCP observed for level 0 and 
level 1 optimization (α/β=1.5 Gy, fig. 3-19b) for the prostate cohort was also 
negligible (similar to the negligible difference between level-1 and level-0 
optimization result for α/β=10 Gy). Although level 1 optimization results in 
marginally better TCP at Iso-toxic NTCP compared to level 0, the difference 
considering uncertainties in TCP & NTCP model parameters is not significant. Level 2 
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optimization, however, results in a significant improvement in the TCP compared to 
level 1 & level 0 strategies with 1 fraction yielding the highest TCP for all patients 
which is attributable to α/β=1.5 Gy. Single fraction or very low number of fractions 
regimen would mean that the fractions will be quite large (> 5Gy) and thus 
exceeding the applicable range of the L-Q cell kill model.  
Figure 3-20 shows the changes in the population-average TCP at fixed NTCPpop for Level 0 dose escalation for 
three different Marsden TCP model parameter sets for prostate tumours (treated at 20 fractions). The blue 
lines correspond to α/β=1.5 Gy, red corresponds to α/β=5 Gy and green to α/β=10 Gy.   
Uzan & Nahum (2012) published four sets of Marsden TCP model parameters for 
different assumed values of α/β (Table 3-3). Three of these have been used to 
perform optimization on the available patient datasets to observe the variation this 
produces on the results of the optimization strategies presented here. Figures 3-20 
to 3-22 compare the effect of different model parameters on level 0, 1 and 2 
optimizations applied to the cohort. The blue lines correspond to α/β=1.5 Gy, red 
corresponds to α/β=5 Gy and green to α/β=10 Gy. 
 
 
 
 
 
 
 
 
Figure 3-21 above shows the changes in the population-averaged TCP & NTCP for Level-1 optimization at a 
constant 20 fractions for three different Marsden TCP model parameter sets (corresponding to α/β=1.5 Gy, 
α/β=5 Gy and α/β=10 Gy) for the prostate tumour and multiple OAR complications. The blue line corresponds 
to α/β=1.5 Gy, red corresponds to α/β=5 Gy and green to α/β=10 Gy. 
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Figure 3-22 above shows the changes in the population-averaged TCP & NTCP for Level-2 optimization at 
optimized number of fractions for three different Marsden TCP model parameter sets for a prostate tumour 
and multiple OAR complications. The blue lines correspond to α/β=1.5 Gy, red corresponds to α/β=5 Gy and 
green to α/β=10 Gy.  
The use of different TCP-model parameters relating to different α/β values (1.5, 5 & 
10 Gy) for prostate tumour (see table 3.6) clonogens shows that the percentage 
difference in level-0 estimates of TCP between α/β1.5 Gy vs 10Gy is 13.6% and α/β5 Gy vs 
10 Gy is 4.7% at 10% Iso-toxicity. Similarly, for level-1 optimization the percentage 
difference in TCP at 10% Iso-toxicity for α/β1.5 Gy vs 10 Gy and α/β5 Gy vs 10 Gy are 13.5% 
and 4.7% respectively. The corresponding results for level-2 optimization are 10.7% 
for α/β1.5 Gy vs 10Gy is and 1.7% for α/β5 Gy vs 10 Gy.  
Figure 3-23 shows the optimum fraction numbers at which level 2 TCP-NTCP curves of figure 3-22 were 
obtained for different α/β values of prostate tumour. Also see Appendix B, figure A - Plot of TCP vs no. of 
fractions 
Table 3.6 Assessing variation in TCP for prostate tumour for various Marsden model parameter sets at 
NTCPpop=10% 
 α/β=1.5 Gy α/β=5 Gy α/β=10 Gy 
Level 0 TCP 75.2 66.3 61.6 
Level 1 TCP 75.8 67.0 62.3 
Level 2 TCP 85.6 73.2 74.9 
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Thus, it can be seen that changes in model parameters have a big influence on 
treatment individualization - the use of correct parameters for modelling cannot be 
over-emphasized. A low α/β=1.5 Gy ratio for tumour clonogens indicates that large 
fractions are best and a high α/β=10 Gy results in smaller fractions yielding the best 
therapeutic response as demonstrated by Figure 3-23. It is emphasized that 
repopulation for the prostate tumour has been set to zero.  
3.4 Discussion 
The aim of the current analysis is to demonstrate the improvement that 
radiobiological-model based individualization and optimization of radiotherapy 
treatments can bring for (non-small-cell) lung and prostate tumour patients 
(compared to the current fixed-regimen approach). TCP and NTCP models have 
been used for individualizing the prescription dose and the number of fractions in 
this chapter. The results compare the overall effect of optimization for the entire 
cohort of lung and prostate cancer DVH datasets.  
The results section started with the presentation of the QC check between ‘RadOpt’ 
software and ‘Biosuite’ assessing consistency in calculating TCP and NTCP & Level 1 
optimization. The largest percentage error in the calculation of TCP & NTCP when 
comparing the systems was <1% which is acceptably small.  
Three types of optimizations were carried out on both lung and prostate patient 
DVH datasets. In level 0, the dose is escalated for each patient (and the entire 
cohort similarly) and the effect on TCP & NTCP is noted. Level 1 optimization 
calculates maximum achievable TCP based on NTCP based Iso-toxicity at fixed 20 
fractions for both cohorts. Level 2 optimization escalates TCP at a given NTCP (Iso-
toxicity) and further searches for the smallest number of fractions achieving the 
same TCP-NTCP optimization results. The order of preference in the optimization is 
to first achieve Iso-toxicity then optimize TCP (reduce NTCP if the TCPcap is reached) 
and then optimize the number of fractions. The results are averaged over the entire 
cohort (after all patient plans are optimized) for all the strategies and displayed on 
the TCP-NTCP plot to make population strategy comparison easier.       
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3.4.1 Discussion: Lung Cohort Optimization  
In the lung cohorts, it is seen in Figure 3-12 that the level-2 individualization and 
optimization strategy is superior to level 0 and level 1 strategies. The TCPpop =44% 
and NTCPpop=8.6% for the standard clinical 55 Gy 20 fraction regimen. Now looking 
at level 1 & 2 TCP-NTCP graphs shown in Figure 3-12, it is observed that level 1 
optimization at 8.6% Iso-toxic limit yields 60% TCPpop at 20 fractions and level 2 
optimization yields a TCPpop of 63% at 15 fractions (for most of the patients). Thus, 
compared to the current scenario, using radiobiological optimization the TCPpop can 
be improved by about 16% using level 1 optimization and by about 19% applying 
level 2 optimization (for a reduced number of fractions). On an individual basis, it is 
observed that the nominal prescription dose can be individualized over a wide 
range at a given (Iso-toxic) NTCP value (Figure 3-14) for individual patients. 
Similarly, the optimum number of fractions can also be considerably different for 
each patient at a given Iso-toxic NTCP limit (Figure 3-13). Thus, it is shown that 
individualization and optimization of lung treatments based on radiobiological 
models can yield improved therapeutic responses in individual lung cancer patients.  
Evidence in favour of radiobiology-based dose escalation is presented by Machtay 
et al. (2012) who use the BED formulation to analyse various planning studies and 
show that BED is associated with local regional control and survival rates for NSCLC 
patient cohorts. Further, Onishi et al. (2007) give a similar account of association 
between the BED and local regional control rates reported by various other studies 
treating Stage I NSCLC through Stereotactic Ablative Radiotherapy (SABR). Huang et 
al.(2015) demonstrate a correlation between BED and TCP in their radiobiological 
model-based analysis searching for the optimal fractionation scheme in Stereotactic 
Body Radiotherapy (SBRT) of NSCLC. Ohri et al. (2012) developed a TCP model that 
linked 2-year overall survival to tumour size and BED specifically applicable to 
NSCLC SBRT patient data.   
Christodoulou et al. (2014) and  Méry et al. (2015) give a very detailed account of 
the latest approaches to radiotherapy where Iso-toxic dose escalation in patients is 
also reported.  Further clinical evidence in favour of Iso-toxic dose escalation comes 
from clinical trial results reported by the Maastro Group (van Baardwijk et al., 2008, 
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2010, 2011, 2012); they reported improved clinical results from employing 
individualized radiotherapy prescription to patients based on recommended 
tolerance doses to OARs. The results demonstrate that significant therapeutic gain 
can be achieved for a cohort by implementing radiobiological model based dose 
individualization and optimization techniques. The software presented in this thesis 
is ideally suited to assess population treatment response trends which can aid 
clinical lung radiotherapy treatment development.  
3.4.2 Discussion: Prostate Cohort Optimization 
It was observed from figure 3-19 to figure 3-21 that level 1 Iso-toxic optimization for 
the prostate cohort did not yield significant improvement over level 0 dose 
escalation. This result was markedly different to lung cohort optimization of the 
same level. To investigate this further, data for individual patients was analysed and 
correlated to the tumour & OAR behaviour and to the observed response. Let’s 
focus on level 0 & level 1 results relevant to prostate tumours (α/β=1.5 Gy) and 
rectum OARs (α/β=3 Gy with n=0.09, m=0.13 – LKB NTCP model parameter).  
Table 3-7 Analysis of TCPpop and NTCPpop for level 0 escalation to understand the small improvement in TCP as 
a result of level 1 optimization 
Table 3.7 shows that when prescription dose increases from 60 Gy to 66 Gy for a 
fixed fraction number (20 here), the rise in TCPpop is 12.5% against the rise in 
NTCPpop (1.6% to 9.6%) which is 8%. The difference in the slope of TCP versus dose 
and the slope of rectum NTCP versus dose is very small (rectum is a serial organ and 
the rise in NTCPrectum is dominated by Dmax and not the Dmean of the OAR DVH). This 
also demonstrates that the room for optimization by means of increased fraction 
size is limited as offered by level 1 optimization (where DVH dose is escalated up to 
a set Iso-toxic NTCP- maximum 10%). Thus, Level 1 optimization, in this case, is 
unlikely to provide any notable benefit compared to level 0 optimization beyond 
the 60 Gy prescription dose.   
Level 0 
DSF 
Dose 
(Gy) 
Level 0 
TCP 
TCP Std. 
deviation 
Difference 
Level 0 
NTCP 
NTCP 
Std. 
deviation 
Difference 
0.9 54 45.0% 1.8%   0.1 0.0%   
1 60 62.7% 1.5% 17.7 1.6% 1.0% 1.0 
1.1 66 75.2% 1.1% 12.5 9.6% 4.0% 8.0 
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Prostate tumours are very slow growing and thus the effect of repopulation is 
considered to be negligible. Uzan & Nahum (2012) published the Marsden TCP 
model parameters after performing a fitting exercise on the set of patient data from 
the MRC RT01 randomised controlled trial. The ambiguity with prostate tumour 
modelling arises from the lack of consensus between different research groups over 
the value of α/β. Bentzen & Ritter (2005) have written about the ambiguity in the 
derivation of α/β of prostate tumours using clinical data reported by 2 different 
research groups.   
The trial PR5 by the national cancer institute of Canada estimate prostate tumour 
α/β as 1.12 Gy (-3.3,5.6) (Bentzen & Ritter,2005; Lukka et al., 2005) and a study by 
Valdagni et al. (2005) estimated the same quantity at 8.3 Gy (0.7,16). The debate 
about the correct α/β value for the prostate tumour continues but there is strong 
evidence supporting α/β=1.3-1.8 Gy (Dearnaley & Hall, 2017) without correcting for 
overall treatment time, and α/β=1.93 Gy (or α/β=4.14 Gy ‘worst’ case scenario) 
considering the effect of overall treatment time as per Vogelius & Bentzen (2013).  
The current analysis shows the effect of changes in α/β of prostate tumours from a 
radiobiological viewpoint (assessed through treatment individualization results of a 
set of prostate patient data).  
Figure 3-24 Comparison of Population TCP prediction for various α/β values compared to recent clinical trial 
results for 60Gy20# regimen 
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Comparison of population TCP of the current dataset using (α/β=1.5, 5 and 10 Gy 
for a 60-Gy 20 fraction regimen) with recently published clinical trial results 
(Dearnaley & Hall, 2017) suggests that without considering the time factor for 
proliferation, α/β is likely to be low (close to α/β=1.5). A TCP model fitting exercise 
for different values of α/β using the latest clinical results is likely to provide a better 
estimate of the absolute value of α/β for prostate tumours as shown in figure 3.24.  
It is seen in figure 3.24 that average population TCP (using the current prostate 
tumour Marsden TCP model parameter set derived by fitting model to MRC RT01 
trial outcome data) at 60 Gy prescription dose in 20 fractions is nearly 14-15% lower 
than the average tumour control rate result of the PROFIT trail and nearly 25% 
lower than that of the CHHiP trial result. It is to be noted that MRC RT01 was based 
on a 37 fractions schedule and the current analysis is for 20 fractions treatment 
which would mean that tumour repopulation is could to have been a contributory 
factor to this large difference in the predictions of TCP for prostate tumour. Based 
on the prostate tumour TCP model parameter set (α/β=1.5 Gy), it was observed 
that Iso-toxic dose escalation at large fraction sizes (low total no of fractions) is still 
advantageous compared to fixed fraction uniform dose escalation. The current 
outcome data from PROFIT, CHHiP and HYPRO trial also suggests a similar trend. As 
latest outcome data on prostate treatment is available, refinement of prostate TCP 
& NTCP model parameters is thus necessitated which will reduce error in absolute 
predictions by the models and thereby in RadOpt software module results. RadOpt 
allows alteration of model parameters so once the new parameter set is available, 
the strategy comparison analysis could be repeated seamlessly.   
3.4.3 Uncertainty analysis 
The absolute uncertainty on TCP or NTCP model predictions associated with the 
current results can be categorised into two types.  
1) Uncertainty in the results due to systematic error  
The optimization algorithm uses the dose scaling factor ‘variable’ to optimize TCP 
and NTCP for a given fraction number regimen. The optimization algorithm is set to 
minimize the cost function to the tolerance of 10-4. Thus, the error in percentage on 
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any calculation is 0.01% for optimized TCP and NTCP calculation contributed by the 
optimization algorithm. This is the systematic error on the output from the 
optimization algorithm.        
2) Uncertainty in results due to uncertainty associated with the used model 
parameters. 
Different methods were investigated to try and address this source of uncertainty 
which contributes to error in the results derived by the RadOpt software module.     
One of the ways to assess the error on the model prediction (i.e. TCP or NTCP) 
would be to calculate the root mean square error (RMSE) of the model fit to clinical 
data. The RMSE provides an estimate of the distance between the predictive model 
line fit and the data points used to fit the model. None of the publications from 
which the model parameters have been derived report the RMSE of the fitting curve 
(over clinical outcome or toxicity data) that would facilitate quantifiable assessment 
of the uncertainty on the assessed variables (i.e. TCP assessed from fitting outcome 
data or NTCP assessed by the fitting of toxicity data). 
Uncertainty associated with any model fit is dependent on the input data quality 
and fitting algorithms employed. Data quality here relates to homogeneity in 
treatments (e.g. use of concurrent therapies), planning criteria, data collection & 
reporting methods; and homogeneity in the patient population (age group, disease 
classification stage, secondary co-morbidities, etc.).  Model parameters are mostly 
reported with 68%-95% confidence intervals by individual research groups. In order 
to estimate realistic parameters & associated uncertainty in prediction, clinical data 
reported by various groups should be used for fitting as undertaken in the 
QUANTEC series of publications (Jackson et al., 2010). With technical advances in 
treatment planning and delivery systems, the outcome data reported has shown 
improvement in toxicity control rates which requires updating of data fitted model 
parameters (e.g. Results of MRC RT01 compared to PROFIT Trial or CHHiP Trial) with 
updated 95% confidence interval limit for fitted parameters.  
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The uncertainty analysis undertaken on L-K-B NTCP model and Marsden TCP models 
used in this research work is reviewed in the next section. It is important to 
reiterate that TCP/NTCP model parameter fitting was not the aim of this research 
thesis. It is acknowledged that the absolute uncertainty in model calculations 
should be addressed, or at least the gap between model derived predictions and 
actual outcome data should be demonstrated. It is planned to address the latter by 
updating the graphical display of RadOpt software to allow plotting of reference 
clinical outcome data in parallel to the software output.      
3.4.3.1 NTCP model related uncertainties 
The L-K-B model parameters have been derived and reported in the literature by 
Marks et al.(2010), Gagliardi et al.(2010) and Gulliford et al. (2012).  As the L-K-B 
model is empirical in nature, the model parameters are derived by fitting the model 
to reported data. The data fitting aims to achieve a fit that passes through all the 
data points included in the fitting process.  
The LKB NTCP model is dependent on the fitting of three parameters (n, m and 
TD50) that are non-linearly co-related with each other. This makes the process of 
estimating error on overall predictions of the model quite complicated. Luijk et al. 
(2003) presented four methods of confidence interval analysis using the covariance 
matrix method, likelihood landscape method, Monte Carlo simulation method and 
the Jackknife method (bootstrapping). Each of these methods was applied to 
parameters of the critical volume model (A. Niemierko & Goitein, 1993b). Luijk et al. 
(2003) concluded that employing likelihood landscape (LL method) as demonstrated 
by Schilstra & Meertens (2001) would be the best-suited method to establish 
confidence intervals on fitted “CV model” parameters (accounting for non-linear 
interdependences of various model parameters being fitted).  LL method requires 
extensive computation whereas covariance matrix method was shown to fail when 
parameter correlations for a given model are non-linear (which is the case with the 
LKB model parameters).  
Ideally, if the outcome data is available at one’s own organisation, model parameter 
fitting should be carried out on this data using fitting techniques as demonstrated 
by Schilstra & Meertens (2001). Comparing the results of this exercise to the 
109 | P a g e  
 
published model parameters for a given model & OAR should allow error estimation 
in NTCP calculations. The outcome data for the patient datasets used in this thesis is 
unavailable, so the above error analysis cannot be carried out.  
The LKB NTCP model parameters used in this thesis are reported with confidence 
interval limits (derived using maximum likelihood fitting) after fitting over various 
reported clinical results data [See Marks et al.(2010) for Radiation Pneumonitis in 
Lung radiotherapy NTCP model parameters & Michalski (2010) for Rectal Injury in 
Prostate radiotherapy NTCP model parameters].  Using the lower and higher 
confidence interval limits quoted in the literature to form an assessment of 
uncertainty in NTCP calculations for radiation pneumonitis and rectal bleeding 
complications is likely to be incorrect as the correlation between n, m and TD50 is 
non-linear.  
Further, the average rectal bleeding (grade 2 or lower) NTCP (assuming rectum α/β= 
3 Gy) for the current DVH datasets (56 patients – 2%) was compared to the CHHiP 
trial results for 60 Gy 20 fractions arm (CHHiP-  11.9%; Dearnaley et al., 2016) and it 
was found that the population average NTCP was significantly lower than the results 
of the CHHiP trial. For, the 74 Gy 37 fractions regimen the cohort rectal bleeding 
NTCP was 3% and CHHiP trial reported (13.7%). The change in NTCP (from 60 Gy 20 
fraction to 74 Gy 37 fraction) was ~1% in both model predictions versus trial results.  
There is a clear underestimation of the population NTCP in this case, although the 
relative change in NTCPpopulation is predicted correctly by ‘RadOpt’.  After comparing 
the NTCP prediction for each patient dataset on both ‘BioSuite’ and ‘RadOpt’, it is 
believed that either the cohort made available for this analysis was very small or 
consisting of largely favourable patients or that the NTCP parameters need re-fitting 
(which is very likely the case considering the recent availability of results from large 
clinical trials). A comparison of results between ‘BioSuite’ and ‘RadOpt’ only 
signifies consistency in application of the TCP & NTCP models across the two 
systems developed at our institute; with BioSuite having been adopted/distributed 
widely. The error contributed by the algorithms of ‘RadOpt’ software thus remains 
low. Further, RadOpt allows the user to alter the NTCP/TCP model parameters, 
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which will enable users to use more recently published parameters to calculate 
results. Model parameter refitting is out of the scope of this research work, but if 
access (DVH plus outcomes) to data from a recently concluded trial like CHHiP or 
PROFIT is gained, a complete refitting and error analysis of the model parameters 
could be carried out.  
Grade II radiation pneumonitis risk (NTCPpop) predicted by ‘RadOpt’ for the lung 
patient cohort is 8.6% for the 55 Gy 20 fraction regimen. Assuming the population 
of patients in the available database of 59 DVH datasets is representative, the 
calculated NTCPpop prediction is compared with published data by Lester et al. 
(2004), Clenton et al. (2005), Faria et al. (2006), Pemberton et al. (2009), Din et al. 
(2013) and Maguire et al. (2014) who reported clinical outcome data for 
hypofractionated accelerated NSCLC radiotherapy treatment. Faria et al. (2006) 
reported a radiation pneumonitis grade II risk of 6.2% (n=32), Clenton et al. (2005) 
reported this risk as 6.6% (n=90) and Pemberton et al. (2009) found the risk was 
14% (n=140). Din et al. (2013) reported a combined grade I/II risk of radiation 
pneumonitis for the 55Gy 20 fraction regimen to be 15% (i.e. the grade II radiation 
pneumonitis risk is likely to be lower than 15%). Maguire et al. (2014) only reported 
the risk of radiation pneumonitis grade III but it was as high as 8.3% (n=128, 69 
concurrent arm, 59 sequential arm) whereas Lester et al. (2004) had no grade III 
complication (n=97). Based on the above data, it is observed that grade II radiation 
pneumonitis predicted by RadOpt software (8.6%, n=59) is within the clinically 
reported range (6-15%, mean 9-10%) with a difference of ~2% from the mean. 
3.4.3.2 TCP model related uncertainties 
The Marsden model (which is a mechanistically derived model) is used for TCP 
calculations in the current research work. The parameters of the Lung tumour 
model used here were reported by Carver et al. (2015), Baker et al. (2015) and 
Nahum et al. (2011). Nahum et al. (2011) used outcome data reported by Bentzen, 
Saunders, & Dische (2002), Martel et al. (1999) and Clatterbridge Cancer Center 
data to estimate lung TCP model parameters quoted in table 3.1. Nahum et al. 
(2011) reported excellent fit to the data and also undertook uncertainty analysis by 
repeating the fitting exercise 50 times over TCP sampled from a normal distribution 
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of reported TCP values plus 5% 
standard deviation. The resulting 
data fits accrued an average 
standard deviation of 0.1% in α 
and σα and about 5% in Tk and 
Td. The resultant effect in TCP 
calculations due to these errors 
in individual parameters would 
be minimal. It is emphasized 
that the co-relation between the 
parameters is non-linear and 
thus to assess the absolute error a log-likelihood analysis spanning extreme 
variations in the parameter is likely to provide a more robust assessment of the 
errors associated with TCP calculations. The SOCCAR trial results of 2-year overall 
survival (46%) for sequential radiotherapy (55Gy 20 fraction) is very well predicted 
by the software results for level 0 (TCPpop - 44%) as shown in figure 3-13 (Maguire et 
al., 2014). Lester et al. (2004) reported a 2-year survival of 44.4% in 135 lung cancer 
patients treated with accelerated hypofractionated 3D CRT in their study. However, 
the total dose varied from 50-55Gy delivered over 15-20 fraction, but 72% of the 
patients received 55Gy in 20 fraction treatment. Din et al. (2013) reported a 2-year 
survival of 50% in an NSCLC cohort of 609 patients treated with a 55Gy 20 fraction 
regimen across 4 different centres in the UK. Based on the above, it is inferred that 
the Lung TCP model prediction has an absolute difference of 2-3% in the population 
average TCP compared to the mean for the 55Gy 20 fraction outcome results.  
Carver et al. (2015) employed the likelihood landscape methodology to establish 
correlation and uncertainty on fitted α and σα model parameters of the Marsden 
TCP model over the studies reported by Bradley et al. (2005) and Kong et al. (2005). 
Their findings suggest that robustness of the likelihood landscape method is high 
when estimating uncertainties over the fitted parameters if sufficient data are 
available for analysis. They also report that there is a significant correlation 
between the α and σα parameters, and uncertainties in fitted α and σα cause a 
Figure 3-25 Comparison of reported tumour control for each 
dose/fractionation schedule (CCO – Nahum,2011; UMCC – 
Martel, 1999; CHART – Bentzen, 2000) with predicted control 
for fitted parameters; = 0.307 Gy-1= 0.037 Gy-1,Tk = 20.9 days, 
Td = 3.7 days. (With permission from Nahum et al.,2011) 
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significant effect on Lung tumour TCP calculations. Using a similar uncertainty 
analysis method, Baker et al. (2015) published the latest Lung Marsden TCP model 
parameters that are used to generate the optimization results shown in figure 3-15. 
Their fitting showed an excellent fit of predicted model data to the clinical data (fig 
3-26). However, an absolute fitting error was not reported which could be used to 
assess the propagated error in results derived through ‘RadOpt’ software.  From a 
comparison of clinical outcome data and TCP calculation from ‘RadOpt’ software, it 
is concluded that the lung TCP model parameter set has an absolute error of 2-3% in 
its prediction and fits the outcome data from multiple sources well.  
For the prostate TCP model error analysis, the average TCP of the prostate cohort 
DVH dataset was calculated using the TCP model parameters published by Uzan & 
Nahum (2012) using the α/β=1.5 Gy.  This was undertaken considering the latest 
evidence from results of the reported trials in Dearnaley & Hall et al. (2017) that 
report prostate tumour α/β to be 1.8 Gy (CHHiP) whereas results of the PROFIT trial 
α/β suggest it is 1.3 Gy. Further, there is ambiguity concerning the use of a time 
factor which adds to the uncertainty of predictions by models as reported by 
Dearnaley & Hall (2017), Tree et al. (2013) and Vogelius & Bentzen (2013). 
Figure 3-26 Comparison of TCP model prediction with reported local control at 2 years. Published 3D-CRT for 
mixed-stage disease (  ), published stage I SABR (  ), parameter fit to combined 3D-CRT and SABR data (x), 3D-CRT 
only model (   ), SABR only model (    ).  Reproduced from Baker et al. (2015)  
113 | P a g e  
 
 As per ‘RadOpt’ calculations, the average prostate tumour TCP was 63% compared 
to the CHHiP report of 91% and the PROFIT trial report of 79% for 5-year 
biochemical (bfs) or clinical recurrence free survival for the 60-Gy 20-fraction 
regimen. For the 2 Gy/fraction regimens (74Gy 37 fraction CHHiP the 5-year bfs was 
88% and for 78 Gy 39 fraction PROFIT regimen it was 79%. For the 2 Gy/fraction 
regimen, RadOpt average TCP prediction was 60% (74Gy 37 fraction) and 65% (78Gy 
39 fraction). Thus, the relative change in TCP due to change in regimen is <5% which 
is in line with clinical results. However, the absolute TCP is underestimated for both 
the regimens (fig 3-27). The model parameters for calculating prostate tumour TCP 
thus need to be updated using the latest available trial results to form absolute 
error estimates.    
3.4.3.3 Error on use of recommended dosimetric tolerance limits  
Marks et al. (2010) in making recommendations of dose volume limits to restrict 
radiation pneumonitis (after radiotherapy) state that “Recommending dose/volume 
limits is challenging because there are no clear and consistent ‘‘thresholds’’ for 
candidate metrics (i.e., the response function is often gradual), and the 
‘‘acceptable’’ risk level varies with the clinic scenario. Radiotherapy fields for lung 
cancer may be appropriately large for target coverage; physicians and patients 
often need to accept the significant pulmonary risks. Furthermore, there are marked 
interpatient variations in pre-RT lung function that may impact symptom 
Figure 3-27 The ‘RadOpt’ based TCPpop compared with the recently published Prostate radiotherapy clinical 
trial results. Black circles encompass specific arms of the reference studies. All the point grouped by the 
circle are same regimen (e.g.  group 1 has 60Gy20# for results of CHHIP & PROFIT along with one point from 
RadOpt output).  
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development, and tumour-related dysfunction may improve after RT. Despite these 
caveats, it is prudent to limit V20 to <30–35 %and MLD to <20–23 Gy (with 
conventional fractionation) if one wants to limit the risk of RP to <20% in definitively 
treated patients with non–small-cell lung cancer.”  
It may well be that V20 < 30-35% or MLD <20-23 Gy is the best radiation 
pneumonitis predictor, but the error around this clinically used limit is not given in 
the literature.   
Similarly, for rectal incontinence (after prostate radiotherapy treatment) the dose-
volume limits currently recommended & used for planning do not include any error 
associated with the dose or the % volume irradiated.  As per Michaliski et al. (2010)  
“The following dose–volume constraints are provided as a conservative starting 
point for 3D treatment planning: V50 < 50%, V60 < 35%, V65 < 25%, V70 < 20%, and 
V75 < 15%. However, they have yet to be validated as ‘‘relatively-safe’’.For typical 
DVHs, the NTCP models predict that following these constraints should limit Grade 2 
or > late rectal toxicity to <15% and the probability of Grade 3 or > late rectal 
toxicity to <10% for prescriptions up to 79.2 Gy in standard 1.8- to 2-Gy fractions.” 
As of now due to differences in treatment practice, data-collection methods and 
restrictions on access to collected data, it is not possible to quantify the error in 
predictions even for the dosimetric constraints currently recommended. Using TCP / 
NTCP models is a step towards quantification of this error. Ideally, if the complete 
treatment & follow up data of clinical trials (like CHIPP & PROFIT) was made 
available to a researcher, quantification of the error on TCP & NTCP model 
parameters would be facilitated.   
3.4.3.4 Uncertainty Analysis Summary 
In summary, the uncertainties associated with toxicity prediction of TCP and NTCP 
models used in this thesis have been investigated. The systematic uncertainty 
contributed by the algorithm in the calculation is reported to be of the order of 
0.01%. The absolute difference in population average TCP calculated by the 
Marsden TCP model (Lung tumour parameter) for our data and outcome data used 
by Nahum et al. (2011) was about 2% indicating a low absolute error in model 
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prediction. The uncertainty propagated in the results due to inherent uncertainties 
in the model parameter could not be quantified further using methods described in 
detail by Luijk et al. (2003) due to the lack of outcome data. However, log-likelihood 
error analysis of the lung model parameters set published by Baker et al. (2015) and 
used for analysis in this chapter fitted well to clinical data with a small 95% 
confidence interval window for α= 0.293 (0.286 to 0.302) Gy-1 and σα = 0.051 (0.042 
to 0.067) parameters. Further, assessment of the effect of the absolute error on 
model predictions for prostate tumour TCP is currently very high and necessitates 
refitting of parameters.  
However, it is important to reiterate that the primary goal of this chapter was to 
establish a methodology & create a software to allow comparison of treatment 
strategies over a population in order to assess trends in population response due to 
changes in treatment strategies. The functionality to undertake Iso-toxic 
prescription dose optimization (level 1) and Iso-toxic dose-fractionation 
optimization (Level 2) is also built into the software. The therapeutic gain for a 
population is the key metric that is provided by ‘RadOpt’ software when comparing 
two strategies (be it changes in regimen, models or treatment optimization 
strategies).  
3.5 Conclusion 
In this chapter, an analysis of radiotherapy treatment data for lung and prostate 
tumour cohorts was performed to assess if individualization of radiotherapy 
prescription dose and fractionation can improve the overall population tumour 
control probability as a function of the population-averaged normal tissue 
complication rate. The TCP and NTCP calculations by the in-house software were 
‘quality checked’ against BioSuite software (Uzan & Nahum, 2012) to ensure 
consistency and precision in the use of models. The architecture of the software 
algorithm built to perform the analysis was described and the assumptions made 
were discussed. Three different levels of dose optimization on both tumour cohorts 
were performed. Initially, only a single OAR toxicity constraint was considered for 
the optimization but this was subsequently extended to other OAR constraints in 
order to make the analysis as clinically realistic as possible. The analysis for both 
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cohorts was performed using various sets of ‘best estimates’ of model parameters; 
it was shown that individualization of prescription dose and fractionation (level 2) is 
beneficial for both lung and prostate cancer cohorts (α/β=10,3 and 1.5 Gy).  
It is concluded that individualization of radiotherapy dose prescription has the 
potential to significantly improve radiotherapy outcomes; this is particularly the 
case for lung cancer radiotherapy for which current outcomes are poor. 
Furthermore, it has been found that for lung tumours the average number of 
fractions required to achieve the highest TCP is around 15 compared to current 
regimens of 20 or more fractions. This is a very favourable result from the point of 
view of resources and patient convenience; a reduced number of fractions mean 
fewer visits for the patient and consequently a greater patient throughput. The 
above finding from this study should be cautiously approached and validated by 
clinical data. 
There is much controversy regarding the actual α/β value of the prostate tumour. 
The level 2 optimization results for α/β=1.5 Gy indicate that hypofractionation 
would be the best course of treatment. However, the best course of treatment 
needs to be ascertained using multiple factors like clinical outcome reports for 
various regimens, laboratory tumour cell survival analysis and radiobiological 
modelling analysis (considering the uncertainty in results due to the lack of robust 
model parameters). The point being made is that now a tool/software system is 
available by means of which analysis of large sets of cohorts can be done to assess 
the actual population behaviour, predict effects on the population response due to 
changes in regimens, parameters or even cohorts and present the data in an easily 
understandable format. This is believed to be an original contribution to the field of 
radiotherapy quite apart from the results of using this system to analyse different 
cohorts as presented here.  
1) For future work, I would like to implement data fitting to model the relation 
of specific Vxx for a given OAR and related NTCP as shown in plot 4 of figure 
3-4. That analysis is to be accompanied by a statistical report display which 
will provide information on errors associated with the fitting and the related 
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confidence interval. This will allow clinicians to estimate the relation 
between dosimetric constraints and OAR toxicity for a given set of cohort 
data.   
2) Secondly, I would like to develop a flagging system to segregate results into 
a true positive, false positive decision matrix and develop a validation 
marker to associate results with clinically observed data. This is to be 
implemented by calculating the squared difference of TCPpop & NTCPpop 
observed for a set of data processed using RadOpt software and reported 
clinical outcome data for the same regimen for the same indication. 
Accounting for errors associated with a model’s absolute prediction, a 1 or 0 
to TCPflag variable and NTCPflag variable are to be assigned. 
TCPscore=√ (|TCPpop – TCPclinical|2 – TCPerror2) 
NTCPscore=√ (|NTCPpop – NTCPclinical|2 – NTCPerror2) 
 
 
 
TCPflag= 0  if TCPscore > Set threshold value*  
            =1  if TCPscore <= Set threshold value* 
NTCPflag= 0  if NTCPscore > Set threshold value*  
            =1 if NTCPscore<= Set threshold value* 
In the 2 X 2 matrix shown above, the values of calculated TCPflag and NTCPflag 
are to be input which will provide an indication of the validity of the 
observed results compared to clinical data.  The method critically depends 
on how the ‘absolute error’ on TCP and NTCP model predictions is quantified 
and the value of the threshold (* above) that assigns the ‘flag’ a zero or one 
which is under consideration as of now. This process will also require 
building a library of clinical outcome data for all clinically used regimens for 
a given tumour type.  
Decision Matrix 
TCP flag 
0 1 
NTCPflag 
0 True Negative False Positive 
1 False Positive True Positive 
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3  4  
Chapter 4 Radiotherapy Treatment 
Optimization based on Patient-Specific 
Tumour Radio- sensitivity Information 
4.1 Introduction 
Exploring different strategies for individualizing radiotherapy treatments using 
radiobiological models and then analysing the results is the key idea of this thesis. 
The focus of the previous chapter was on individualization of tumour prescription 
dose & fraction number (using dose-volume information) which provided evidence 
in support of the individualization techniques (or ‘levels’) proposed by Nahum & 
Uzan (2012). The TCP model employed in the previous chapter takes into account 
heterogeneity in tumour-clonogen radiosensitivity over a population through the 
parameter σα (Nahum & Sanchez-Nieto, 2001). It has been shown by Gerweck et al. 
(2006) and West et al. (1997) that tumour radiosensitivity is an important marker 
that helps determine therapy response. Chapman (2003, 2014) discusses in detail 
the mechanisms responsible for tumour cell killing: the radiosensitivity parameter α 
describes ‘direct’ or ‘one-hit’ unrepairable damage and the parameter β 
corresponds to the combination of sub-lethal damage events, separated in time, 
that result in cell death.   
Another important set of variables that would aid tumour-response and/or normal-
tissue tolerance/complication prediction are biomarkers (e.g. H2AX, [18F]HX4) 
[Dubois et al., 2011; Olive & Banáth, 2004]. Correlations between biomarker 
expression and treatment response have been established in several studies. 
However, variability in results from different groups has been observed which 
suggests a need for technique standardization (Menegakis et al., 2009; Olive & 
Banáth, 2004).  
Thus, if patients could be stratified into smaller groups of radiosensitivity 
(determined from some yet to be discovered, fast and minimally invasive biomarker 
driven assay), it is hypothesized that model predictions would be more accurate, i.e. 
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more ‘individualized’. It is assumed that there is a genetic profiling test / 
multivariate-factor analysis that can stratify patients into different sub-groups 
based on intrinsic tumour radiosensitivity.  
The benefit of having this patient specific information in individualization of 
radiotherapy treatment is explored in this chapter. It is emphasised that the 
investigation described in what follows is based on tumour radiosensitivity rather 
than on normal-tissue radiosensitivity; ideally one would have knowledge of both.  
The Marsden TCP model is used for TCP calculation and the L-K-B model is used to 
calculate NTCP, that are explained in detail in chapter 2 (section 2.3, 2.4). Model 
parameters used in the TCP and NTCP models are shown in table 4-1 and table 4-2.  
MARSDEN TCP MODEL 
Tumour Lung Lung2 Prostate1 Prostate2 Prostate3 Prostate4 
α (Gy-1) 0.307 0.293 0.3 0.258 0.218 0.155 
ασ 0.037 0.051 0.114 0.099 0.082 0.058 
α/β (cGy) 1000 1000 1000 500 300 150 
Clonogenic Density 10^7 10^7 10^7 10^7 10^7 10^7 
Repopulation Constant 3.7 3.7 - - - - 
Delay to repopulation (days) 21 21       - 
Reference 
Uzan 
(2012) 
Baker et al. 
(2015) 
Uzan 
(2012) 
Uzan 
(2012) 
Uzan 
(2012) 
Uzan 
(2012) 
Table 4-1 The Marsden TCP model parameters used in this analysis are shown above 
LKB NTCP MODEL 
End Point 
Radiation 
Pneumonitis 
Oesophagus 
Complication 
Myelopathy Heart 
Rectal 
Bleeding 
Faecal 
Incontinence 
Bladder 
Complication 
  
m 0.45 0.44 - 0.64 0.13 0.42 -  - 
n 1 0.32 - 0.13 0.09 1 -  - 
TD50 (cGy) 3140 5100 -   7690 10570 -  - 
α/β OAR 
(cGy) 
300 1000 87 250 300 300 600 600 
Vxx V20 - - V30 V50 V50 V80 V65 
Vxx Limit 30% - - 46% 50% 50% 15% 50% 
Dmean (cGy) - 3400 -       -   
Dmax (cGy) - - 5000           
Reference 
Uzan (2012) 
Chapet et al. 
(2005)  
Kirkpatrick 
(2010) 
Martel 
et al. 
(1998) 
Michalski 
et al. 
(2010)  
Peeters et 
al. (2006) 
Viswanathan 
(2010) 
  
Marks et al. 
(2010) 
    
Wei 
(2008) 
    
  
  
Table 4-2 LKB NTCP model parameters and dose-based constraints for different endpoints/complication; 
accounted for in this analysis are shown above.  
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4.2 Methodology 
4.2.1 Radiosensitivity based Stratification of cohorts and TCP calculation 
The Marsden TCP model accounts for patient radiosensitivity in terms of mean 
radiosensitivity αx and standard deviation σα spread across a population as shown in 
Figure 4.1 below. The x-axis represents patient specific tumour radiosensitivity with 
standard deviation . If the patient’s clonogens are highly radiosensitive or highly 
radio-resistant, the patient will belong to the tail end of the normal distribution 
beyond the +2σ, +3σ or -2σ, -3σ dashed lines away from αmean= αx.  
 
 
 
 
 
 
 
 
Figure 4-1 The normal distribution is shown in the figure marked by dotted lines indicating the area covered 
by mean+/-standard deviation. For the purpose of this research work, the variable assumed to be normally 
distributed is tumour radiosensitivity (x) with population mean αx and its standard deviation given by σα.  
The Marsden TCP model assumes that radiosensitivity of tumour clonogens for a 
specific patient is not known and that radiosensitivity in a given cohort is normally 
distributed, bounded by αx-3σ to αx+3σ as in figure 4-1. However, if the patient 
population can be stratified into sub-groups of low, medium and high 
radiosensitivity through a biopsy or genetic test, the patients’ radiosensitivity will 
now belong to a specific subpopulation of the original cohort (green, yellow or blue 
zone indicated in figure 4-2 (tumour radiosensitivity of each patient tumour is 
indicated by the red circles).  
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Figure 4-2 Normal distribution of patients’ tumour radiosensitivity ‘x’ with αx being mean 
radiosensitivity and σα being the standard deviation. The yellow area represents patients’ 
radiosensitivity spread across αx+/-σα and the green & blue regions are patients’ radiosensitivity 
spread across αx+/- σα to αx+/-3 σα. The green and blue regions account for 31.6% (15.8% each) of 
the population, and the yellow region accounts for 68.4% of the population (Denker, 2012). 
Two methods of accounting for the normally-distributed variation in tumour 
radiosensitivity in calculating the TCP for a given patient using the Marsden TCP 
model are described next.  
1. In method 1, it is assumed that absolute patient tumour radiosensitivity is 
unknown and radiosensitivity is randomly chosen from a normally 
distributed pool and assigned to the patients’ tumour. For each sample 
drawn signifying absolute radiosensitivity xi, TCP(x)i is calculated using the 
Marsden model TCP equation (eqn.4-2 with αx=xi and σx =0). An average of 
TCP(x)i for i=1…n should result in a TCP estimate accounting for normally 
distributed radiosensitivity across a population provided that n is large. This 
method is similar to bootstrapping involving random sampling and averaging 
over a large sample to account for the normal distribution of radiosensitivity 
parameter in the calculated TCP.   
Thus, per method 1 radiosensitivity ‘x’ is sampled from the normal 
distribution (with αx mean and σα standard deviation) n times and TCP is 
calculated as per equation 4-1.  
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                                                 𝑇𝐶𝑃 =
[∑ 𝑇𝐶𝑃(𝑥)𝑖
𝑛
1 ]
𝑛
                                      Eqn. 4-1 
2. The second method of accounting normally distributed radiosensitivity in 
the TCP model would be to integrate and normalize the TCP(x) [i.e. dP(x) in 
figure 4-2] function over the normal distribution where αx is the mean 
radiosensitivity and σα is the standard deviation of the normal distribution as 
shown in equation 4-2. 
              𝑇𝐶𝑃 =
[∫ TCP(x)dx
α𝑥+3𝜎𝑥
α𝑥−3𝜎𝑥
]∗𝑒[−(𝛼− ᾱ)
2/2σα
2]𝑑𝛼
𝜎𝑥√(2𝜋)
                                  
where TCP(x) is given by  
 𝑇𝐶𝑃 =  ∏ 𝑒
[−𝜌𝑐𝑙𝑉𝑖∗𝑒
{−(𝛼𝐷𝑖(1+
𝛽
𝛼
𝑑𝑖)−(𝑙𝑛2(𝑇−𝑇𝑘)/𝛼𝑇𝑑))}]
𝑖                               Eqn. 4-2 
A Matlab® based simulation was conducted to verify that method one and two 
described above yielded the same TCP for a given DVH. A secondary aim of the 
simulation was to determine the number of random samples required to equate the 
TCP calculation of equation 4-1 and 4-2 to form an equivalence between both the 
methods.  
A single DVH was used for calculating TCP for both the methods. Based on 
calculations undertaken TCPEqn 1 = TCPEqn 2 when n= ~1000 (i.e. TCPmethod 1 requires 
1000 samples with randomly generated radiosensitivity values to be less than or 
23.4% 23.4% 23.4% 23.3% 23.3% 23.3%
Marsden TCP= 23.3%…
20.0%
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Figure 4-3 The figure shows the change in standard deviation in TCP calculation using method 1 for different 
number of samples. The calculation of TCP by method 2 is shown by the blue line for comparison with method 1.  
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equal to TCPmethod 2 by 0.1 (absolute value with a standard deviation of 0.01) with a 
maximum absolute error of 1%. A graph showing the variation in TCP through the 
sampling method (i.e. dependence on no. of samples for a low standard deviation) 
versus method 2 based Marsden model calculation is shown in fig 4-3. TCP 
calculation of a stratified subgroup of patients based on radiosensitivity can be 
achieved if radiosensitivity is sampled from different parts of the normal 
distributions as indicated by yellow, green and blue zones of the distribution shown 
in figure 4-1.    
Using method 1, radiosensitivity(x) is sampled from a given region 
(yellow/green/blue region in fig 4-2) n times (minimum sample size 1000 to give a 
standard deviation of 1% as seen in fig 4-3). Then the TCP(x) is calculated and the 
average of TCP (x1….n) is taken to get the TCP of the patient accounting for the 
radiosensitivity spread over the subpopulation of the cohort applying equation 4-1. 
On the other hand, the TCP of patients belonging to a given subgroup can be 
calculated using the Marsden Model by integrating the radiosensitivity ‘x’ over the 
selected region of radiosensitivity of the normal distribution with altered limits of 
the integral (relevant to the chosen subgroup – e.g. for green subgroup - αx-σα to αx-
3σα). Thus, TCPgreen, TCPyellow and TCPblue (with reference to fig 4-2) would be 
calculated that would be the population averaged TCP of the subgroups of the 
patients which are part of the whole population (with radiosensitivity in the range 
αx+3σα to αx-3σα). Theoretically, a weighted averaged TCP of the subpopulation 
should equate to the TCP calculated for the population as a whole using the 
Marsden TCP model as shown in equation 4-3. 
0.16*TCPgreen+0.68*TCPyellow+ 0.16*TCPblue= TCP (Eqn4-2…Marsden TCP) = TCP (Eqn4-1 for n=1000)      
          …...Eqn. 4-3 
The cohorts represented by the green/yellow/blue regions in fig 4.2 are part of the 
whole population represented by the normal distribution (αx, σα) and we do not 
sample the radiosensitivity of each patient (as part of the subpopulation 
green/yellow/blue) rather integrate over the region of the normal distribution. 
Thus, σα remains unchanged for the subgroup TCP calculation as the subgroups’ 
124 | P a g e  
 
cohort is not individually sampled. Further, statistically σ of a subpopulation (with 
mean α) drawn out of a population will be lower by a factor √n (n=number of 
samples of the subpopulation) but here is no clinical data to validate that 
assumption. Thus, σα is used for the TCP calculation of subgroups to account for 
radiosensitivity spread within the cohort.   
If that were not the case, equation 4-3 would not hold true. This assumption is 
verified in the results section [e.g. table 4-4 Box (8,5) compared to Box (11,5)]. Also, 
the complexity of optimization algorithms used in this chapter mandated 
maximization of computing efficiency and compared to method 1, method 2 was 
significantly faster. As the difference between TCP calculation by either method was 
minimal, method 2 was implemented. Next, the methodology employed to 
demonstrate the effect of radiosensitivity data on treatment optimization 
achievable for different clinical scenarios is explained. These are described in detail 
in subsection 4.2.3 of the methodology section. 
It is aimed to optimize treatment prescription dose and fractionation in an Iso-toxic 
(aka Iso-NTCP) manner as applied in chapter 3 (level 1 & 2). In order to make the 
analysis computationally viable, the computation is restricted to data for the 
tumour and a single primary OAR endpoint. For the lung tumour cohort, the RTOG 
grade 2 radiation pneumonitis risk, and for the prostate tumour cohort the RTOG 
grade 2 rectal bleeding endpoints are considered as the principal dose-limiting 
toxicity endpoint. The TCP and NTCP model parameters used are available in table 
4-1 and table 4-2. The Marsden-model Lung tumour parameters (table 4-1) used are 
shown under the column with title Lung (αx=0.307 Gy-1, σα=0.037) and similarly for 
Table 4-3 Stratification of patients with normally distributed radio-sensitivity into subgroups 
3-group stratification       
Radiosensitivity Level Lower limit Upper limit  AUC % 
Low x-3σ x-σ 15.7% 
Medium x-σ x+σ 68.3% 
High x+σ x+3σ 15.7% 
Full range x-3σ x+3σ 99.7% 
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prostate tumours the parameters under column with title Prostate4 (α/β=1.5 Gy) 
are used for TCP calculations of this chapter. 
The above-mentioned optimizations (Level 1 and 2) are undertaken for two 
situations  
1) Optimizations ‘without’ the availability of radiosensitivity information at the 
treatment planning stage  
2) Optimizations ‘with’ the availability of radiosensitivity information at 
treatment planning stage (which allows stratification of patients on the basis 
of subgroups) 
Iso-toxic dose individualization (level 1) and optimum dose & fraction number 
individualization (level 2) is performed over the entire cohort (for each patient DVH 
dataset in turn) and the results are reported as population-averaged TCP, NTCP, and 
optimal fraction number for each cohort for both the clinical scenarios listed above. 
The percentage patient dropout for each of the cohorts is also reported which is 
the number of patients having TCP<10% (post level 1 or level 2 optimization 
TCPthreshold) divided by the total number of patients in the cohort. This parameter 
helps in estimating the number of patients that are not likely to benefit from radical 
radiotherapy treatment. The interpretation of data generated for this analysis is 
notably dependent on the choice of TCPthreshold value which should be clinically 
relevant. The different levels of dose individualization are explained in the next 
section which are applied to the clinical scenarios mentioned above (detailed in 
section 4.2.3).    
4.2.2 Individualization and Optimization 
4.2.2.1 Level 0 TCP Calculations – ‘without’ radiosensitivity stratification and ‘with’ 
stratification 
The level 0 is a TCP calculation at the standard prescribed dose (55Gy20# for lung 
cohort and 60Gy20# for the prostate cohort). Firstly, level 0 TCP-NTCP analysis is 
performed where the TCP and NTCP of the patient is calculated for the standard 
prescription using the Marsden TCP Model (also explained in section 2.3, Chapter 
2). The results provide the population-averaged TCP, forming the level 0 results 
without radiosensitivity stratification information. These TCP calculations would be 
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similar to those observed in Chapter 3 for Level 0 calculations with a dose scaling 
factor of 1 (if the same TCP model parameters and DVH is used). Now the patients 
are stratified into radiosensitivity subgroups and a level 0 TCP-NTCP calculation is 
performed for each patient considered in each radiosensitivity group and the 
variation in the TCP and NTCP of the patient is then compared to the standard 
prescription based TCP & NTCP calculations (55Gy20# for lung tumours and 
60Gy20# for prostate tumours). 
Figure 4-4 The flow diagram of the program that performs all the calculations is shown here. The program can be 
divided into 3 sections (Input, engine, output) and we use the escalator, optimizer and selector modules (refer 
Chapter 3, section 3.2.2-3.2.4) to perform the optimization. 
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4.2.2.2 Level 1 & 2 Optimization -- ‘without’ radiosensitivity stratification and ‘with’ 
stratification 
The Level 1 optimization is a radiobiological model based Iso-toxic dose escalation 
at fixed fraction number wherein dose to the tumour is escalated until a given NTCP 
OAR dose tolerance limit is reached. Level 2 optimization refers to radiobiological 
model based Iso-toxic dose escalation where the tumour dose is Iso-toxically 
escalated (like level 1), but with an additional search criteria of finding the minimum 
number of fractions (yielding the highest TCP at an Iso-toxic NTCP). The dose-
response curve of a tumour is sigmoidal in shape and plateaus beyond a given 
prescription dose (i.e. the slope of the curve becomes very small as dose increases) 
as shown in figure 4-5. A limit on dose escalation at this point is placed (called 
TCPcap – 95% is selected here). This is done as the increase in therapeutic gain from 
further dose escalation is very low.  An upper limit on TCP is thus actioned (i.e. 
TCPcap) to limit dose escalation for level 1 and level 2 optimizations. An observation 
of the dose-response curve in Nahum & Uzan (2012) demonstrates this as shown in 
figure 4-5. 
Figure 4-5 A NSCLC patient DVH based dose escalation is shown above. The slope of the NSCLC control 
probability curve reduces significantly from radiobiological evaluation 95% - 100% with dose rising by ~7 Gy on 
the x-axis as shown by the black bars. For the same change in the prescribed dose NTCP of radiation 
pneumonitis increases by ~3%. Thus, the relative  therapeutic benefit of increasing prescribed dose after 
achieving a 95% TCP is very low. Courtesy: Nahum and Uzan (2012) 
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The optimizations are Iso-toxic whereby the algorithm is set to increase the dose 
and hence the TCP until a fixed NTCP constraint is reached. The dose multiplication 
factor that allows the optimizer to escalate dose to the tumour DVH to achieve 95% 
TCP is of course applied to the OAR DVH to obtain the patient’s OAR toxicity 
probability (i.e. as long as the set NTCP limit is not crossed). For some patients, 95% 
TCP is achieved at a lower dose scaling factor than that yielding the current NTCP 
limit. This results in a lowering of the mean population NTCP (NTCPpopulation | 
NTCPpop) for a cohort/subgroup. For example, if the NTCP limit is set to 7%, the 
NTCPpop might be around 6.5% as some of the patients hit the TCPcap and the 
optimizer/selector then reduces the dose scaling factor (and hence the NTCP). The 
comparison between different clinical scenarios may become problematic if the 
NTCPs are not equal.  
To mitigate that, a NTCP-aim limit is set that allows dose escalation for individual 
patients such that the NTCPpop achieved is equal to the pre-set value making results 
comparable across the cohorts. The NTCP limit for Lung Radiation pneumonitis risk 
of 17% corresponds to a V20 of 30% for healthy lung tissue. Similarly, the rectal 
bleeding risk of 10% corresponds to V50<50% for rectum. These values were 
derived from a Vx – NTCP correlation exercise that is described in detail in chapter 6 
and are the absolute individual NTCP limits used in the optimizations for the 
conventional fractionation scheme. L-K-B NTCP model used here accounts for the 
effect of fractions through the EQD2 based DVH correction method introduced by 
Fowler (2001). Thus, the change in NTCP limit (based on Vx-NTCP co-relation) for a 
change in fractionation is not required. 
Assuming that patients can be stratified into radiosensitivity subgroups; the 
computations now correspond to tumour radiosensitivity over a smaller area of the 
normal curve (yellow, green or blue zone – Fig 4-2). All the patients in the cohort 
are placed in the different subgroups, one at a time, and treatment individualization 
is performed. The flow chart explaining the process is shown in Figure 4-4. The TCP 
& NTCP model parameters, patient specific radiosensitivity subgroup information, 
tumour DVH and OAR DVH are passed to the program modules as inputs.  
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For level 1 dose individualization, the number of fractions is kept constant at 20 for 
both lung and prostate cohorts. The patients are now considered to belong to a 
given radiosensitivity subgroup (thus, the TCP calculations will only account for the 
radiosensitivity spread for that subgroup, e.g. αmean+σα to αmean+2σα for high 
radiosensitivity group fig 4-1). 
The level 1 dose optimization is performed over the entire cohort to determine the 
average maximum prescription dose at 20 fractions not exceeding an average NTCP 
limit of 5%, 7%, 10%, 13% and 17% for radiation pneumonitis in the Lung cohort and 
1%-10% for rectal bleeding in the prostate cancer cohort. Thus, a level 1 
prescription dose and the optimized TCP for each patient of the cohort in the given 
tumour radiosensitivity subgroup will be available. This process is then performed 
considering the cohort to belong to each radiosensitivity subgroup, one at a time. 
The mean of these TCPs and NTCPs yields the optimum level 1 population response 
for each subgroup.  
For level 2 dose fractionation individualization, the same procedure as above is 
performed along with optimization of the number of fractions for each patient DVH 
dataset, considering all patients in the same tumour radiosensitivity subgroup (i.e. 
all the patients are considered to belong to one sub group at a time). So, for level 2 
individualization, an optimized TCP, NTCP, prescription dose and fraction number 
for each patient is calculated. After that the optimised prescription doses and 
fraction numbers of all the patients are then averaged to yield the level 2 optimised 
population dose and fractionation. This exercise is performed for average Iso-toxic 
NTCP limits (5%, 7%, 10%, 13% & 17% for the lung cohort) one at a time to produce 
an optimum TCPpop versus Iso-NTCPpop curve.  
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4.2.3 Clinical Scenarios 
For both types of optimizations (Level 1 & 2), calculations are performed for the 
following clinical scenarios and in the order below for all the cohorts. Depending on 
the clinical scenario the calculation of TCP changes as explained below. The change 
in the calculation is in the value of α and range of σ α supplied as parameters to the 
model.  
For any scenario described below, the output of Level 1 optimization is a Dose 
scaling factor (DSF), TCP (calculated using DSF, prescription dose, α, σ α), and the 
NTCP limit. The output of Level 2 optimization is a dose scaling factor (DSF), optimal 
fraction number, TCP (calculated using DSF, prescription dose, α, σ α), and the Iso-
toxic NTCP limit. 
Case 1) “Standard Optimization” No radiosensitivity information about the patient 
is available before or after individual treatment optimization.  
During the optimizations for this scenario, the TCP is calculated for each tumour 
DVH with a mean radiosensitivity α and standard deviation +/-3 σ α. The Marsden 
TCP model assumes normally distributed radiosensitivity across a population. 
Thus, the output of level 1 & 2 optimization will be  
Level 1 optimization output = (TCP (α+3σ, α-3σ), Iso-toxic NTCP, DSF std  at 20 fractions)  
Level 2 optimization output = (TCP (α+3σ, α-3σ), Iso-toxic NTCP, DSF std  at Optimized 
fraction #)  
 
The results of case 1 (levels 1 & 2) optimization will be equal to results of the 
optimization methodology used in chapter 3 (as long as input files and parameters 
are unchanged) 
Case 2) “Without” – Patient-specific radiosensitivity information is only available 
post treatment and the TCPs for the Iso-toxic Prescription doses (of case 1) are re-
calculated using the updated radiosensitivity information about the patient’s 
tumour. 
131 | P a g e  
 
Range of radiosensitivity:  Low Radiosensitivity - (α-3σ, α-σ) 
    Medium Radiosensitivity - (α-σ, α+σ) 
    High Radiosensitivity - (α+σ, α+3σ) 
The TCP is now recalculated for the same patients per group: 
Level 1 optimization output = (TCP(α  Range) ,Iso-toxic NTCP, DSFstd  at 20 fractions)  
Level 2 optimization output = (TCP(α  Range) ,Iso-toxic NTCP, DSFstd  at optimized 
fraction #)  
 
Use of the “α range” to correct the case-1 optimized TCP allows inclusion of 
radiosensitivity information about the patient retrospectively. This facilitates a 
subgroup-wise comparison of case 2 and case 3 results (in a retrospective vs 
prospective type comparison) 
Case 3) “With” – Here, patient specific radiosensitivity information is made use of 
before individual treatment optimization and is used in the optimization.    
In this case, TCP calculations are undertaken in the optimizations using the “α 
range”. This results in optimizations that have accounted for patient-specific 
radiosensitivity. The output of the optimizations is shown below  
Level 1 optimization output = (TCP(α  Range) ,Iso-toxic NTCP, DSF Radiosensitivity optimized  at 
20 fractions)  
Level 2 optimization output = (TCP(α  Range) ,Iso-toxic NTCP, DSF Radiosensitivity optimized  at 
optimized fraction #)  
The optimizations have two limiting factors:   
1) Iso-toxicity in terms of absolute NTCP and 
 2) TCP upper-bound limit.  
The absolute Iso-toxicity NTCP limit is set to ensure that the optimization does not 
result in prescription doses that would cause clinically unacceptable damage in any 
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patient. The TCP upper bound limit is set as 95% as an increase in TCP beyond 95% 
would require a very large increase in prescription dose for a negligible clinical gain. 
This was explained in detail in section 4.2.2.2 
The result of this entire analysis is a table of TCP & NTCP of radiosensitivity groups 
versus optimization levels with & without radiosensitivity information (e.g. table 4-
4). This analysis is then repeated for average Iso-toxicity limits of 5%, 7%, 10%, 13% 
and 17% for the lung cohort and 1%, 3%,5%.7% and 10% for the prostate cohort. 
The final result is a TCP-NTCP graph for level 1 optimization and one for level 2 
optimization comparing the ‘without stratification’ case 2 to the ‘with stratification’ 
case 3 over a range of NTCP limits (e.g. figure 4-9). The above analysis is also 
undertaken for a 5-group radiosensitivity classification to assess if there is any 
benefit of finer patient radiosensitivity segregation. The patient dropout for each of 
the cohorts in each subgroup is also calculated and compared to the patient 
dropout for the non-stratified optimization analysis (Patient dropout is defined at 
the end of section 4.2.1).  
The exercise is performed using the DVH datasets for two anonymised cohorts, one 
of 59 lung patients (originally prescribed 55Gy20#) and the other of 56 prostate 
patients (originally prescribed 60Gy20#).  
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4.3 Results  
4.3.1 Lung Cohort Results 
Table 4.4 shows level 0 calculations plus optimization results for level 1 and level 2 
strategies performed over a lung cancer cohort. All the results in this section are 
population averages and display the cumulative effect of having/not having 
radiosensitivity information on Iso-toxic radiotherapy treatment optimization.  
4.3.1.1 Level 0 – TCP NTCP calculations (3 Group) 
Level 0 analysis is shown in figure 4-6 where TCPpop & NTCPpop calculations for a lung 
cohort belonging to the low / medium / high radiosensitivity group are compared to 
generic population radiosensitivity based TCPpopulation & NTCPpopulation estimates. It 
can be seen that TCP calculated using generic population radiosensitivity (assumed 
to be normally distributed over the whole population) overestimates individual 
TCPs for the radio-resistant group of patients (Level 0 Case 3-Low, table 4-4) and 
underestimates it for the highly radio-sensitive group of patients (Level 0 Case 3-
High, table 4-4).    
Also, a weighted average TCP of the population in the stratified group yields the 
same TCP as in the case of ‘without’ scenario which validates the subgroup TCP 
calculations. This can be observed from table 4-4 comparing box (8,2) & (8,4). As the 
Figure 4-6 The variation in population TCP calculations “with” the use of radiosensitivity based stratification 
shown for cohorts falling in “low”, medium - “med” and “high” radiosensitivity subgroups compared to TCP 
calculations “without” patient radiosensitivity information (Cohort Average TCP). NTCP remains unaffected as 
normal tissue radiosensitivity is assumed to be constant across the population.    
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normal tissue radiosensitivity variation is not accounted for, NTCPpopulation for ‘with’ 
& ‘without’ stratification case is the same.  
4.3.1.1 Level 1 Optimization (3 Group) 
To see the effect of having the ability to stratify patients (on the basis of 
radiosensitivity) on level 1 Iso-toxic optimization look at figure 4-7 (row 5 & 6 of 
table 4-4).  It is observed in Figure 4-7 that when Iso--toxic conditions are 
maintained (7% NTCP here) TCP would be higher ‘with’ radiosensitivity knowledge 
compared to ‘without’ it (in all subgroups).  To compare the overall gain in both the 
scenarios the weighted average TCP and NTCP is calculated [Table 4-4 box (8,5) & 
box (8,6) shows a definite therapeutic gain]. The use of stratification leads to a 2.2% 
improvement in the stratification based TCPpop compared to the case 2 based TCP 
optimization at same average Iso-toxic NTCP. TCPpop of ‘low’ group is higher than 
the ‘without’ scenario TCPpop – this unexpected finding is due to TCP saturation 
observed in some of the patients driving the average TCPpop higher for ‘with’ 
category compared to ‘without’ category. This is critically analysed in the lung 
cohort results discussion section (refer section 4.4.1).  
Comparing row 5a and 6a in table 4-4, it is seen that 66% patients may have 
dropped out of radiotherapy treatment if information about their tumour 
radiosensitivity had been available compared to a 37% drop-out rate for the 
Figure 4-7 shows level 1 lung treatment optimization results for ‘without’ case 2 and ‘with’ case 3 scenarios with 
respect to radiosensitivity stratification. Also, the result of level 1 case 1 - no stratification scenario is shown for 
comparison.  
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‘without’ stratification scenario. Also, for patients in the high radiosensitivity group, 
only 12% would have dropped out compared to 37% patients as per ‘no 
stratification’ / ‘without’ case optimization.  The dropout of patients (TCP post 
optimization < 10%) observed is high as the NTCP is limited to average 7% which 
restricts dose escalation in many cases. The effect of this in the low radiosensitivity 
group is most noticeable. A low tumour radiosensitivity requires higher doses to 
achieve a high TCP but this also raises NTCP faster and as the radiosensitivity of 
OARs is assumed to be constant, a low optimized DSF (i.e. with low TCP resulting in 
higher dropout) results. However, if this NTCP limit is increased to 17%, the dropout 
for the level 1 no-stratification scenario (case 2) is found to be zero, versus 22% in 
the level 1 case 3 (‘with’) optimized low radiosensitivity subgroup and 1.7% in 
medium radiosensitivity subgroups (0% dropout in high radiosensitivity subgroup 
for both the cases). In summary, the dropout rate is affected by the choice of Iso-
NTCP limit which drives the dose escalation (that drives the TCP up). Further, it is 
important to note that these results are based on limited amount of retrospective 
datasets and need to be further validated by data from larger and varied population 
datasets and along with radiosensitivity data to be clinically useful.    
4.3.1.2 Level 2 Optimization (3 Group) 
Figure 4-8 (Rows 7 & 8 of table 4-4) shows the results of employing level 2 
radiotherapy optimization ‘with’ (case 3) or ‘without’ (case 2) patient-specific 
Figure 4-8 A level 2 optimization to compare ‘with’ and ‘without’ radiosensitivity information scenario with 
respect to radiosensitivity stratification. The results of level 2 case 1 - no stratification scenario is shown for 
comparison.    
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tumour radiosensitivity information. At ~7% average NTCP, the weighted-average 
population TCP [box (8,8) in table 4-4], i.e. combining all subgroups, shows a 8.35% 
improvement over the population TCP achieved without using the radiosensitivity 
information [box (8,7) table 4-4]. The percentage patient dropout for level 2, case 3 
for the low radiosensitivity subgroup was 19% higher than that for level 2, case 2 
result. Also, for the high radiosensitivity group, the patient dropout was lower by 
13%. This shows that many patients maybe be considered for a different treatment 
option or strategy had the tumour specific radiosensitivity been known. 
Furthermore, the percentage of patients showing the highest TCP at 15 fractions is 
considerably different in the case 3 based results (Low-56%, Medium-80%, High-
90%) compared to the standard ‘no’ stratification scenario case 2 based results 
(80%) shown in box (10,8) & box (10,7) in table 4-4. 
Columns 8 and 9 (table 4-4) are weighted averages of TCPs and NTCPs of various 
subgroups. The difference between level 1, case 2 weighted average TCP & NTCP 
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[Table 4.4 box (8,5), (9,5)] and level 1 case 1 [Table 4.4 box (11,5), (12,5) calculated 
using the program used for chapter 3] is negligible. These calculations are 
performed using independent programs and quality check the TCP, NTCP and Level 
1 optimization results obtained for this chapter. The same is true for calculations of 
level 2 optimization. The programming is thus observed to be consistent across 
algorithms used for chapter 3 & 4 of this thesis. The uncertainty in model 
parameters and their contribution to error in absolute predictions by the models is 
acknowledged but here the model predictions are used in relative terms to 
compare scenarios in the current analysis which suggests that uncertainty in the 
results is mostly contributed by the tolerance limit of the optimizer module cost 
function (set to 0.001 – systematic error).   
The results for 3-group stratification for both Level 1 and Level 2 indicate that using 
radiosensitivity information for treatment individualization significantly impacts the 
highly radiosensitive or radio-resistant subgroup treatment optimization. The 
‘medium’ subgroup is minimally affected by the application of radiosensitivity 
information for optimization.  
4.3.1.3 Lung Cohort Result - 5 Groups Stratification 
A similar analysis was performed with the patients stratified into 5 subgroups 
(radiosensitivity level – very low, low, medium, high, very high) instead of 3 (Low, 
Medium, High) and the results are reported in table 4-5.   
Use of radiosensitivity based stratification improves overall population TCPpop 
estimates by 2.29% for level 1 [Box (12,6) – Box (12,5), table 4-5] and by 7.95% [Box 
(12,8) – Box (12,7), table 4-5] for level 2 optimization compared to the scenario 
where patient specific radiosensitivity information is not used in optimization. 
Further, in the case of 5 subgroups, the number of fractions required by different 
subgroups for achieving optimal TCP varies considerably, but most of the patients 
achieve optimized results at 15 fractions. Comparing rows 7a and 8b in table 4-5, it 
is seen that if the patients were in the very low radiosensitivity group, an extra 34% 
patients could have dropped out of the treatment if the tumour radiosensitivity 
information had been available to optimize treatment regimens and in the very high 
radiosensitivity cohort 26% of patients could have been prescribed curative 
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optimized treatments compared to level 2, case 2 optimization where they would 
have dropped out of treatment. It is important to mention again that the % drop-
out would decrease if the Iso-toxic NTCP limit were increased, as the increase in 
dose escalation would increase the TCP. For level 2 optimization (case 3), 15 
fractions remain the ideal regimen for the majority of the patients in all the 
subgroups but there is a notable variation in the percentage of patients for whom 
15 fractions are ideal, when sequentially observing results for very low to very high 
radiosensitivity subgroups. Also, if the radiosensitivity information had not been 
available 15 fractions would have been the optimum fraction schedule for 80% of 
the patients. This is shown in row 7 of table 4-5, Box (14,7).  
Comparing table 4-5 Box (14,7) to table 4-5 row (8a), it is observed that for most of 
the patients belonging to the very low or low radiosensitivity groups, 15 fractions 
would not be an optimum fractionation schedule.  
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4.3.1.4  3 - Group Stratification versus 5 - Group Stratification 
For the lung cohort, level 1 and 2 optimizations are performed next at various Iso-
toxic NTCPpopulation limits in the 5%-17% NTCP limit range for 3- and 5-group 
stratification scenarios. The TCP-NTCP graphs below compare the ‘with’ and 
‘without’ cases over the NTCP range at different Iso-toxic limits. 
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Figure 4-9 TCP-NTCP graph for comparing Level 1 optimization for ‘with’ and ‘without’ radiosensitivity 
information scenarios for various Iso-toxicity limits for 3 radiosensitivity subgroup (High, Medium “med”, 
Low) stratification – Lung Cohort 
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Figure 4-10 TCP-NTCP graph for comparing Level 1 optimization for ‘with’ and ‘without’ radiosensitivity 
information scenarios for various Iso-toxicity limits for the 5 radiosensitivity subgroup (Very High “Vhigh”, 
High, Medium “Med”, Low, Very Low “Vlow”) stratification – Lung Cohort. 
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It can be seen that the group of patients furthest from the mean population 
radiosensitivity are the ones experiencing the highest variation in TCP values. The 
Figure 4-9 & Figure 4-10 show that the improvement in TCP estimates for highly 
radiosensitive and highly radio-resistant groups compared to the medium 
radiosensitivity group from case 2 ‘without’ to case 3 ‘with’ is relatively large.  
This can be observed by comparing the increasing gap (indicative of therapeutic 
gain) between ’with’ and ‘without’ cases for different radiosensitivity subgroups as 
the Iso-toxic limit is increased.  A similar trend can be seen for level 2 optimization 
over a range of NTCP limits in fig. 4-11 & fig. 4-12. 
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Figure 4-11 TCP-NTCP graph for comparing Level 2 optimization for ‘with’ and ‘without’ radiosensitivity 
information scenarios for various Iso-toxicity limits for 3 radiosensitivity subgroup (High, Medium “Med”, 
Low) stratification – Lung Cohort. 
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Figure 4-12 TCP-NTCP graph for comparing Level 2 optimization for ‘with’ and ‘without’ radiosensitivity 
information scenarios for various Iso-toxicity limits for 5 radiosensitivity subgroup (Very High “Vhigh”, High, 
Medium “Med”, Low, Very Low “Vlow”) stratification – Lung Cohort 
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A comparison of the overall weighted average population TCP & NTCP of the 3-
group and 5-group stratification (fig. 4-13) reveals that as the resolution of 
stratification increases the therapeutic gain improves slightly. Quantification of this 
therapeutic gain can be done at a fixed Iso-toxic level for patients in a given 
radiosensitivity subgroup. The highest difference in TCPpop is ~5% as seen in the low 
radiosensitivity group at 12.5% Iso-toxic NTCP, where 5 levels is superior to 3 levels. 
The high radiosensitivity group shows the same trend but the improvement in TCP 
at any given NTCP is very small (~1%). The medium radiosensitivity group does not 
show any improvement.     
Another important finding reported here is that radiosensitivity stratification would 
notably affect extremely radio-resistant patients, who could be considered for 
palliative treatment / alternative treatment. On the other hand, highly 
radiosensitive patients might be prescribed a less ‘aggressive’ treatment (i.e. 
individualized treatment in terms of total dose and or a number of fractions) to 
achieve a cure. It is arguable that the above results depend on the categorization of 
patients solely based on a statistically chosen range of radiosensitivity that is not 
validated clinically. However, such stratification tests if they were available could 
aid in categorising patients who could be considered for a different treatment 
pathway (possibly a clinical trial/research regimen) after gathering further clinical 
evidence (further tests that help ascertain if the patient may benefit from 
alternative treatment).         
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Figure 4-13 The comparison between 3 group (High, Medium “Med”, Low radiosensitivity) versus 5 group 
(Very High “Vhigh”, High, Medium “Med”, Low, Very Low “Vlow” radiosensitivity) stratification for lung 
patient cohorts after level 2 optimization. 
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4.3.2 Prostate Cohort Results 
In this section, the results of applying level 0, 1 and 2 optimizations to prostate 
patient datasets are presented considering a tumour α/β=1.5 Gy and 5% Iso-toxic 
NTCP limit. Also, TCP was calculated with parameters labelled “prostate4” in table 
4.1. The 3-subgroup stratification results are shown in table 4-6 and 5-subgroup 
stratification based results in table 4-7. Looking at Level 0 (case 2 vs case 3) in table 
4-6 for the standard prescription (60Gy20#), TCP-NTCP calculations show that TCP is 
severely underestimated for the radiosensitive subgroup patients (high) and 
severely overestimated for the radio-resistant (low) subgroup patients if the 
radiosensitivity based stratification is unavailable or is not used in the TCP 
calculations. The 5-subgroup tumour radiosensitivity stratification shown in table 
4-7 shows similar results.  
 
Comparing Level 1 optimization result shown in case 3 [Table 4-6, Box (8,6) (9,6)] 
scenario, the weighted average TCP & NTCP of the entire population is marginally 
better (same TCP at a lower NTCP) than for the case 2 scenario [Box (8,5) (9,5)]. The 
case 3 weighted average TCP is similar to that of the case 2 weighted average TCP 
Table 4-6 Radiosensitivity (3 group) based Radiotherapy Individualization 5% Iso-toxicity- Prostate Tumour (α/β=1.5 Gy) 
No 1 2 3 4 5 6 7 8 9 10 11 12 
1   TCP NTCP TCP NTCP TCP NTCP TCP NTCP 
No of 
Fractions 
Case 1 
TCP 
Case 1 
NTCP 
2 
Level 0 
Case2 
62.5 1.6 62.5 1.6 62.5 1.6 62.5 1.6 20         
3 Group Low Med High 
All 
(weighted 
average) 
    
No stratification 
Optimization  
Case 1  
4 
Level 0 
Case3 
0.0 1.6 68.0 1.6 95.0 1.6 61.5 1.6 20       
5 
Level 1 
Case2 
0.0 5.0 80.1 5.0 95.0 5.0 69.8 5.0 20     70.8 5.0 
6 
Level 1 
Case3 
0.0 5.0 80.1 5.0 95.0 0.01 69.8 4.2 20       
7 
Level 2 
Case2 
0.5 5.0 90.7 5.0 95.0 5.0 77.1 5.0 5     78.1 5.0 
8 
Level 2 
Case3 
0.5 2.5 90.5 4.8 95.0 0.0 76.9 3.7 [3 5 5]   
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but is achieved at a lower average NTCP (in case 3). The result for the level 2 
optimization comparison between the case-2 and case-3 weighted average results is 
similar. The lowering of NTCP occurs as the TCP hits the 95% cap (explained 
previously) and thus the optimizer module of the program tries to reduce the NTCP 
in order to keep the TCP at 95%. The % dropout of patients in each of the subgroup 
remains the same and knowledge of tumour radiosensitivity before or after the 
treatment seems to confer no significant benefit except for the high and very high 
radiosensitivity subgroups.   
The population-averaged optimization and individualization results of the 5 sub-
group classification of patients is given in table 4-7 where level 1 & 2 optimization 
results were obtained at 5% Iso-toxic limit for rectal bleeding complication for the 
prostate cohort. The use of 5-subgroup radiosensitivity stratification instead of 3 
subgroups does not appear to improve the population TCP at 5% Iso-toxic NTCP 
[compare table 4-7 box (12,8) to table 4-6 box (8,8)]. The results of performing 
similar analysis over a range of Iso-toxic limits (1-10% NTCP) are shown next in fig. 
4-14 & 4-15 below. There is no significant benefit of level 1 or 2 optimizations with 
use of radiosensitivity information except for the high radiosensitivity group. 
Figure 4-14 TCP-NTCP graph for comparing Level 1 optimization for ‘with’ and ‘without’ radiosensitivity 
information scenarios for various Iso-toxicity limits for 3 radiosensitivity subgroup (High, Medium “Med”, Low 
radiosensitivity) stratification – Prostate Cohort 
No 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
1 TCP NTCP TCP NTCP TCP NTCP TCP NTCP TCP NTCP TCP NTCP No of Fraction Case 1 TCP Case 1 NTCP
2 Level 0 Case 2 62.5 1.6 62.5 1.6 62.5 1.6 62.5 1.6 62.5 1.6 62.3 1.6 20.0
3 Group No Stratification Optimization
4 Level 0 Case 3 0.0 1.6 0.0 1.6 68.0 1.6 95.0 1.6 95.0 1.6 61.4 1.6 20.0
5 Level 1 Case 2 0.0 5.0 0.0 5.0 80.1 5.0 95.0 5.0 95.0 5.0 69.7 5.0 20.0 70.8 5.0
6 Level 1 Case 3 0.0 5.0 0.0 5.0 80.1 5.0 95.0 0.0 95.0 0.0 69.7 4.2 20.0
7 Level 2 Case 2 0.0 5.0 0.5 5.0 90.7 5.0 95.0 5.0 95.0 5.0 77.0 5.0 5.0 78.1 5.0
8 Level 2 Case 3 0.0 0.0 0.5 2.5 90.5 4.8 95.0 0.0 95.0 0.0 76.8 3.6 [ 1 3 5 5 5]
All (weighted average)VLow Low Med High Vhigh
Table 4-7 Radiosensitivity (5 group) based Radiotherapy Individualization 5% Isotoxicity- Prostate Tumour (α/β=150 cGy)
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Figure 4-15 TCP-NTCP graph for comparing Level 2 optimization for ‘with’ and ‘without’ radiosensitivity 
information scenarios for various Iso-toxicity limits for 3 radiosensitivity subgroup (High, Medium “Med”, Low 
radiosensitivity) stratification – Prostate Cohort 
Looking at Figure 4.14-4.15, it can be seen that the low and high radiosensitivity 
groups seem to have either very high TCP or very low TCP across the range of Iso-
toxic optimization conditions. This suggests that the effect of a change in the value 
of α has a significant effect on the TCP; however, the difference between the ‘with’ 
and ‘without’ scenarios on level 1 & 2 optimizations over a range of NTCP values is 
negligible. Nevertheless, as the TCP is affected significantly by a change in α, the 
patients that are highly radio-resistant or radiosensitive should be evaluated further 
to be considered for alternative treatment. Only level 2 optimization yields a 
significant advantage, achieving a high TCP for a low NTCP for the cohort.  Although 
the variation in TCP & NTCP across the subgroups is high, the variation in 
optimization results between case 2 and case 3 scenarios is very low which invites 
discussion on possible reasons behind such results (see section 4.4.2).  
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4.4 Discussion 
The aim of this investigation was to assess the potential effect of tumour 
radiosensitivity based stratification of patients on radiotherapy individualization. 
Level 1 and level 2 individualizations would yield individual patient-specific 
prescription doses and fraction numbers that are expected to improve therapeutic 
gain (in terms of TCP & NTCP) for a given patient. The use of stratification (assessed 
through a clinically valid method) firstly will aid the clinician in deciding if palliative 
or curative treatment is preferable for a given patient and level 1 & 2 optimizations 
on top of that for curative cases will give an indication of the improvement in the 
tumour control that can be achieved for each patient (by means of increased dose 
at a set toxicity level). It is emphasized, however, that this exercise utilizes a single 
OAR (the principal toxicity-governing OAR) per tumour type and has a dependence 
on the radiobiological models used; absolute predictions from which are susceptible 
to large uncertainties especially in the case of prostate tumour model predictions. 
Analysis of a large heterogenous set of patient tumour cells for radiosensitivity 
quantification through a clinically validated study is warranted to validate the above 
set of results obtained for this model based retrospective study.  
The above optimizations are performed for each patient dataset in the order of 
scenarios explained in 4.2.2. A population-average (TCPpop & NTCPpop) is formed to 
compare the ‘with’ case 3 and ‘without’ case 2 stratification scenarios for each 
subgroup.  The Case 2 calculation allows comparison with the Case 3 calculation 
thereby enabling an assessment of the benefit to patients of using this 
radiosensitivity knowledge pre-treatment. This assessment in the form of a 
prospective vs retrospective comparison at a subgroup level.  
The TCPpop & the NTCPpop for a subgroup (with ‘n’ patients) is formed by averaging 
the TCP1..n and NTCP1..n obtained for each level of optimization.  The average based 
results give an idea about the overall variation across the cohort, but when 
considering individual patients, the TCP/NTCP optimization may be different than 
the trend indicated by the averaged TCPpop and NTCPpop. This is because 
‘mean’/’average’ as a metric is statistically susceptible to bias due low sample size 
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of an experiment and particularly affected by outliers. Although, for the current 
analysis the “median” metric would not be a representative central tendency 
assessment statistic as the median fails to account for all the samples when there is 
a duplication of numbers in a sample. Therefore, the mean of optimized TCP was 
chosen to assess the population response (i.e. the central tendency).   
4.4.1 Discussion: Lung Cohort Result 
Results of this analysis as seen in Figure 4-7 & Figure 4-8 for Level 1 &2 optimization 
for the Lung patient cohort are unexpected [ Figure 4-7 TCP ‘low’ column ‘with’ 
subgroup is higher compared to TCP ‘low’ column ‘without’ – The expectation was 
exactly the opposite for the low radiosensitivity subgroup]. The low radiosensitivity 
group ‘with’ stratification has a higher population TCP at Iso-toxic 7% NTCP 
compared to the radiosensitivity corrected ‘without’ case. This can be attributed to 
the proportion of highly favourable patients in the dataset and its effect on the 
TCPpopulation. The term ‘highly favourable patient’ is explained below.   
The Iso-toxic escalation of tumour dose is likely to be affected by the location of the 
tumour in relation to the OARs (with respect to level 1 & 2 optimizations). Further, 
if the patient is highly ‘favourable’ (i.e. has a small tumour, tumour is isolated-
located away from OARs, high tumour radiosensitivity), a high TCP can be achieved 
at a lower than standard NTCP limit through level 1 & 2 optimization as all of these 
factors improve control probability by either allowing improved dose escalation or 
more efficacious cell kill due to radiation exposure (per the Marsden TCP model 
based optimization).  
Ideally, if a patient is radio-resistant the average TCP of level 1 optimization for 
‘with’ stratification case 3 will be lower than ‘without’ case 2. The above remains 
true as far as TCP calculation alone is concerned but not for L1 or L2 optimization 
(where TCP is a complex function of the Iso-NTCP based dose scaling factor) of 
individual patient datasets.  From the optimization algorithm point of view, if this 
same patient is very favourable (i.e. let us say; has a very small anatomically 
isolated tumour) then the optimized prescription dose (level 1) that will achieve a 
95% TCP will be very low irrespective of the radiosensitivity subgroup he/she 
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belongs to. Now if in a radio-resistant cohort of patients, there are many favourable 
patients then the average TCP of the population is still going to be high. The effect 
of variance in radiosensitivity is minimal on the TCP as the patient is favourable.  
Also, for favourable patients assumed to belong to the low radiosensitivity sub-
group, a somewhat higher dose will be required to raise the TCP to the upper-
bound limit compared to those in the other radiosensitivity sub-groups. Therefore, 
the dose-scaling factor (DSF) set by the L1 or L2 optimizer will be higher in this case 
than for the same patient in any of the other radiosensitivity groups, as a higher DSF 
will be required to ‘hit’ the TCPcap. This will not be the situation in the ‘standard’ 
optimization (case 1). The DSF used to calculate the case 2 ‘without’ TCP will be 
lower resulting in a lower TCP as compared to the optimized L1 or L2 case 3 ‘with’ 
TCP.   
Thus, for ‘favourable’ patients in the low radiosensitivity group, the TCP(α  low range, case 
3) can be higher compared to TCP(case 2) as L1 optimization requires a lower dose to 
reach the upper bound TCP limit. A few extremely favourable patients can drive the 
population TCP(α  low range) higher for the low radiosensitivity group compared to the 
population TCP(radiosensitivity corrected) group. Please refer section 4.2.3 for details of the 
cases [1-3] referred above. 
Also, the TCPpop of the low subgroup (table 4-4, Box (2,6) & Box (2,8)) are lower than 
‘standard’ case 1 L1 & L2 optimization results (table 4-4 Box (11,5) & Box (11,7)); 
which is as expected. The improvement in TCPpop observed in the low 
radiosensitivity group for case 3 (L1 & L2 optimization) compared to case 2 (L1 & L2 
optimization) is most likely to be a result of a bias created in the TCPpop due to TCP 
saturation (i.e. TCP=95%) for highly favourable patient datasets.  If the cohort has 
many favourable patients and is also highly radio-sensitive on the average, a high 
population TCP will be achieved at a reduced NTCP (i.e. reduced total dose). This is 
because the optimizer module is programmed to reduce the NTCP if at a given dose 
scaling factor the optimizer achieves 95% TCP.  
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Another important aspect that adds to uncertainty in the observed results is the 
prediction accuracy of the models used. Although the parameters used for the 
Marsden Model and L-K-B NTCP model are derived from clinical outcomes, the 
parameters used are fits to data and thus add to the uncertainty of absolute 
calculations (addressed in section 3.4.3 of Chapter 3). However, the current analysis 
uses model predictions to form a relative comparison between ‘with’ and ‘without’ 
clinical scenarios and thus as long as model parameters used currently are not 
changed significantly (unlike prostate tumour α/β changing from 10 Gy to 1.5 Gy) 
the results will be acceptable (with low precision but not misleading). It is important 
to note that these results are based on limited amount of retrospective datasets 
and need to be further validated to make them truly comparable to what is 
observed in clinical practice. 
In summary, it was shown that radiosensitivity information makes the most impact 
for patients at the extreme ends of the radiosensitivity normal distribution. 
Possessing patient specific radiosensitivity information can have significant 
implications in treatment optimization as the number of fractions that yield the best 
TCP at fixed NTCP level exhibits a large variation when one goes from the most 
radio-resistant to the most radiosensitive group in both the 3- and 5-subgroup 
stratification analysis (especially for lung patients). This is also demonstrated in 
table 4.5 row 8a where the percentage of patients with 15 as optimum fraction 
number varies considerably for different subgroups. The point made here is that 
having access to patient-specific radiosensitivity information for individualization 
and optimization of treatments could have a notable effect on the treatment 
selection and resource management - this is demonstrated for the lung cohort in 
table 4-4 & table 4-5 by comparing the percentage patient dropout and optimum 
fractions for patients in case 2 and case 3 (level 2 optimization). It is also important 
to note that the interpretation of the above results for the highly radiosensitive 
group lies on the chosen value of TCPcap variable and for the radio-resistant group 
lies on the chosen TCPthreshold value which for the purpose of this analysis is based on 
mathematical/statistical considerations. 
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4.4.2 Discussion:  Prostate Cohort Results 
The Level 0 calculation of TCP for the prostate patient datasets (table 4-6) showed 
that radiosensitivity of the patients when divided into sub groups, notably affects 
TCP calculations and optimization results; except for the medium radiosensitivity 
group. However, it was also observed that availability of information pre- or post-
treatment was not very effective in improving the optimization results (comparing 
level 1 case 2 versus level 1 case 3, table 4-6). The purpose of comparing case 1 and 
case 2 analysis was to retrospectively assess the improvement on the TCP that could 
have been attained in the optimization (using radiosensitivity information), which 
was not the case for the prostate cohort. The limited gain observed was for the high 
or very high radiosensitivity group of cohorts where TCP=95% was achieved at a 
relatively lower NTCP for case 3 scenario. Investigating case 1 and case 2 NTCP 
values of all the patients it was found that the average NTCP across the cohort was 
1.4% and average TCP was 62.4% without any optimization for the 60 Gy in 20 
fraction regimen (prostate tumour α/β=1.5 Gy). 
Further, the prostate tumour TCP parameters employed were α/β=1.5 Gy, α=0.155 
and σα=0.058 which suggests that the possible change in the value of α is almost a 
third of the mean value. This is likely to affect TCP calculations significantly as one 
moves from a low radiosensitivity (resulting in almost zero TCP at Iso-NTCP limit - 
table 4-6 [Box (2,6), Box (3,6) | Box (2,8 ), Box (3,8)]  sub group cohort to a high 
radiosensitivity sub cohort (resulting in 95% TCP at really low NTCP table 4-6 
[Box(6,6) -Box(7,6)]. Further, for level 2 optimization (optimization of the number of 
fractions) it is observed that a low prostate tumour α/β=1.5 Gy leads to higher TCP 
at lower numbers of fraction [table 4-6 Box (6,8), Box (7,8)].  
Thus, due to the large effect of σα on TCP calculation the optimizer finds a solution 
of achieving 95% TCPpop at 5 fractions for <1% NTCPpop for the highly radiosensitive 
group which seems unrealistic especially considering the fact that variation in 
normal tissue radiosensitivity is not accounted for in the current analysis. The 
algorithm is heavily reliant on the response of two separate models and 
uncertainties in prediction by these models affect the results of the optimizer which 
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can result in false positives/negatives. Refitting of both TCP and NTCP parameters 
over larger datasets is likely to yield more accurate model predictions reducing 
uncertainty in the results of the optimization algorithm. Another factor possibly 
contributing to such results for the prostate cohort is the lack of use of multiple 
OAR based optimization.  
4.5 Summary and Conclusions 
In this chapter, the availability of patient-specific tumour radiosensitivity 
information has been assumed and its effect analysed in a hypothetical clinical 
scenario. The cohort was divided into 3 and 5 radiosensitivity subgroups and the 
TCP & NTCP ‘with’ and ‘without’ radiosensitivity information for each subgroup was 
calculated. Further, level 1 and level 2 individualization & optimization of the 
treatment DVH datasets was carried out and the effect of having patient specific 
radiosensitivity information on optimized TCP and NTCP was analysed. For the lung 
cohort dataset, at 7% Iso-toxic NTCP, individualization of treatment would result in 
an average TCP increase of 17% (but with a very high dropout rate 44%) for the low 
tumour radiosensitivity subgroup but only 2% for the highly radiosensitive tumour 
cohort (with a 12% absolute reduction in dropout rate) when comparing clinical 
scenarios of case 3 ‘with’ to case 2 ‘without’ (using level 2 optimization). Dropout 
rate as discussed previously is directly affected by the choice of a threshold value of 
TCP (categorising a patient to not qualify for a given treatment strategy) and 
indirectly affected by the specified dose limiting Iso-NTCP. A higher threshold value 
of TCP will increase the dropout rate (as fewer patients will cross the TCP threshold) 
and setting a higher Iso-NTCP value will reduce the dropout rate (as more patients 
will be able to achieve the threshold TCP). Stratification of patients into 5 
radiosensitivity subgroups, as opposed to 3, results in slightly improved (1-2%) 
individualized level 2 TCP for lung tumour treatment but not for prostate.  
HYPRO/CHHiP trials quote a relatively high control probability (nearly 90% average 
tumour control with 9-10% average grade 2 GI toxicity – Dearnaley & Hall, 2017) 
without the use of stratification and it is likely that in the distant future dose 
escalation may reach a plateau. Robustness of the results especially for the prostate 
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tumour dataset is likely to increase with use of model parameters ascertained 
based on the latest clinical outcome data. 
Further work would include assessing the effect of patient-specific normal-tissue 
radiosensitivity variation on treatment individualization. Having patient-specific 
information on OAR radiosensitivity is likely to improve the current NTCP estimates 
and this would certainly affect (Iso-NTCP) individualization and optimization of 
radiotherapy treatments.  
As a part of the future work for this research chapter, the following updates and 
development to the software are planned to be undertaken.  
➢ Output results of this program to RadOpt software GUI interface 
allowing users to interact with the graphs in an improved manner 
forming a better user interface. 
➢ Program ‘handles’ in the code that allow interaction with other software 
systems like treatment planning systems.  
➢ I would also like to accommodate TCP and NTCP models implementing 
proton radiobiology in the current program and assess the effects of 
optimization on patients’ TCP and NTCP for proton treatment datasets. 
Another line of thought is exploring the relationship of OAR radiosensitivity to 
tumour radiosensitivity. How would a relation between OAR radiosensitivity and 
tumour radiosensitivity affect Iso-toxic treatment optimization and what would be 
the benefit of having this information?  Also, accounting for other dose-limiting 
OARs whilst performing “level 1 & 2 optimizations” is recommended as that may 
improve the robustness of optimization results, as shown in the results of chapter 3.  
 
5  
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Chapter 5 Radiobiological Inverse-
Planned Treatment Individualization 
and Optimization 
5.1 Introduction 
Current treatment planning best practice involves the use of dose-volume based 
criteria. Dose deposition in the target volume is generally aimed to be uniform 
accounting for the microscopic spread, geometric setup errors and motion artifacts. 
At the same time, sparing of OAR from radiation dose is emphasized. A clinically 
acceptable plan requires the prescription dose to be deposited in the tumour whilst 
not exceeding the OAR’s dose tolerance limit. The prescription dose (the total dose 
to be delivered in a fixed number of fractions) for a given type of tumour (non-
small-cell lung and prostate here) is continually evolving as clinical outcomes evolve.  
Radiobiological models are occasionally used to retrospectively assess treatment 
plans. Radiobiological modelling applied to radiotherapy data allows assessment of 
a treatment plan or aids comparison of two or more competing plans accounting for 
the behaviour of tumour/OAR in response to radiation exposure. The use of 
radiobiological models in the treatment planning process was advocated in AAPM 
report 166. Also, ICRU report 83 recommended that NTCP be reported in research 
studies (AAPM Task Group 166, 2012; ICRU, 2010).  
5.1.1 Treatment planning 
Treatment planning is performed with the active participation of a planner who 
defines the beam characteristics and the beam direction using a CT scan of the 
patient to conform a high dose of radiation to a specific target volume.  In ‘forward 
treatment planning’, the planner has absolute control of the system and decides on 
all the parameters of the geometric plan; the calculation of the total planned dose is 
then performed by the software. ‘3D-CRT’ treatment plans are usually forward 
planned.  
The introduction of IMRT and VMAT technologies has enabled treatment planners 
to better spare the normal tissues for a given target dose (De La Fuente Herman et 
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al., 2010; Deb & Fielding, 2009). The complexity of treatment planning has 
increased with the advent of IMRT/VMAT that allow better OAR sparing and thus 
forward planning is becoming less feasible. Further, automation in treatment 
planning (Inverse treatment planning) provided by current treatment planning 
systems (TPS) allows the development of complex plans in a relatively short time. In 
inverse treatment planning, the planner starts by loading the TPS system with a 3D-
CT image dataset. The OARs and target volumes containing the tumour are then 
‘contoured’ on the CT ‘slices’ as per the protocol followed at the centre using the 
TPS. Further, the planner inputs a list of objectives to be maximized and constraints 
not to be violated in relation to the target volume in the TPS. Inverse treatment 
planning is now undertaken which is an iterative process whereby the planning 
system, using an optimization algorithm, searches for the optimal solution to 
achieve set objectives and satisfy constraints.  
Figure 5-1 Flowchart showing the forward and inverse treatment planning processes. 
154 | P a g e  
 
Once the planner inputs the patient dataset, beam information (e.g. beam energy 
and beam angles) and the plan criteria, the inverse planning algorithm searches for 
the optimal solution, i.e. the treatment plan yielding a dose distribution with 
optimal objective value and satisfied constraints. The diagram in Figure 5-1 
indicates how forward and inverse treatment planning approaches work.  
The iterative inverse treatment planning algorithm aims to minimize the difference 
between the target dose distribution and the achievable dose distribution in terms 
of improving the objectives as much as possible while satisfying the constraints. The 
difference between the desired dose and the dose at each iteration is a score used 
to drive the optimization. 
𝑪𝒐𝒔𝒕 𝒇𝒖𝒏𝒄𝒕𝒊𝒐𝒏 = 𝒇(𝑫𝒅 − 𝑫𝒊)                        Eqn. 5-1 
Where Dose D = ∑ Ci,j*Wj   for j=1-n  with Dd= DoseDesired, Di=Dose iteration ;  
Wj is the weight of bixel j  
Cij determines the dose contribution of bixel j to voxel i  
 
This score assigned to every plan used for comparison is also known as a cost 
function calculated as shown in equation 5-1 (Webb, 2003). The algorithm adjusts 
the beam characteristics, e.g. the MU and the leaf positions of each control point 
(or segment) from which the bixel weights are computed in every iteration to 
reduce the cost function to its minimum value. As per communication with 
Raysearch Labs, the RayStation system algorithm optimizes segment MU (aka 
segment weights) and leaf positions, from which the fluence map (bixel weights) are 
computed, from which the dose distribution is computed. Different objectives and 
constraints can be given different weighting and sophisticated optimization 
algorithms can be built to improve the solutions; minimizing the time a system 
takes to converge to an optimal solution (Bokrantz, 2013). The idea of using 
biologically based functions to optimize treatment plans was initially presented by 
Wu et al. (2002). The first implementation of radiobiologically based planning was in 
the Monaco treatment planning system which made use of the EUD function to 
optimize treatment plans (Alber et al., 1999; Pyshniak et al., 2014; Semenenko et 
al., 2008). Since then, RayStation and the Pinnacle research planning systems have 
developed alternatives which allow scripting of custom functions or use of the TCP 
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and NTCP models as objectives or constraints (Uzan et al., 2016).  Further, the 
research version of RayStation TPS (RaySearch Laboratories®) used in this work was 
customised with the Marsden model-based TCP cost function.  In the next section, 
the RayStation treatment planning system is introduced.  
 
 
 
 
 
 
 
 
 
 
 
 
 
5.1.2 The RaySearch Treatment Planning System 
RaySearch Laboratories, Sweden provided a ‘research’ version of their treatment 
planning software RayStation to pursue the research described in this chapter. The 
workflow of the planning system is of tab-based navigation format and the interface 
is very user friendly. The system allows import of data in the DICOM format from 
multiple radiotherapy and imaging archival systems. The most important tabs of the 
system for this study are shown and described in the sections below. 
Figure 5-2 RaySearch Laboratories' Raystation Treatment planning system user-interface 
1 3 
2 
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5.1.2.1 Patient Data Management 
This module of the user interface enables the user to import/export patient CT 
datasets and generate plan reports. Further, it enables editing of patient 
identification data if necessary.   
5.1.2.2 Patient Modelling 
This ‘tab’ allows the user to create and modify structures on the CT dataset. The 
software has tools that enable addition and subtraction of structures to form new 
structures (i.e. lung-GTV). Also, there are features for manual and automatic 
contouring, 3D editing, region-of-interest statistics and many others. 
5.1.2.3 Plan design 
This ‘tab’ enables the user to create a treatment plan for a given patient. The 
system requires the user to input plan identification information, prescription 
information, radiotherapy treatment technique and clinical delivery system model 
specification (e.g. Elekta Synergy 10 MV Photon Beam). The beam specification 
(Gantry rotation, Energy, Iso-centre) is also fed to the system in this tab. This is 
necessary information to initiate the treatment planning process. There are options 
to add, copy and edit available treatment plans as well.  
5.1.2.4 Plan Optimization 
The plan optimization tab of the user interface is divided into three sections. On the 
top are the plan evaluation tools, at the bottom is the optimization criteria 
specification section and, on the right, is the 3D CT based plan visualization tool. 
This is highlighted in Figure 5-2 with yellow boxes marked 1, 2 and 3.  
5.1.2.5 Optimization section 
This section has multiple tabs that allow the user to input optimization objectives 
and constraints, beam weighting and beam optimization settings for the inverse 
planning algorithm. The objective/constraints section is mostly used in this work. 
The planning criteria listed in tables 5.1 and 5.2 are input in this section. The 
objectives can be either physical-dose based or radiobiological-model based. The 
constraints can however be any combination of physical and radio-biological 
metrics. There is also an interlinked-library (separate module to the treatment 
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planning system) of radiobiological models pertaining to specific OARs and tumours. 
They also provide a reference to find a given publication where the model was 
originally cited and allow customization of organ-specific parameters as required by 
the user. For this analysis, LKB NTCP and Marsden TCP models have been used. The 
parameters used for the models are the same as those used in chapters 3 & 4 (See 
table 3.1 and table 3.2 in Chapter 3 for details). 
5.1.3 Goals 
The aim of this chapter is to use radiobiological models to create inverse 
radiotherapy treatment plans and compare them to standard dose-volume 
(objective/constraint) based plans. 
For each radiotherapy patient dataset, a standard inverse treatment plan [DB-plan] 
is initially formed (Plan 1- clinically acceptable in terms of standard dose-based 
objectives & constraints) using dose-based metrics as cost functions (uniformity of 
dose, total dose, minimum dose, maximum dose). Next, a plan is created on the 
same patient with the same fractionation schedule using radiobiological constraints 
and objectives (RB-Plan). These two plans are ranked using TCP & NTCP models and 
the DVH based metrics used clinically. The DVHs are also used to compare plans. 
The question to be answered is “Between the DB-plan and the RB-plan which is 
better therapeutically?”  
A secondary aspect to this chapter was to question the current clinical norm of 
“uniform target dose”. “Uniform dose to target (PTV)” is a standard dose-volume 
based objective used in clinical treatment planning; it regulates dose variation 
across the target structure (ICRU report 50 requires the dose in the target to be 
between the range defined by -5% to +7% of the prescription). The introduction of 
VMAT & IMRT and the improvement in treatment delivery technology (IGRT, OAR 
Motion tracking/gating) has resulted in better sparing of normal tissues for a given 
tumour dose.  In line with the above considerations, extra DB- plans were created 
after removing the uniformity in PTV requirement to assess the effect of this 
objective in relation to finding an optimal plan for a patient (for both lung and 
prostate patient datasets). 
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Our DVH based retrospective optimization of Lung Patient data in Chapter 3 
suggests that 15 fractions was the optimal number of fractions for NSCLC patients 
(based on retrospective level 2 optimization of DVH datasets).Thus, as a tertiary 
aim, a second set of plans at 15 fractions were created for the lung patient datasets 
to evaluate if radiobiology based individualized hypo-fractionation at 15 fractions 
resulted in therapeutically better or worse lung treatment plans. The radiobiological 
metrics TCP and NTCP of the generated plans are used to compare the plans along 
with dose-based metrics & DVHs of the OARs.   
5.2 Methodology 
5.2.1 RayStation System Quality Assurance 
Initially, the radiobiological model calculations of RayStation were checked against 
those of ‘Biosuite’ (C++ based) and ‘RadOpt’ (MATLAB based), both independent 
radiobiological modelling software developed at Clatterbridge Cancer Center. Two 
plans were created; one each for a lung and a prostate patient CT dataset and TCP 
was calculated for the ‘PTV’ & ‘GTV’ structures and NTCP for the ‘total lung’ or 
‘rectum’ structures using RayStation, Biosuite & RadOpt software. The calculations 
were checked for different fractionation schedules to ascertain if repopulation in 
tumours was accounted for by RayStation in the same way as in BioSuite and 
RadOpt (& vice versa). This relative TCP calculation check over independent systems 
ensured the consistency of application of the Marsden TCP & LKB NTCP models 
across all systems.   
5.2.2 Inverse Treatment Planning Methodology 
The current analysis was performed on 4 anonymised patient datasets 
(radiotherapy treatment plans with structures) with all the structures delineated by 
a clinician. There are two lung cancer and two prostate cancer patient datasets. The 
objectives and constraints to be used in forming the treatment plans have been 
established with the help of current planning recommendations in the literature 
and from current/past protocols used at Clatterbridge Cancer centre (ISTART & 
CHHiP Protocols).  
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For the purpose of this chapter, the following abbreviations for structure names in 
the plans, figures and tables apply/appear. 
• Total – Healthy Lung / Lung-GTV  
• BPlexus – Brachial Plexus 
• CordPRV – Spinal Cord 
• Rectum1 – Rectum 
• Rectum_H – Rectum overlapping Tumour 
For each of the patients, 3 plans have been created using the VMAT technique (full 
rotation single arc) (Bhide & Nutting, 2010; Haslett et al., 2016, 2014). The criteria 
for ranking the plans is based on the (ICRU, 2010) report 83 parameters of 
homogeneity index, TCP and NTCP of the target volume and the OARs respectively 
along with dose volume parameters like V20 Gy for healthy lung, V50 Gy for rectum, & 
Dmax for the spinal cord. Qualitative comparison of the plans is performed by 
assessing DVH data and the dose distributions overlaid on the CT scan ‘slice’ of the 
patient at the iso-centre. 
The RayStation treatment planning system (described in section 5.1.2) has been 
used to create all the treatment plans. All the plans require an external ROI (Region-
of-Interest) encompassing the patient body surface to be delineated; this ROI 
defines the area of dose deposition and includes the selection of a dose-
specification point (set as the centre of GTV in this work for all the plans). The plans 
were made with the beam specification of the Elekta Synergy® 6 MV (Lung 
Treatment Plans) and 10 MV (Prostate Treatment Plans) radiotherapy unit - this was 
selected from a list of available options in the RayStation System. The TCP, NTCP, 
homogeneity index and dose-volume based metrics (for OARs) are reported for all 
plans. For this analysis, LKB NTCP and Marsden TCP models have been used. The 
parameters used for the models are the same as those used in chapters 3 & 4 (See 
Table 3.1 and 3.2 in Chapter 3 for details). 
5.2.2.1 Lung Cancer Treatment Plans 
The analysis is divided into two phases for each lung patient dataset. Phase 1 (plan 
1 & 2) compares a dosimetric constraint/objective based inverse treatment plan 
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(DB-plan) to a radiobiological constraint/objective based inverse treatment plan 
(RB-plan) for a conventional fractionation schedule (20 fractions for lung tumours). 
Phase 2 (plan 3) makes the same comparison but the plans are generated with 15 
fractions and only for the lung patient CT datasets. Plan 4 (55Gy 20#) is an 
additional DB-plan created to assess the effect of removing ‘uniformity’ 
requirement of a plan. Plans 1-4 are explained in detail below. The structures were 
delineated by a clinician and thus the naming convention was left unaltered. 
The aim of this exercise is to generate an isotoxic RB-plan and rank it against a 
conventional DB-plan. 
➢ Plan 1 
The first plan has been made using only DV constraints for a 20-fraction schedule. 
The objectives & constraints for the NSCLC treatment plan are given in Table 5-1. 
The tumour is delineated as the GTV and PTV. The objective of the planning exercise 
is to create a plan imparting a quasi-uniform 55 Gy dose to the tumour (PTV). If 
objectives and constraints are in conflict, the optimizer always prioritizes the 
constraints since they are not allowed to be violated for an optimal solution. A 
dose-scaling function is available and was used to ensure the DB-plans were within 
95% to 107% of the prescription dose (for the DB-plan). The OARs are healthy lung, 
oesophagus, heart, spinal cord and the brachial plexus that could receive maximum 
dose / maximum Vxx as per the clinical OAR dose limits shown below.  
Table 5-1 The objectives & constraints for the NSCLC treatment DB-plan 
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➢ Plan 2 
The second plan is an isotoxic inverse plan formed using radiobiological model-
based objectives and constraints (where possible) for the same patient’s CT dataset 
for a 20-fraction schedule. The objective is to maximize TCP over the PTV with NTCP 
of healthy lung & oesophagus not exceeding that of plan 1 (i.e. isotoxic to DB-plan). 
Further, none of the OARs should exceed the clinically recommended OAR tolerance 
doses.  The constraints are shown in Table 5-2. The constraints are marked with an 
“asterisk” in the constraint column and the rows without an asterisk indicate 
objectives.  
➢ Plan 3 
Plan 3 is similar to Plan 2 in terms of planning objectives/constraints but is 
developed for a 15-fraction schedule. The NTCP constraints for the OARs from a 15 
fraction DB-plan (adjusted for fractionation for each OAR using the EQD2 correction) 
were used as radiobiological constraints for the same OARs in Plan 3. The formation 
of plan 3 is undertaken only for the lung patient datasets. 
➢ Plan 4  
Plan 4 is similar to the DB-plan created for each patient but the uniformity objective 
is replaced with a minimum D95>=prescription dose and a Dmax=107*prescription 
dose. This is referred to as DB-plan(non-uniform). This is undertaken to assess the effect 
of a ‘uniformity’ objective on the optimizer’s ability to find an optimal plan for the 
patient.   
 
Table 5-2 The objectives & constraints for the lung treatment RB-plan 
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5.2.2.2 Prostate Cancer Treatment Plan 
 
➢ Plan 1 & 2  
For prostate patient datasets, 3 plans for each patient were created to compare 
standard dose-volume-based treatment planning to a radiobiological model-based 
approach. The reference prescription for the dose-based plans was 60 Gy in 20 
fractions. The list of objectives used for creating the DB-plans is given in Table 5-3.  
Table 5-3 The objectives & constraints for the prostate treatment DB-plan 
The objective functions used to make the RB-plans are given in Table 5-4. The 
uniform dose to PTV objective function (of the DB-plans) is replaced by maximizing 
the TCP (using PTV structure) for the RB-plan. The use of Min DVH D95>=60 Gy is to 
make the system search for a clinically acceptable plan or converge on a close to 
clinically acceptable plan, i.e.  the optimizer is pushed to achieve a minimum dose in 
the PTV. The physical dose to the rectum is replaced by the NTCP of the rectum in 
terms of rectal bleeding NTCP and faecal incontinence NTCP for the RB-plans. The 
NTCP limits for both of these complications are derived from the NTCP analysis of 
the DB-plan structures’ DVHs. The clinical goals used for assessing a prostate 
treatment plan for validity are given in Table 5-5 
Table 5-4 The objectives & constraints for the prostate treatment RB-plan 
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➢ Plan 3 
For prostate treatment datasets, an extra dose-based plan was also formed without 
the uniformity objective but achieving a “D95>=Prescription dose” objective. Other 
applicable constraints and objectives were similar to those used for plan 1. As 
mentioned earlier, this was undertaken to assess the effect of “uniformity” on the 
planning system’s ability to form an optimal treatment plan.  
5.2.3 Plan Ranking and Analysis 
Qualitative and quantitative methods were employed to rank plans that were 
generated by the dosimetric parameter and radiobiological parameter approach. 
The plans were compared qualitatively by assessing the plan colour wash in 
transverse, sagittal and coronal planes of the patients’ CT scans. The DVHs were 
also examined & compared and finally the radiobiological (TCP, NTCP) and 
dosimetric parameters (Vxx, Dyy) for each OAR and PTV were compared. The 
prescription dose for the purpose of assessment and comparison of plans was 
defined as the average dose in the PTV.  
The RayStation interface allows setting of clinical goals that function as plan 
assessment metrics along with the DVHs and ROI dose statistics. As an example, the 
values of clinical goals for the lung treatment plans (as shown in table 5-6) are 
recorded for all the plans for ranking purposes. The ‘value’ column provides the 
absolute value of the clinical goal extracted from a given plan and the results 
Table 5-5 Clinical goals to assess Prostate treatment plans 
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column provides a very quick visual check to assess if the objective and constraints 
have been met (green tick mark icon) or not (orange exclamation mark icon). The 
clinical goals used for plan ranking and assessment can differ from the planning 
objectives & constraints used by the inverse plan algorithm. This functionality 
allows the user to assess multiple clinical parameters for a given plan at the same 
time.  
For example, the user can check the value of V20Gy for the healthy lung (ROI ‘total’ in 
Table 5-6) and also see the associated LKB NTCP prediction if required. Similarly, D95 
and the TCP (Marsden model based) of the ROI ‘PTV’ can be simultaneously 
assessed. The system can also report the homogeneity index of the plan. Further, 
the clinical goals table is fully customisable as per user requirement.   
 There is a plan evaluation tab provided in the system that allows comparison of up 
to 3 treatment plans simultaneously. It offers both qualitative and quantitative 
assessment metrics as described in the section above. 
  
Table 5-6 Treatment plans assessment metrics - NSCLC treatment plan 
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5.3 Results & Analysis 
The results of the QC exercise are shown below in Tables 5-7, 5-8, and 5-9. The TCP 
values (Marsden model) for various target-volume DVHs as calculated by RayStation 
(RS), BioSuite and RadOpt agree closely with a variation of less than 1%. Further, 
this variation is the same irrespective of ‘repopulation’ (ON/OFF) criteria.  
Table 5-7 TCP computed by RayStation, Biosuite & RadOpt 
In order to check the implementation of repopulation in the TCP model in 
RayStation, the values of the parameters Tpot & Tdelay were varied and the RS and 
BioSuite TCP values were compared for a single-bin DVH (65 Gy dose, 133.5 cc 
volume, 30 fractions). 
Table 5-8 TCP comparison of RayStation vs Biosuite for variations in Tpot & Tdelay 
The results show that the agreement between the two systems is acceptable. Next, 
the NTCP calculations for prostate and lung-tumour OAR structures across the three 
systems are compared:  
Table 5-9 LKB NTCP comparisons between RayStation, BioSuite & RadOpt 
It is seen that the error in the calculation is again less than 1% and is probably 
largely attributable to the way all the three systems are programmed to calculate 
the NTCP based on the LKB model (i.e. different programming languages 
implementing the same model). The 3 systems are therefore deemed comparable in 
Target 
volume File 
PTV 
(cc) Fractions Repopulation RS (TCP) 
RadOpt 
(TCP) 
Biosuite 
(TCP) 
Lung-PTV Pat1Plan1 239.7 20 On 81.0% 80.5% 80.5% 
Lung-PTV Pat1Plan2 239.7 20 On 45.0% 44.3% 44.3% 
Lung-GTV Pat1Plan1 79.7 20 On 98.0% 98.0% 98.0% 
Lung-GTV Pat1Plan2 79.7 20 On 66.0% 65.9% 66.0% 
Prostate-PTV Pat1Plan1 279.1 32 Off 76.0% 75.7% 75.7% 
Lung-PTV Pat1Plan1 239.7 20 Off 55.0% 55.2% 55.1% 
Tpot (days) Tdelay (days) RS (TCP) BioSuite (TCP) Difference 
3 20 42.4% 41.3% 1.1% 
5 30 58.7% 57.9% 0.8% 
7 20 55.4% 54.9% 0.5% 
Dataset RayStation (NTCP) RadOpt (NTCP) Biosuite (NTCP) 
Pt1Plan1_Lung 10% 9.3% 9.3% 
Pt2Plan1_Lung 7% 7.5% 7.5% 
Pt1Plan1_Rectum 4% 3.8% 3.8% 
Pt2Plan1_ Rectum 1% 1.6% 1.6% 
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terms of radiobiological model calculations. Next, dose-volume-based inverse 
planning is compared to radiobiological-model-based inverse planning.  
5.3.1 Lung Cancer Treatment Plan Comparison 
A library of lung DVH datasets (59 patients) with PTV and healthy lung DVHs was 
used for this comparison. Using these DVHs, a TCP library plot (from PTV DVHs) and 
a NTCP library plot (from Healthy Lung DVHs) was created as shown in figure 5.3.  
This allowed visualization of the range of the TCPs & NTCPs and their spread across 
a small population. Further, in the same figure, the TCP and the NTCP of the DB-
plans of patient 1 and 2 are plotted to check if the DB-plans were similar to the TCP 
and the NTCP of clinical plan data. As depicted in the figure 5-3, TCP and NTCP of 
both the patients shown by the green and red crosses are within the same TCP and 
NTCP ranges as of the patients in the DVH library indicating that DB-plans formed 
for this chapter are clinically representative. 
Next, the DB-plan and the Isotoxic RB-plan are compared for both lung cancer 
patients for the 20-fraction schedule. For the creation of the RB-plans the objective 
was to maximize TCP (Marsden model) of the PTV at an isotoxic NTCP (Radiation 
Pneumonitis NTCP as observed for the DB-plan of the respective patients for a given 
fractionation schedule).  To achieve this, the optimization algorithm tries to 
increase the dose in the PTV of the RB-plans which thus increases the average dose 
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Figure 5-3 TCP and NTCP Library plot for the lung cohort data 
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(viz. Prescription Dose) associated with them, however, it is emphasized that RB-
planning is not based on the aim to have a specific prescription dose.  
Table 5-10 Quantitative comparison of DB-plan and RB-plans for Lung cancer patients 
Similarly, the oesophagitis risk for all the plans is 1% different for compared plans 
for each patient and lower for the RB-plans20# compared to DB-plans20#. From the 
dosimetric perspective, the DVHs (Figure 5-4) of the DB-plan20# and RB-plan20# for 
patient 1 demonstrate that RB-plan achieves superior sparing of oesophagus and 
healthy lung (‘total’ – in Figure 5-4) in the mid and low dose ranges. However, the 
maximum dose observed is higher for the RB-plan20# compared to the DB-plan for 
the healthy lung and oesophagus OARs. Considering healthy lung OARs’ parallel 
organ architecture (n=1), the higher max dose is unlikely to increase the risk of 
radiation pneumonitis. The increase in the max dose for oesophagus in the RB-
plan20# compared to the DB-plan is marginal (table 5-10). The max dose to the spinal 
cord OAR of the RB-plan20# is marginally lower than that for the DB-plan. The dose 
to heart in all the plans for patient 1 was zero except in the DB-plan(Non-Uniform). 
Comparing the DVHs of DB-plan and RB-plan20# for patient 2 in figure 5-5, it is 
observed that RB-plans significantly spare all the OARs. The max dose of the healthy 
lung OAR is higher in the RB-plan compared to the DB-plan but dose sparing in the 
low-mid dose range is far superior in the RB-plan. The radiation pneumonitis risk for 
Parameter  Patient 1  Patient 2 
Plan DB-plan 
DB-plan 
(Non- 
Uniform) 
RB-
plan 
RB-
plan 
DB-
plan 
DB-plan 
(Non- 
Uniform) 
RB-plan 
RB-
plan 
Plan Dose (cGy) 5700 5774 7429 7055 5650 5819 6894 6497 
No of Fractions 20 20 20 15 20 20 20 15 
Tumour TCP (PTV) 68% 71% 97% 99.9% 40% 51% 78% 85% 
Radiation Pneumonitis 
NTCP 
3% 4% 3% 4% 8% 7% 7% 8% 
Total Lung (V20) 10.1% 10.6% 6.8% 8.8% 18.8% 18.2% 15.6% 15% 
Esophagitis NTCP 0% 0% 0% 0% 2% 2% 1% 0% 
Spinal Cord (Dmax cGy) 1671 1518 1662 1011 3028 2942 2108 2289 
Heart (V57 cGy) 0 55 0 0 71 69 68 63 
Homogeneity Index 
(100% Vol) 
0.87 0.86 0.61 0.73 0.89 0.86 0.60 0.63 
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all the plans for respective patients as measured by LKB NTCP model is the same 
(i.e. about 1% difference at the most- table 5-10).  
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The set dosimetric constraint for spinal cord is Dmax = 48Gy (based on ISTART trial 
protocol) and it is seen that all the plans for patient 2 are well below this limit for 
spinal cord myelopathy. Also, the V20Gy of healthy lung for the RB-plans is ~2-3% 
lower than for the DB-plans for both patients. It is pointed out that healthy lung and 
oesophagus were the only organs for which radiobiological constraints were used 
(as reliable LKB model parameters for other OARs were not available).  The dose to 
heart in all the plans for patient 2 was similar and very low (measured using V57Gy). 
Thus, it is established that RB-plans created here are Iso-toxic or better (relatively 
safer) in terms of dosimetric and radiobiological model based metrics.   
The next important aspect of this exercise was to compare the dose deposition and 
TCP for the PTV. A higher planned dose is observed in the PTV with a significant 
increase in TCP for RB-plans of both patients (planned dose is a metric calculated by 
the system although the objective was to maximize TCP). It can be observed that 
the TCP of the RB-plans (for both patients) is higher than the TCP of the DB-plans by 
~30-40% (Table 5-10). Analysis of the DVHs in fig. 5-4 and fig. 5-5 shows that the RB-
plans deposit more dose in the target structure. The homogeneity of dose 
deposition (across 100% of the PTV) of the DB-plan is higher compared to the RB-
plan in both the patients (table 5-10). Also, 100% of the PTV receives more than 55 
Gy dose in the RB-plan (fig. 5-4 and fig. 5-5). This was expected as the goal of the 
planning exercise was to increase the therapeutic ratio for the RB-plans whereas 
the DB-planning explicitly requires a quasi-uniform dose to the tumour PTV.   
The DB-plan(non-uniform) (plan 4) created for both patient 1 and patient 2 are isotoxic 
as far as OAR toxicity constraints are concerned (table 5-10). The relaxation in the 
‘uniformity’ objective in the DB-plan(non-uniform) has resulted in a gain in the overall 
dose deposition in the target. The improvement in the target TCP for patient 1 was 
3% and for patient 2 it was 11% (table 5-10). It is interesting to note that the gain in 
the TCP is achieved for a nominal (3%) reduction in the homogeneity index for both 
the patients.   
Next, the 15-fraction RB-plan (plan 3) is compared to the 20-fraction DB & RB-plans. 
For patient 1, the RB-plan (15 fractions) is comparable to the RB-plan (20 fractions) 
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in terms of Iso-toxicity and in terms of TCP (with a slight improvement in the 15 
fractions RB-plan TCP).  The max dose to the spinal cord for the 15 fractions RB-plan 
is lower for patient 1 and comparable to the max dose in the RB-plan (20 fractions) 
which is still lower than the standard DB-plan. For patient 2 the TCP of the RB-plan 
(15 fraction) is 7% higher than that of the RB-plan (20 fractions) with a slight 
increase in dose to OARs. Overall, it is observed that RB-plans are superior 
compared to the DB-plan for all the lung patients. The 15-fraction RB-plan achieves 
the highest TCP for a similar NTCP (lung-GTV, i.e. healthy lung & Oesophagus 
toxicity) and a reduced maximum dose to the spinal cord (patient 1). The DVHs of 
principal OARs of all the plans for both the patients are shown in fig. 5-4 and fig. 
5-5.    
Visual qualitative comparisons of plans 1-3 of each patient are presented in Figure 
5-6 and Figure 5-7. Transverse, coronal and sagittal CT slices are overlaid with 
colourwash doses (aligned at the isocentre). The scale in the colour wash is in % of 
55 Gy to make the comparison consistent across all the plans. For patient 1 in Figure 
5-6, in the transverse section of the DB-plan, it is seen that the right lung is 
comprehensively covered by the 25-50% Iso-doses for the anterior to posterior 
walls; however, the RB-plan20# spares the anterior right lung (covered by the 10% 
Iso-dose area). Further, the 15 fraction RB-plan spares the oesophagus and spinal 
cord distinctly as seen in the transverse slice compared to both the other plans. 
Similarly, dose in the sternum in the coronal slice is quite high for the DB-plan 
compared to the RB-plan as seen in the coronal section. 
For patient 2 (Figure 5-7), a hot region of dose deposition can be observed in the 
left lung in the transverse section of the DB-plan which is reduced in the RB-plan20# 
and non-existent in the 15-fraction RB-plan. The sparing of the healthy lung in the 
RB-plan15# for patient 2 is considerably better than that in the 20-fraction RB-plan. 
Furthermore, both the RB-plans are better at sparing healthy lung than the DB-plan 
for both the patients.   
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5.3.2 Prostate Cancer Treatment Plan Comparison 
Having access to a library of about 56 prostate patient DVH datasets (60Gy 20 
fraction schedule), a TCP and a NTCP (rectal bleeding risk) library plot was created. 
The observed TCP and NTCP of the DB-plans (Patient 1 and 2) were added to the 
same plot to assess the clinical equivalence of DB-plans created for this chapter. It is 
observed in figure 5-8 that the DB-plan NTCPs (yellow Dots) are very close to the 
normally observed NTCPs of clinical plans. The TCP of the DB-plan (Grey Dots) DVHs 
are found to be slightly higher than the TCPmax observed in the cohort (figure 5-8). 
However, the TCPs of the DB-plans are slightly higher than the highest TCP for any 
tumour DVH in the library but with a very small difference indicating that the 
patients were most likely favourable and certainly do not invalidate the plans 
formed here.  
Figure 5-8 TCP and NTCP Library plot for the prostate cohort data 
Table 5-11 compares the DB-plans and RB-plans for the two prostate cancer cases. 
Firstly, iso-toxicity between DB-plans and the RB-plan (for each patient) is assessed 
by evaluating the NTCP of various endpoints (principal dose limiting side-effects) 
followed by a comparison of the dosimetric parameters that are currently used to 
assess the risk of OAR toxicity. Then, the tumour dose and TCP of the plans are 
compared.  
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Table 5-11 Quantitative comparison of DB- and RB-plans for the prostate cancer cases 
 
It can be seen in Table 5-11 that the NTCP for rectal bleeding for all the plans is 
below 6%. The risk of faecal incontinence is also below 9% for all the plans. Further, 
the risk of rectal bleeding and faecal incontinence in the RB-plans is lower by about 
2-4% than for the DB-plans for both patients. It can also be seen that the TCP of the 
RB-plan for both the patients is higher than that of the DB-plans. The RB-plan of 
patient 1 was achieved by the optimizer after about 100 iterations and it is not 
Isotoxic compared to the DB-plan (as Rectal Bleeding NTCP is only 4% which is 
better than the DB-plan).   
To ensure Isotoxicity, the dose in the RB-plan of patient 1 was subjected to scaling 
such that the NTCP would be 7% and the gain in the TCP would be comparable. But 
it was not possible to do so as it was found that other constraints were being 
violated if the plan dose was to be scaled or the intensity of radiation from a given 
beamlet could not be increased. The comparison of dosimetric parameters of 
Rectum (V40.8 Gy) suggests that RB-plans are very effective at sparing the rectum OAR 
(8-19% volume) at the cost of a slight increase in V60Gy of the rectum (~2% volume). 
The rectum being a serial-parallel OAR (n=0.09 for rectal bleeding) / (n=1 for faecal 
incontinence), the effect of higher doses in RB-plans should be carefully considered. 
V40.8 Gy for the bladder OAR is same (<1% difference) for the DB-plans and the RB-
plan of both the patients.  
Parameter Patient 1 Patient 2 
Plan DB-plan 
DB-Plan 
Non-
Uniform 
RB-plan 
DB-
plan 
DB-Plan 
Non-
Uniform 
RB-plan 
Plan Dose (cGy) 6100 6400 6862 6105 6300 6670 
Fractions 20 20 20 20 20 20 
PTV (TCP) 68% 71% 73% 70% 72% 74% 
Rectal Bleeding NTCP  6% 4% 4% 5% 4% 3% 
Faecal Incontinence NTCP 9% 7% 5% 7% 6% 5% 
Bladder (V40.8Gy) 23.5% 18.7% 22.6% 41% 36.9% 40.1% 
Rectum (V40.8Gy) 57.8% 45.8% 26.3% 42.4% 34.6% 27.2% 
Rectum (V60Gy) 3.6% 3.6% 4.4% 4.8% 4.2% 2.9% 
PTV Homogeneity (100% 
Vol) 
0.92 
0.78 
0.71 0.93 
0.79 
0.71 
Femoral Head (Right) V40.8Gy 0% 0% 0.9% 0% 0% 0% 
Femoral Head (Left) V40.8Gy 0% 0% 1.3% 0% 0% 0% 
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The comparisons of the DVHs of important structures of the DB-plans and the RB-
plan for prostate patient 1 and prostate patient 2 are shown in fig. 5-9 and fig. 5-10. 
The solid lines represent the DB-plan structures and dotted lines represent the RB-
plan structures. For both patients, it can be observed that the PTV DVH of the DB-
plans show a sharp drop in %volume at 60 Gy indicating uniform dose across the 
tumour. For the RB-plan the minimum dose to 100% target volume is ~57 Gy with 
the maximum at about 76 Gy. It can be seen that the RB-plans for both the patients 
achieve superior rectal sparing even when the average dose to the tumour is 
significantly higher than that in the DB-plan.  
A visual comparison of therapeutic gain is shown by the yellow and blue bi-
directional arrows; these show the relative sparing of the rectum and the increase 
in tumour dose for the RB- vs DB-plans for patients 1 &2 (fig. 5-11 & fig. 5-12). The 
distance between the PTV DVH and the rectum DVH which expresses the 
therapeutic gain is higher for the RB-plan compared to the DB-plan.  
Plan 3 DB-Plan(non-uniform) 
From table 5-11, it is observed that DB-Plan(non-uniform) that does not have ‘PTV dose 
uniformity’ as an objective, spares the rectum greatly compared to the standard DB-
plan (assessment of V40.8 Gy or V60 Gy) in both the patients. It is also observed that the 
DB-plan(non-uniform) spares the bladder better (~4% volume) in both the patients. From 
a radiobiological perspective, the NTCP of the principal OAR is lower and the TCP is 
higher for the DB-Plan(non-uniform) than that of the standard uniform PTV objective 
based DB-plan.  
Thus, the DB-plan(non-uniform) has a higher therapeutic ratio than the standard uniform 
DB-plan which is a critical finding from this work and this is attributed to 
improvement in treatment delivery technique (IMRT/VMAT). Schwarz et al. (2005) 
compared 3D CRT and IMRT planning techniques to assess the potential of dose 
escalation in 10 selected NSCLC patient plans (2.25 Gy/fraction schedule in the 
control arm). They also showed that dose in the tumour could be escalated by up to 
35% by allowing heterogeneity of dose deposition in the tumour. Nielsen et al. 
(2014a, 2014b) published their findings based on a study of 20 NSCLC stage I-III 
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plans (66Gy/33fraction control arm vs dose escalated arm) where they performed 
dose escalation allowing inhomogeneous dose distribution in the PTV. They 
compared the plans using two TCP models (Martel TCP model and Marsden TCP 
model) and showed that mean dose in the tumour can be escalated without 
increasing lung toxicity compared to the standard homogeneous tumour dose 
approach used for the control arm.  
Further, the RB-plan is found to be therapeutically better than the DB-Plan(non-uniform) 
(table 5-11) except for sparing for the bladder which is better in the DB-Plan(non-
uniform) for both the patients. This finding should be validated over a larger cohort. 
The CT slices in transverse planes aligned at the iso-centre are compared for patient 
1 and 2 in Figure 5-11 and Figure 5-13. It can be seen in the transverse section for 
both patients that the RB-plans spare the dose to rectum much better than the DB-
plans. Another observation is that in the DB-plans, if the rectum were to be spared 
further, additional structures like (RECTUM_H Figure 5-11 & figure 5-12) would 
need to be built to instruct the optimizer to spare this volume whereas with RB-
plans just one single constraint on NTCP achieves superior sparing. This suggests 
that radiobiological-model-based inverse planning helps improve optimizer 
efficiency. This deserves further study. 
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Figure 5-12 Qualitative comparison of DB-plan and RB-plans using Dose colour wash at Iso-centre in CT slices in 
transverse, coronal and sagittal plane for patient 1 
Rectum 
Bladder 
PTV 
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Figure 5-14 Qualitative comparison of DB-plan and RB-plans using Dose colour wash at Iso-centre in CT slices in transverse, 
coronal and sagittal plane for patient 2 
Rectum 
Bladder 
PTV 
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5.3.3 Dose Escalation (Standard versus Radiobiologically Based) 
 
5.3.3.1 Lung Cohort Isotoxic Dose Escalation 
To assess the change in TCP over a range of Iso-toxic NTCP, treatment plans at 
different Iso-toxic limits were created for a lung patient dataset.  The TCP values of 
all the RB-plans created for the lung patient were extracted and plotted against the 
NTCP of the principal OAR. This resulted in TCP vs NTCP plots that allowed an 
overall comparison of dose escalation in radiobiologically inverse planned 
treatment plan versus dose-volume based treatment plan (Figure 5-15).  
To create the TCP vs NTCP plots of the DB-plan, the dose of the DVHs was scaled 
until the dose tolerance limit of any of the OARs was not exceeded and then the 
TCP and NTCP were calculated from the respective DVHs. DB-plan constraints are 
dose-volume limits that do not account for the biological response of the OAR. 
Using EUD based constraints, one of the behavioural aspects of the tissue biology 
(serial or parallel behaviour) can be taken into account. It is seen for lung-tumour 
patient 2 in figure 5.15 that isotoxic radiobiological optimization is superior to dose-
volume based inverse planning over a range of NTCP values (NTCP relates to 
radiation pneumonitis risk). The same Isotoxic dose escalation for Patient 1 was not 
undertaken as it was a very favourable case, with a small tumour volume in a 
relatively ‘isolated’ anatomical location in the lung.  Overall, it can be observed that 
Figure 5-15 TCP-NTCP plots comparing Isotoxic dose escalation between radiobiological inverse treatment 
planning to dose-volume inverse planning for an NSCLC patient.  
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radiobiological inverse treatment planning is superior to dose-based optimization 
for lung patient 2 (blue vs red curve, fig. 5-15).   
5.3.3.2 Prostate Cohort Isotoxic Dose Escalation 
Isotoxic dose escalation for the prostate plans was not successful as the optimizer 
could not escalate the dose to PTV without increasing the dose to ‘Rectum’ which 
resulted in a breach of rectal bleeding or faecal incontinence toxicity endpoint. The 
results for prostate patient dose escalation are somewhat different (compared to 
the lung cohort) as multiple toxicity endpoints limit escalation of dose for both the 
patients. The rectum is associated with rectal bleeding (LKB model n=0.09) and 
faecal incontinence (LKB model n=1) endpoints. The LKB model parameter ‘n’ is 
suggestive of the serial or parallel architecture of the OAR and rectum has 
associated endpoints that are attributed to both the extremes making dose 
escalation particularly challenging. However, radiobiological isotoxic dose 
optimization does not allow escalation of dose if either endpoint toxicity limit is 
breached for a given OAR.  This is a unique feature associated with radiobiological 
inverse planning.  Also, for some of the DB-plans of all the patients, dose scaling 
could not be performed as the intensity of radiation could not be scaled up for a 
given set of beamlets of the beam from some angles. This observed restriction is 
believed to be related to maximum fluence that can be physically delivered through 
a given beam segment.   
  
186 | P a g e  
 
5.4 Clinical Relevance, Conclusion and Future Work 
In this chapter, radiobiological inverse treatment planning was compared to dose-
volume-based (i.e. conventional) inverse treatment planning using an advanced 
commercially available treatment planning system that offers radiobiological cost-
function based inverse treatment planning.  
For the two-lung cancer patient CT datasets, two 55Gy in 20 fractions inverse VMAT 
treatment plan (DB-planstandard and DB-plan(non-uniform)) and two isotoxic inverse plans 
(with a 20-fractions and a 15-fractions schedule) using radiobiological model-based 
constraints/objectives (RB-plan) were created.  
The TCP of the RB-plans for both NSCLC cases was higher by ~30% compared to the 
DB-plans. It was also observed that sparing of healthy lung volume was about 2-4% 
(V20) better for the RB-plans compared to the DB-plan. Thus, in terms of therapeutic 
ratio and principal OAR volume sparing it is reported that radiobiologically based 
inverse treatment plans are superior to standard dose-volume-based inverse plans 
for both lung patients in this study. It is demonstrated that the RB-plans without 
uniform dose objectives yield increased TCP, lower or isotoxic NTCP and increased 
dose sparing of principal OARs compared to the DB-plans. It was also demonstrated 
that 15-fraction schedule plans were better for both NSCLC patients in line with the 
results observed in Chapter 3 that suggested that individualized isotoxic treatment 
plans at 15 fractions were better than the 20-fraction schedule based plans for lung 
patients. It should be noted that the difference in the TCP for 20 versus 15 fractions 
depends on the value assumed for the potential tumour doubling time (tpot).   
For the two prostate cancer CT datasets, a standard 60 Gy 20 fractions plan and a 
radiobiologically based inverse treatment plan were created. Further, an additional 
DB-plan (without the target-dose uniformity objective) was created to assess the 
effect of uniformity objective on the treatment plan quality. All the plans were 
assessed using a combination of clinical dosimetric parameters and radiobiological 
metrics. It was found that RB-plan had a higher TCP than the DB-plan by 4-5%. The 
RB-plans were superior as far as OAR sparing was concerned in both dosimetric and 
radiobiological terms. The NTCP of rectal toxicities for the RB-plans was lower than 
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that of the DB-plans by about 2-4%. The V40.8 Gy for the bladder was the same for 
both the set of plans or slightly lower for the RB-plans.  
Inverse treatment plans with NTCP constraints of 5%, 7%, 10% and 13% for 
radiation pneumonitis for the NSCLC patient 2 were also created. The inverse DB-
plans were re-scaled using 5 dose-scaling factors to obtain the corresponding TCP 
and NTCP values to make an overall comparison of the dose-escalation strategy 
versus an isotoxic radiobiological optimization strategy. Overall, the 
radiobiologically isotoxic dose escalation strategy comparison plot (TCP vs NTCP 
plot - figure 5-15) for the NSCLC patient 2 showed that isotoxic radiobiological dose 
optimization could be very beneficial yielding very favourable therapeutic gains. 
Due to multiple complications (with opposing response architecture, i.e. rectal 
bleeding LKB parameter n=0.09 and faecal incontinence n=1) associated with the 
rectum OAR, isotoxic dose escalation could not be successfully carried on the 
prostate patient set. Clinically, this is a very important finding as dose-based 
optimization would not have accounted for multiple toxicity endpoints for a given 
inverse treatment plan optimization.   
Another observation from this analysis is that the use of radiobiological-model-
based OAR NTCP as constraints in treatment planning is likely to result in a notable 
reduction in planning complexity as additional artificial structures required to 
increase the sparing of organs like rectum may not be necessary (as per the 
observation of both the RB-plans created for the prostate patient datasets). The 
probable explanation is that the radiobiological characteristics of the organs 
concerned are embedded in the NTCP model ‘mathematics’. With dosimetric 
constraints, the solution finding process becomes rather linear (of binary nature) 
however with the involvement of model-based cost functions a degree of flexibility 
is available.  The correctness of the absolute prediction by models considering the 
uncertainty associated with model parameters can be questioned. It has been 
demonstrated that radiobiological model-based plans that are therapeutically 
better compared to the standard plans, (in terms of TCP, NTCP and dose-based 
metrics) can be formed using the currently available TCP & NTCP model parameters. 
Evidence of the effectiveness of this should be sought in clinical trials.  
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In this work, the effect of not using the orthodox uniform target dose as an 
objective in the treatment plan of lung and prostate patient datasets was also 
assessed. Based on the findings of this chapter, treatment plans (DB-plans) without 
uniform target dose constraints (replaced by a minimum dose to the target and or a 
D95>Prescription dose) can result in therapeutically better treatment plans that 
spare OARs and deposit a higher dose into the tumours. None of the plans 
generated for this analysis exceeded clinically recommended dose tolerance limits 
and attained the target dose deposition limits set as per the defined clinical trial 
protocols.  
It was observed that for lung patient datasets, RB-plans are superior both in 
standard dosimetric terms and radiobiological terms. Further, hypofractionated 15-
fraction RB-plans are observed to be better than the 20 fraction DB-plans and RB-
plans. This provides evidence supporting the results of level-2 iso-toxic dose 
escalation for the lung cohort in chapter 3 of this thesis where it was found that 15 
fractions regimen was superior to 20 fraction regimen for most lung cancer patient 
datasets. For the prostate patient datasets, it was shown that the RB-plans are 
therapeutically better than the DB-plans and it was also demonstrated that with the 
currently available state of art technology, the “uniform target dose” objective 
should be reassessed clinically. It is acknowledged that for the safety of the patient, 
the plans formed using any of the methods described (i.e. constraints used for 
planning) in this chapter should always be vetted in terms of both dosimetric and 
radiobiological parameters.     
Although the RB-plans generated were therapeutically better than the DB-plans (for 
both lung and prostate cancer patient CT datasets), it is to be noted that delivery of 
the high dose PTV distribution should be undertaken carefully. A “target miss” due 
to inter fraction tumour motion or change in the size of the tumour is a practical 
reality that can result in ineffective treatment causing tumour relapse or high 
unexpected toxicity due to unnecessary irradiation of OARs. It is recommended that 
such events be avoided by making use of advance imaging techniques like MRI and 
or online adaptive radiotherapy. The results of the pilot BIOPROP study reported by 
Onjukka et al. (2017), where the safety of quasi-radiobiologically optimized 
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treatment plans to boost dose to the PTV (by boosting dose to dominant intra-
prostatic lesions in 28 patients) was established, are encouraging. 
The absolute value of TCP & NTCP calculations are prone to statistical uncertainties 
due to uncertainties/robustness of radiobiological model parameters. Current 
methodology uses absolute values of TCP & NTCP to guide the treatment plan 
optimizer to find a dose distribution that satisfies set constraints & objectives. It is 
thus likely that the plan reported here may be sub-optimal. A cautious approach to 
the implementation of this methodology with critical analysis of such RB-plans in 
line with routine clinical methodology is recommended. Efforts have been made to 
ensure that the DB-plans are clinically acceptable, and the RB-plans are analysed in 
line with constraints and objectives of the DB-plans to ensure that the RB-plans are 
iso-toxic and efficacious (compared to DB-plans in dosimetric terms as well as 
radiobiological terms).    
Looking to the future, it is strongly advocated that a study with a larger number of 
patients be conducted to reinforce the findings of this chapter. Further, I envision 
working on assessing the effects of using different modelling parameters in 
radiobiological inverse treatment planning to explore the sensitivity of the results in 
relation to the values of the model parameters.  
 
6   
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Chapter 6 Iso-toxic Dose Constraint 
Conversion 
6.1 Introduction 
The aim of radiotherapy treatment planning is to create a plan that will deliver the 
prescribed dose of radiation to the tumour without exceeding the tolerance limits 
of adjacent OARs. The most up-to-date guidance on the use of OAR tolerance 
metrics are set out in ICRU Report 83 Section 3.4 (2010); these are based on dose-
based metrics such as Vxx (%OAR volume receiving at the least dose xx Gy), Dmean 
and Dmax. ICRU Report 83 also suggests reporting NTCP values in research studies.  
In the current chapter, a methodology that converts a physical dose-based metric 
for one regimen to the corresponding metric for a different regimen is developed. 
This conversion methodology uses the LKB NTCP model that is well established in 
the literature in relation to OAR toxicity risk prediction using the OAR DVH. The 
currently used method to convert constraints across different regimens uses the 
EQD2 Wither’s formula and is susceptible errors that are discussed in the next 
section. 
The Iso-effect relationship initially developed and proposed by Withers et al. (1983) 
enabled an alternative fractionation regimen to be derived that would generate an 
equivalent risk of biological damage to the reference regimen. The Withers’ formula 
is as follows: 
                                                 
𝑫𝒏𝒆𝒘
𝑫𝒓𝒆𝒇
=  
{𝟏+(
𝛃
𝛂
)𝒅𝒓𝒆𝒇} 
{𝟏+(
𝛃
𝛂
)𝒅𝐧𝐞𝐰} 
                             Eqn. 6-1 
The above formula is based on the LQ expression for cell killing and its two key 
coefficients are α and β. The values for these parameters in the case of tumour 
clonogens are derived from in-vitro techniques that vary and need standardization 
as per Chapman (2003,2014). For normal tissues, the α/β ratio has been deduced 
from fitting observed toxicity data from large trial datasets. The latter method was 
used by Fowler (1990) and Van Dyk, Mah, & Keane (1989) to estimate the normal 
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lung α/β ratio. Further, the α/β ratio was assumed to be low (α/β = 3 Gy) for all late 
responding tissues and high (α/β = 10Gy) for early responding tissues (Mayles, 
Nahum & Rosenwald, 2007). This is a highly questionable generalization for a 
number of tissues (e.g. α/β = 1.3-1.8 Gy for the prostate tumour as per a recent 
publication by Dearnaley & Hall (2017), analysing recently reported prostate cancer 
clinical trial results).  
The α/β-ratio-based BED formula fails to consider the volume effect associated with 
normal tissue toxicity. Marks et al. (2010) suggest that a normal lung tissue α/β 
ratio = 3 Gy and Michalski et al. (2010) suggests α/β=3 Gy for rectal tissue; however, 
the radiotherapy related toxicity for these tissues are quite different based on 2 
Gy/fraction doses. Assume V50 Gy<50% in 2 Gy fraction is used as a constraint in 
radiotherapy for limiting radiation pneumonitis in lung and rectal incontinence in 
prostate therapy. Using the LQ based BED formula, an equivalent toxicity-limiting 
constraint for 3Gy/fraction treatment for both normal lung and rectal tissue will be 
V42 Gy<50%. Normal lung tissue has been shown to have a parallel architecture [n = 
1, Marks (2010)] and the rectum, on the other hand, has a serial architecture [n = 
0.09, Michalski (2010)] and thus the radiation based toxicity associated with both 
these tissues at different doses is likely to be quite different. Thus, the new            
V42 Gy<50% constraint derived for 3Gy/fraction regimen may not be optimal for the 
rectum and or the lung tissue.  Further, the current BED based Vxx conversion 
method is based on a single point on the DVH and does not account for the range of 
dose (in a DVH) that contribute to tissue toxicity. 
Michalski (2010) suggests that keeping V50 Gy<50% or V60 Gy<35% is likely to minimize 
rectal bleeding risk to less than 15% in conventional 2 Gy/fraction treatments up to 
79 Gy. However, if the V50 Gy<50% in 2 Gy/fraction regimen is converted to a 3 
Gy/fraction regimen using the BED formulation, the new constraint would be V41.7 
Gy<50%. There is no validation available that shows if using V41.7 Gy<50% considering 
3 Gy/fraction plan is iso-toxic to V50 Gy<50% used for 2 Gy/fraction plan in terms of 
assessing rectal bleeding risk. One may certainly argue that based on the results of 
CHIPP trial, the observed average rectal bleeding toxicity in 2Gy/fraction arm (using 
V50 Gy<60% constraint) was the same as average toxicity of 3Gy/fraction regimen 
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(using the V40 Gy<60%) whereas for the HYPRO trial regimen the difference in 
average GI toxicity between the 2 regimens was 6% ( and 8% in the case of the Fox 
Chase regimens) (Dearnaley & Hall, 2017). 
A validity of EQD2 based conversion is questioned as it fails to account for the 
considerable variation in dose range observed in a DVH (i.e. lowest to highest dose 
in the DVH) and relies on a single point on the DVH to form an iso-toxic equivalent 
constraint. High uncertainty around these calculations is suspected as the biological 
behaviour of the OAR is not accounted for in the Wither formula based conversion 
method. LKB NTCP models allow one to address the above concerns and thus is 
employed in the development of a new Iso-toxic parameter conversion method. 
The next section describes the methodology employed.  
6.2 Methodology 
In this chapter, a method is developed to convert a Vxx ‘dose-limiting’ normal-tissue 
DVH parameter from one (‘standard’) dose-fractionation regimen to an alternative 
regimen. The principle followed here is that the fractional volume for a fixed dose 
level can be modified to account for changed fractionation. This differs from the 
standard approach in which the fractional volume is fixed and the dose level is 
modified according to the BED expression. A comparison between both the 
methods to convert constraints across different regimens is presented in the 
discussion section.  The lung cancer patient database (or cohort) consists of around 
59 DVH datasets, with dose prescriptions in the range 52.5-55 Gy with fraction sizes 
around 2.6-2.75Gy. For prostate cancer, there are approximately 56 patients in the 
database/cohort and these were prescribed 60-62 Gy in 20 fractions. The 
prescription dose range quoted was estimated by calculating the mean dose to the 
PTV DVH for each of the patient DVH datasets as I was provided only with 
anonymised DVH datasets and no other information about the DVHs. The DVHs for 
normal lung, oesophagus, spinal cord and / or heart (OARs) were available for the 
lung cohort. For the prostate cohort, the DVHs of bladder, rectum and femoral 
heads were available.  
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The LKB NTCP model was used for the purpose of this analysis. The parameters used 
for the LKB NTCP model are shown in Table 6-1.  
Table 6-1 The table of NTCP model parameters used for the purpose of the calculations in this chapter 
The Marks et al. (2010) paper recommends V20<30% as an acceptable planning 
constraint in relation to lung radiation pneumonitis. Similarly, for spinal cord and 
heart, Dmax and V25-40 have been shown to correlate with spinal cord complications 
and pericarditis incidence respectively. The corresponding parameters for rectal 
complications and bladder complications are V35 & V50 respectively [V20, V35, V50 
correspond to % volume of OAR receiving at least 20, 30 or 50 Gy respectively]. 
All patient DVHs for a given OAR are loaded into an in-house algorithm that 
calculates the specified Vxx and the NTCP of the DVH for a given dose-fractionation 
schedule and model parameters. As an example, consider the standard lung cancer 
cohort prescribed 55 Gy in 20 fractions. The normal lung DVH (Total lung-GTV) was 
analysed to assess the risk of radiation pneumonitis, i.e. the NTCP. The program is 
supplied with the 55 Gy prescription dose (Dpres), 20 fractions and the DVH as input. 
The V20 from the DVH and the corresponding NTCP (LKB model) are then calculated. 
A plot of V20 versus the NTCP for all the patients in the database receiving 55 Gy in 
20 fractions was produced. Using this plot, the NTCP value corresponding to the 
V20≈30% for lung radiation pneumonitis is found. Each point on the plot represents 
a patient DVH dataset whose VxxGy and NTCP is calculated to form the plot. 
Now it is assumed that there is a change in treatment schedule and a new 
prescription dose (Dpnew) fraction scheme is proposed (say 40 Gy in 15 fractions). 
The mean dose of the OAR is changed by multiplying all the doses in the DVH by the 
factor (Dpnew/ Dpres). For the NTCP calculations corresponding to these converted 
DVHs, the standard correction for fraction size is made to the DVH doses using the 
EQD2 correction, exactly as for the NTCP calculations belonging to the standard 
fractionation regimen. A second plot of V20 versus NTCP is thus created. 
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NTCP vs Vxx datasets are then plotted for both regimens on a single graph. Further, 
Matlab’s linear regression graphical-user interface was used to fit a polynomial, 
exponential or power law expression to the datasets to yield a function forming 
best co-relation between Vxx and NTCP of the given regimen. The regression uses 
robust fitting and the fitting procedure explores the best fit of the models based on 
R-squared, Adjusted R-squared and root mean squared error goodness-of-fit model 
parameters. Thus, a function is derived as below  
NTCP= f(Vxx) for each regimen  
Now, VxxA of regimen A gives a corresponding NTCPA which is used to calculate VxxB 
in regimen B using the function derived above. The best model fit over the given 
data is accepted (per the criterion in section 6.2.1). 
 
VxxB = f-1(NTCPB) such that NTCPA=NTCPB                                                Eqn. 6-2 
 
For model fitting, exponential and polynomial (2nd Order) models were used. The 
equations for the respective models are given below. 
For the exponential model, the equation was  
                                                                  f(x)= a*e(b*x)                                            Eqn. 6-3 
For the polynomial model the equations were 
                                              f(x)= p1*x+p2 (1st Order)                                                 Eqn. 6-4                                                             
                              f(x)= p1*x2+p2*x+p3 (2nd Order)                                            Eqn. 6-5 
To find the Vxx for a given NTCP value, the f-1(x) of the above functions were 
calculated. Graphically, similar results can be achieved by dropping horizontal and 
vertical lines from both the curve-fit trend lines. Going back to the example, V20 for 
the Dpres-based regimen was 27% corresponding to 17% NTCP, then the same NTCP 
on the (V20 v NTCP) plot for Dpnew would yield the equivalent value of V20 Gy for the 
new scheme (e.g. as shown in fig 6-3).  
V20 Gy vs NTCP plots were created for various treatment schedules:  55Gy20#, 
60Gy30#, 70Gy30# and 40Gy15#. A similar analysis was performed on the prostate 
tumour DVH dataset to find iso-toxically equivalent V50 Gy for 62Gy20#, 80Gy40# 
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(Arcangeli et al., 2012) and 70Gy28# (Kim et al., 2014; Kupelianet al., 2007) as used 
in some of the recent clinical trials. These regimens were selected randomly to 
assess the utility of this method over a broad range of schedules. This procedure 
enables conversion between various regimens iso-toxically (Iso-NTCP). The results 
section shows the data and the line fits along with the trend lines for Grade 2 or > 
radiation pneumonitis & oesophagitis for lung cancer data, and Grade 2 or > rectal 
bleeding & faecal incontinence for prostate cancer cohort data.     
6.2.1 Goodness-of-fit 
The adjusted R2 and RMSE value were used to assess the goodness-of-fit of the 
regression line forming the Vxx-NTCP co-relation. Adjusted R2 accounts for the 
number of independent variables forming the model fit. Thus, if the fitting exercise 
makes use of excess variables to form better fits the adjusted R2 value decreases. 
This helps ensure the model is simple yet a good fit to the data. Adjusted R2 is 
expected to be in a range of 0 to 1 whilst RMSE (root mean squared error) is 
expected to be as small as possible.  
The criterion used to reject a curve-fitting is based on R-Squared, Adjusted R-
Squared and RMSE values for each fitting parameter. R-Squared & Adjusted R-
Squared are expected to be closer to 1 and fitting is rejected for R-Squared or 
Adjusted R-Squared less than 60% with RMSE higher than 15. There are no set 
guidelines for rejecting a model except for R-Squared & Adjusted R-Squared equal 0 
and RMSE equal to infinity. For a perfect fit, RMSE will be zero; however, there is no 
upper bound / recommended absolute limit suggested for it. The choice of these 
parameters reflect the accuracy that is aimed to be achieved out of the fitting 
exercise.    
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6.3 Results 
6.3.1 Lung Cohort  
As stated in the methodology section, the Vxx vs NTCP plot for various regimens 
used in lung cancer radiotherapy for radiation pneumonitis risk is presented. 
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Figure 6-2 (a, b, c, d) show the line fitting of V20 vs NTCP dataset for 55Gy20#, 
60Gy30#, 70Gy30# & 40Gy15# shown in figure 6-1 above.   
Table 6-2: The goodness of fit parameters of R-Squared, Adjusted R-Squared and 
RMSE are shown in the table for the line fits of figures 6.2(a-d) 
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Figure 6-3 shows a graphical method of Iso-NTCP conversion of V20 from 55Gy in 20# 
regimen (using NSCLC cohort data) to 60Gy in 30#, 70Gy in 30# and 40Gy in 15#. 
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Figure 6-4 shows the V35 – NTCP Analysis for the oesophagitis complication. This is 
represented in a similar way as for the radiation pneumonitis complication. 
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Figure 6-5 The linear regression based line fits of V35-NTCP data for each regimen 
are shown in Figures 6-5 (a, b, c, d) below. Table 6-3 provides fitting co-efficient and 
goodness-of-fit information for each of the line fits shown in Figure 6-5.  
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Figure 6-6 below shows the Iso-NTCP based graphical method of converting V35 
from 55Gy in 20# reference regimen to 60Gy in 30#, 70Gy in 30# and 40Gy in 15# 
schedules for oesophagitis complication >= grade 2 in lung cancer radiotherapy 
treatments. 
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6.3.2 Prostate Cohort 
In this section, the result of the Vxx- NTCP conversion for the toxicity endpoints 
rectal bleeding (Fig. 6.7a) and faecal incontinence (Fig. 6.7b) encountered after 
prostate radiotherapy are displayed. The analysis is performed in the same manner 
as for the lung tumour cohort.    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6-7 The Vxx-NTCP conversion for prostate cancer related OAR toxicities. The regimens considered are 
62Gy20#, 70Gy28# and 80Gy40# a) Vxx-NTCP conversion for the rectal bleeding endpoint b) Vxx-NTCP 
conversion for the faecal incontinence endpoint.  
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The fits to the data correlating V50 and NTCP (rectal bleeding & faecal incontinence) 
are assessed using the Adjusted R-Squared and RMSE values associated with the 
fits. These are shown in table 6.4.  
Table 6-4 The line fitting goodness-of-fit parameters for different regimens for line fits in figure 6.7 (a,b). 
The adjusted-R squared values and RMSE values indicate a good fit of the 
exponential model to the data as per the criteria defined in section 6.2.1 in the 
methodology section. Using the fitted models, it was calculated that for the rectal 
bleeding toxicity endpoint V50 Gy=50% for a 70Gy in 28# regimen is equivalent to V50 
Gy=41.2% for 62Gy in 20# and V50 Gy=44% for 80Gy in 40#.  
Faecal incontinence is another endpoint associated with the rectum with respect to 
prostate radiotherapy side effects. The Isotoxic V50=50% for the 70Gy in 28# 
regimen which is equivalent to V50 = 41.70% for 62Gy in 20# and to V50=56.34% for 
80Gy in 40#.  
It can be seen that for the same OAR, two endpoints with different biological 
responses to radiation exposure can be accounted for using this conversion method 
(figure 6.7a & b). If purely dose-based metrics had been used, the clinicians would 
have used the V50 Gy<50% as the dose constraint for limiting dose to the rectum. 
This constraint gives the recommended dose tolerance to avoid rectal bleeding only 
and does not account for faecal incontinence (which is also a side effect of 
radiotherapy related to the rectum).  
  
 
Regimen Rectal Bleeding Faecal Incontinence 
 
Adjusted R-
Squared 
RMSE Adjusted R-
Squared 
RMSE 
62Gy20# (Arcangeli et al., 2012) 0.778 1.374 0.691 1.560 
70Gy28# (W. R. Lee et al., 2016)  0.730 1.759 0.981 0.350 
80Gy40# (Arcangeli et al., 2012) 0.643 2.812 0.981 0.384 
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6.4 Discussion 
In this section, a critical view of the methodology employed is discussed. The results 
are then discussed and analysed including a justification of the use of 
radiobiological modelling to estimate equivalent Vxx for different regimens.  
The absolute error in LKB NTCP model predictions is dependent on the robustness 
of fitted model parameters. The more robust the parameters, the better are the 
predictions. Two important aspects define the robustness of a given model. One is 
the statistical uncertainty surrounding the parameters used to fit a given model to 
clinical outcomes and the second is the quantity and quality of the data used to 
produce the parameters for fitting the model. When using NTCP models with a 
given set of parameters, the accuracy of prediction improves if the cohort for whom 
predictions are made is similar (possibly the same prescribed treatment, tumour 
type and staging) to the original cohort whose data were used to derive estimates 
of current parameters.  The parameters used for each of the models along with 
their references are shown in Table 6-1. 
The technological changes in treatment planning and delivery has improved OAR 
dose sparing and improved dose uniformity in the target. As NTCP models are 
empirical, a periodic review and update of model parameters based on the latest 
clinical outcome data is important to reduce the absolute error in model 
predictions. The latest LKB NTCP model parameters for radiation pneumonitis were 
available from Marks et al. (2010) in the Quantec set of review papers 
recommending dosimetric and radiobiological model parameters related to OAR 
complications.  
For oesophagitis NTCP models, Chapet et al. (2005) and Belderbos et al. (2005) each 
published parameters that were broadly within each other’s confidence intervals. 
Chapet et al. (2005) parameters were selected as their ‘power of study’ was the 
higher of the two. 
NTCP model parameters for the late rectal bleeding endpoint were published in the 
Quantec review by Michalski et al. (2010), Gulliford et al. (2012) and D’Avino et al. 
(2015). The reported parameters (at least one of TD50, n, m) differed from one 
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publication to the other. The Quantec NTCP model parameter set was selected for 
the current analysis as the Quantec papers were comprehensively peer-reviewed.  
For faecal incontinence, Defraene et al. (2012) and Peeters et al. (2005) published 
LKB NTCP model parameters. However, the Peeters et al. (2005) parameter set was 
selected as the 95% confidence interval limits for TD50, n and m were significantly 
narrower compared to the other publication by Defraene et al. (2012), indicating a 
better fit.  
It is to be noted that the choice of model parameters is likely to affect the overall 
results of this method but if the data used for analysis is representative (in terms of 
similar planning technique & OAR position at the least) of the datasets used to form 
model parameters, the errors are likely to be small. Thus, validation of the model 
parameter set selected for analysis is crucial in order to minimize errors associated 
with this technique. An analysis on these lines using a larger set of data should allow 
quantification of the variation in results of this method if different representative 
model parameter sets are used for analysis.  
Figure 6-1 shows the plots of V20-NTCP for four radiotherapy lung cancer 
prescription regimens. The solid lines (blue, red, green and purple) represent the 
exponential-model fits to the data points in the graph for the respective regimens. 
Figure 6-2 shows the individual regression-line fits with the 95% confidence interval 
limits indicated. Table 6-1 gives parameters that help assess the goodness-of-fit of 
the line fitting. 
For the V20-NTCP Lung cohort analysis of radiation pneumonitis toxicity, the 
minimum ‘Adjusted R-squared’ value is 0.829 which indicates an acceptable fit 
(combined with an RMSE of 2.66 & relatively wider 95% confidence interval 
prediction bounds). The highest value of ‘Adjusted R-squared’ is 0.937 (with RMSE 
0.56 and relatively narrow 95% confidence interval prediction bounds) indicating a 
robust fit. A V20 of 30% corresponds to 16+/-1% probability of radiation pneumonitis 
occurrence (1% error is formed by rounding the 0.56% RMSE value of the model 
fitting). Based on a dataset of 100 patients Wang et al. (2013) showed that MLD was 
highly correlated with radiation pneumonitis risk whereas V20Gy was not. This 
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contradicts Marks et al. (2010) who provide a stronger, critically evaluated evidence 
to support a correlation between V20 and radiation pneumonitis risk.  
Similarly, for oesophagitis, the V35Gy-NTCP correlation raw data points along with 
the fitted regression-based models are shown in Figure 6-3. The individual 
regression line fits with 95% confidence intervals and goodness-of-fit data are 
shown in Figure 6-3 and the associated Table 6-2. The lowest adjusted R-squared 
value is 0.838 (along with RMSE of 10.87 and relatively wide 95% confidence 
interval bounds) for the 70 Gy in 30 fractions regimen. The RMSE of this line fit is 
relatively large which indicates high variance but not necessarily a poor fit. This can 
be caused by outliers that affect the model fits and represents one of the pitfalls 
associated with this method.  
The iso-BED based method and iso-NTCP based method use the concept of iso-
effectiveness to convert the constraint but these methods convert the constraint in 
different ways making direct comparison difficult but challenging. As an example, 
V20<30% paired lung volume is taken here. As per table 6-5, it can be seen that the 
iso-BED method changes the dose part of the constraint (‘xx’ of Vxx is affected and 
percentage volume remains constant).   
Table 6-5 BED based Iso-effective constraints of V20<30% radiation pneumonitis constraint for different 
regimens. 
Regimen  BED Dose 
Effective Constraint (BED 
based) 
60Gy30# 20 V20<30% 
55Gy20# 17.4 V17.4<30% 
40Gy8# 12.5 V12.5<30% 
48Gy4# 6.7 V6.7<30% 
60Gy3# 4.3 V4.3<30% 
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Figure 6-8 Iso-BED based constraint conversion and relative error on NTCP calculations. V20<30% constraint for radiation 
pneumonitis prediction and its Iso-BED equivalent in other regimens compared using NTCP modelling  
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If the Iso-NTCP technique is used the percentage volume part of the constraint 
changes. Thus, direct comparison of these methods against each other is 
problematic. However, the aim was to show how the iso- effective BED-based 
method brings variations in overall NTCP and that the conversion method is not iso-
toxic. The BED-based conversion of parameters between regimens simply converts 
the DVH dose scale using the EQD2 formulae which is a linear correction and does 
not account for the volume effect contributing to the complication in the OAR. 
Table 6-5 shows the BED based equivalent constraint derived for various regimens 
(3D CRT, VMAT & SABR regimens) for the 2 Gy equivalent dose constraint used to 
limit radiation pneumonitis (V20 Gy<30%).  If the Iso-BED based constraints were iso-
toxic, plotting curves of Vxx versus NTCP for all the DVHs (after scaling the total dose 
and correcting for the fractionation effect) would be aligned for different regimens. 
It is also expected that iso-effective constraints for different regimens should yield a 
constant NTCP. However, plotting the graph of NTCP and V20 (for 60Gy20#), V17.4 
(for 55Gy20#), V12.5 (for 40Gy8#), and V6.7 (for 48Gy4#) it was seen that the line fits 
were not aligned indicating that Iso-BED based conversion is not isotoxic. Examining 
figure 6.8, it can be observed that NTCP does not remain constant, varying by an 
average of 4-5% when effective constraints (calculated using the BED method) are 
assessed for different regimens. The variation increases for an increase in %volume 
associated with the constraint. However, it is also noted that for smaller changes in 
total dose or dose/fraction, the difference in NTCP is minimal (i.e. if the OAR was 
parallel in nature).   
The NTCP models are organ-specific and moderately well established. Increase in 
dose affects the complication probability in the OAR in a sigmoid fashion governed 
by the serial/parallel architecture of the organ. The NTCP-based method proposed 
here accounts for different types of side effects (acute / late / grade 1/2/3) the 
organ is likely to suffer due to an increase in dose and fraction number or fraction 
size. Using the proposed method, the Vxx conversion between various regimens can 
be performed as long as robust NTCP parameters and representative datasets are 
available for a given complication. It is also important to note that one of the pitfalls 
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of this method is the requirement of data to fit models well to be able to undertake 
this analysis.   
It is acknowledged that there is still room for improvement in the predictive power 
of the models. However, when comparing two different regimens the relative error 
contributed due to use of the same NTCP model is minimal. The absolute error in 
this method is attributable to the robustness of line fits indicated by the RMS value 
which for radiation pneumonitis (V20 constraint conversion fitting for four regimens 
in Table 6.2) was average 1.44 and 1.9 for the rectal bleeding fitting (shown in Table 
6.4). This method of fitting, encompassing a larger set of data points (DVH 
datasets), over varying tumour sizes is likely to yield a representative output 
allowing one to form a chart for converting standard Vxx constraints. Also, 
undertaking this analysis over DVH datasets generated by techniques like 
IGRT/IMRT are likely to yield different results compared to the results formed using 
data from DVHs generated from 3D-CRT plans. This is because complication rates 
observed in IMRT/IGRT are lower than 3D-CRT; which is attributable to improved 
OAR sparing achieved by IMRT/IGRT plans. This is observed when studying 
outcomes of the recent & past reported prostate cancer trials  (Dearnaley & Hall, 
2017). 
The aim of this chapter is to provide a method for radiotherapy professionals to 
quickly and efficiently determine the change in Vxx corresponding to a change in 
treatment regimen. As discussed in the methodology section and showcased in the 
results section, there are two slightly different but complementary techniques for 
converting Vxx Gy from one regimen to another on an iso-NTCP basis. The first 
method uses the f-1(x) of the regression model functions. However, this requires 
some calculation effort (e.g. software for efficient calculation). The second method 
is graphical and requires only a pencil and a scale to convert Vxx Gy from one regimen 
to another. It is emphasised that this conversion method should be used to find 
estimates rather than absolute equivalents of Vxx in different regimens.  
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6.5 Clinical Relevance, Conclusion & Future Work 
In this chapter, a new method of converting dosimetric OAR planning constraints, of 
the form Vxx Gy, from one fractionation regimen to the other has been presented. A 
critical analysis of the currently used BED formula-based method was done initially.  
It is accepted that the BED method is simpler. The method introduced here (iso-
NTCP) accounts for the radiobiology of the OAR as expressed through the LKB NTCP 
model with parameters specific to the complication endpoint. The graphical method 
employed is also relatively simple and efficient. It is acknowledged that the 
formation of Vxx – NTCP plots and relative fitting is likely to be affected by the 
treatment modality of the derived data. However, if the data used to form the plots 
is representative of the treatments under analysis, the currently proposed method 
can provide an efficient way for clinicians to iso-toxically convert Vxx Gy across 
different regimens.  
It is recommended that studies involving larger pools of data that are homogeneous 
(in terms of treatment modality) be used to form robust, endpoint- and regimen-
specific Vxx Gy NTCP conversion tables/charts.   
7   
  
211 | P a g e  
 
Chapter 7 Conclusions 
‘Individualization and optimization of radiotherapy treatments using radiobiological 
models’ is the core theme of this research. The focus has been on three different 
methods to individualize and optimize radiotherapy; additionally, a new method to 
Iso-toxically convert dose-volume-based metrics from one fractionation regimen to 
another is presented. The Marsden TCP model and the Lyman-Kutcher-Burman 
NTCP model were used to perform all the analyses. Multiple OAR complications (for 
both lung and prostate tumour treatments) were accounted for to make the 
analysis as clinically relevant as possible. Anonymised DVH datasets of previously 
treated cancer patients were obtained from the Pinnacle and Eclipse treatment 
planning systems. The algorithms used for the analysis in each chapter were 
developed in-house and programmed in the MATLAB environment version 2015B. 
The TCP & NTCP computations by the in-house software were quality checked 
against the published Biosuite software and against the Raystation TPS. 
In chapter 3, Iso-toxic treatment individualization has been further developed 
through the creation of a software that analyses large sets of patient cohort data. 
For the lung-tumour cohort, an average improvement in TCP of 16% (level 1 at 20 
fractions) and 19% (level 2 at 15-17 fractions) compared to the current 55Gy in 20 
fractions regimen was obtained at the same 8.6% NTCP. It was found that 15-17 
fractions yielded the highest therapeutic gain for the lung cohort. For the prostate 
tumour cohort, assuming α/β=10 Gy, and at 10% NTCPpop, level 1 (20 fractions) & 
level 2 (50 fractions) dose individualization yielded TCP gains of 0.72% and 12.6% 
respectively compared to standard dose escalation (level 0).  Assuming α/β=1.5 Gy, 
it was found that, also at 10% NTCP, level 2 optimization yielded a 9.7% increase in 
TCPpop over level 1 (20 fractions) optimization and nearly average 10% increase in 
TCPpop compared to level 0 optimization. At α/β=10 Gy and at α/β=5 Gy, 50 
fractions (the maximum number investigated) yielded the highest therapeutic ratio, 
(TR) whereas for α/β=1.5 Gy the highest TR was for one single fraction. In either 
case, level-2 individualization significantly improved the TCP compared to level 1 
and level 0. Analysis based on varying the parameters for the same tumour type 
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showed a large variation in the optimization results (e.g. fig 3-15 – level 2 optimized 
TCP for two sets of lung tumour parameters shows 8-10% variation at 8.6% NTCP) 
and this emphasizes the vulnerability of models to the quality of input parameters. 
In all cases, the use of radiobiological-model-based level 2 individualization yielded 
superior outcomes compared to current regimens for lung and prostate cancer 
radiotherapy treatments.   
Selector & optimizer programming modules (chapter 3) and the ‘RadOpt’ software 
were built to perform the analyses. These modules optimize tumour control 
probability at each (Iso-toxic) complication limit in turn (reducing the NTCP if the 
TCPcap is reached). The results are presented in the form of population TCP-NTCP 
plots that allow user-friendly evaluation of the various treatment strategies & 
parameter variation for a given cohort of patients via the ‘RadOpt’ user interface. 
In chapter 4 the effect of incorporating patient-specific tumour radiosensitivity 
information was explored. It was found that radiosensitivity information would be 
most useful for patients whose radiosensitivity was far from the population mean 
value. This was true for both lung and prostate cancer patients. It was also found 
that a finer stratification (5 groups vs 3 groups) of patient radiosensitivity would 
yield improvements for the lung cohort but not for the prostate cohort. The above 
analyses involved only a single dose-limiting OAR.  
Radiobiological-model based inverse treatment planning is explored in chapter 5. 
Dose-volume based inverse treatment plans (DB-plans) developed for a standard 
regimen (55Gy20# for lung tumours, 60Gy20# for prostate tumours) were 
compared to the TCP-NTCP-based inverse treatment plans (RB-plans) created on 
the Raystation TPS. For the lung cancer treatments (n=2 patients), RB-plans (of 20- 
and 15-fractions) yielded superior tumour control with the same or less toxicity for 
the principal OAR. It was also demonstrated for both the patients that RB-plans at 
15 fractions were superior to those at 20 fractions and were superior to all the DB-
plans. A similar analysis for two prostate cancer datasets showed that RB-plans 
were superior to DB-plans in terms of TCP (by 4-5%) and dose sparing of the 
principal OAR (NTCP 2% lower, rectum V40.8Gy – 15 to 30% lower for RB-plans). A key 
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finding was a significant reduction in planning complexity (no additional structures 
needed to be drawn) for the RB-plans to reduce dose to OARs like rectum. Further, 
it was also demonstrated that prostate DB-plans without the homogeneity objective 
yield a therapeutically better dose distribution (NTCP 2% lower, TCP 2-3% higher, 
rectum V40.8Gy – 7 to 12% reduction) at a 14% lower homogeneity index compared 
to the conventional DB-plans. The DB-plan(non uniform) for lung patients were similarly 
superior to the conventional homogeneous PTV dose plans.   
Chapter 6 describes a novel NTCP-based method to convert dose-volume based 
OAR tolerance limits (Vxx) from one fractionation regimen (say 55 Gy in 20 fractions 
for lung tumours) to the other. The limitations associated with the current BED 
formula-based method were presented and it was shown how the new method 
overcomes these limitations (e.g. accounting for the volume effect that plays a vital 
role in causing tissue toxicity, in the conversion). Compared to the Iso-NTCP method 
proposed here, the Iso-BED method showed an overall variation of 4-5% NTCP on 
conversion of V20Gy<30% for lung cancer data for various regimens.  The Iso-NTCP 
method was shown to be able to account for multiple endpoints related to the 
same OAR whilst forming Vxx conversion estimates from one regimen to another. 
The technique would be straightforward to implement in the clinic. 
This research has presented strong ‘macroscopic’ (i.e. patient-cohort based) 
evidence and techniques to support moving away from orthodox methods (fixed 
prescription dose, fixed number of fractions) of dose prescribing in radiotherapy in 
favour of individualized prescribing that takes into account the radiobiology of the 
normal tissues and tumours via NTCP and TCP models. 
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Appendix A: List of Abbreviations 
2-D / 2D Two dimensional 
3-D / 3D Three dimensional 
AAPM American Association of Physicists in Medicine 
AUC Area under the curve 
b.i.d twice a day in latin "bis in die" 
BED Biological Effective Dose 
bNED Biochemical free survival 
cGy centi-Gray 
CHART Continuous Hyperfractionated Accelerated Radiotherapy 
CHIPP Conventional or Hypofractionated High Dose Intensity 
CRT Conformal Radiotherapy 
CT Computed Tomography 
CTV Clinical target volume 
DIL Dominant Intra prostatic lesion 
Dpres Prescription Dose 
DSF Dose Scaling Factor 
DVB Dose Volum Based 
DVH Dose Volume Histogram 
external beam radiotherapy (EBRT) 
FSU Functional Subunit 
GTV Gross tumour volume 
GWAS Gnenom-wide association study 
Gy Gray 
ICRU 
International Commission on Radiological Units and Measurements 
(ICRU) 
IMRT Intensity modulated radiotherapy 
LKB / L-K-B Lyman - Kutcher - Burman 
LQ Linear Quadratic 
LQED Linear Quadratic equivalent dose 
MRI Magnetic Resonance Imaging 
NSCLC Non-small cell lung cancer 
NTCP Normal Tissue Complication Probability 
OAR / OR Organ at risk 
PET Positron Emission Tomography 
Pop Population 
PTV Planning target volume 
QUANTEC Quantitative Analyses of Normal Tissue Effects in the Clinic 
RB Radiobiological model Based 
RE Relative Effectiveness 
ROI Region of Interest 
RTOG Radiation Therapy Oncology Group 
SABR Stereotactic abalative body radiotherapy 
SBRT Stereotactic body radiation therapy 
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SF Surviving fraction 
TCP Tumour Control Probability 
TD50 Dose causing 50% complication rate in a normal tissue 
tot Total 
TPS 
TR 
Treatment Planning System 
Therapeutic Ratio 
VMAT Volumetric Modulated Arc Therapy 
Linac Linear accelerator 
MLC Multi-leaf collimator  
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Appendix B: Additional Material 
Figure A shows the optimum fraction numbers at which level 2 TCP was obtained for different α/β values of 
prostate tumour. 
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Figure B TCP-NTCP plots comparing Isotoxic dose escalation between radiobiological inverse treatment 
planning to dose-volume inverse planning for both NSCLC patient datasets. This figure is provided to show 
that dose escalation in patient 2 was successful but the data points for the RB-plan were limited as it was a 
very favourable patient (i.e. 100% TCP at 4% NTCP, P2 RB-plan). Patient 2 data points were thus excluded in 
the last submission – From old submission 
